Feeds:
Posts
Comments

Archive for the ‘HTN’ Category

 

7 Risks of Beta-Blockers Your Doctor Doesn’t Tell You

Reporter: Aviva Lev-Ari, PhD, RN

 

By Jerry Shaw    |   Monday, 06 April 2015 11:59 AM EDT

According to Patient, beta-blockers are drugs prescribed to many patients to lower blood pressure, treat angina, control abnormal heart rhythms and prevent heart attack. The medication is effective and powerful but there are still beta-blocker risks you should discuss with your doctor.

Beta-blockers slow the heart by blocking adrenaline your body produces naturally. According to WebMD, although many people who take beta-blockers will not have side effects, others may experience fatigue, dizziness or shortness of breath, as well as headache, upset stomach, constipation or diarrhea, or other minor discomforts.

Here are seven risks of beta-blockers your doctor doesn’t tell you:

1. People with asthma or COPD should not take beta-blockers, which may trigger severe asthma attacks or otherwise worsen symptoms, according to the Mayo Clinic. Doctors don’t normally prescribe them for those conditions.

2. If you have diabetes, beta-blockers could prevent warning signs of low blood sugar like a rapid heartbeat. Be sure to monitor your blood sugar as directed if you take beta-blockers, reports the Mayo Clinic.

3. Beta-blockers may trigger a modest increase in triglycerides, fats in the blood, while slightly decreasing high-density lipoprotein, the “good” cholesterol that cleans the arteries of unhealthy cholesterol, according to the Mayo Clinic. Although these effects are generally temporary, be sure you have regular cholesterol checks.

4 Hidden Symptoms Could Cause a Heart Attack; Take This Test to Reveal Them — Click Here Now

4. Beta blockers are occasionally prescribed for other conditions not related to blood pressure. Doctors don’t usually prescribe them for low blood pressure or a slow pulse, which can lower the heart rate, causing dizziness and lightheadedness, according to WebMD. Patients should record their pulse regularly and contact their doctor if the pulse is slower than normal.

5. Beta blockers stimulate the muscles that surround the air passages so they contract and lead to difficulty in breathing, according to MedicineNet.com.

6. Talk to your doctor about all other medications you take, including those sold over the counter. Aspirin, for example, may interact with your prescribed beta-blockers and reduce the effects.

7. Suddenly stopping the medication could increase beta-blocker risks such as heart troubles or even a heart attack. A doctor will advise you on stopping the medication by slowly decreasing the dosage.

SOURCE

https://www.newsmax.com/FastFeatures/beta-blocker-risks/2015/04/06/id/636670/

Sourced through Scoop.it from: www.newsmax.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Use of Beta and Alpha blockers in treatment of Hypertension | Medicine made Easy

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

 

 

This article is to discuss the use of Alpha and Beta blockers in the management of cases of hypertension regarding types,mechanism of action,pharmacological action, indications and side effects of the drugs .

Sourced through Scoop.it from: www.med4al.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Beta-blocker withdrawal linked to negative outcomes in patients with acute … – Healio

Reporter: Aviva Lev-Ari, PhD, RN

 

Patients with acute decompensated HF who discontinue beta-blockers may have an increased risk for mortality and rehospitalization, according to results of a new systematic review and meta-analysis.

Sourced through Scoop.it from: www.healio.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

New BP guidelines reduce antihypertensive therapy eligibility by 6 million … – Healio

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

SAN DIEGO — The number of patients in the US who would be eligible for antihypertensive therapy decreases by 6.1 million under the guidelines written by the panel convened for the Eighth Joint National Committee, according to data presented at the…

Source: www.healio.com

See on Scoop.itCardiotoxicity

Read Full Post »

Sets of co-expressed Genes influence Blood Pressure Regulation: Genome-wide Association and mRNA expression @US National Heart, Lung, and Blood Institute

Reporter: Aviva Lev-Ari, PhD, RN

 

 

NHLBI-led Team Untangles Gene Networks Involved in Blood Pressure Regulation

Apr 16, 2015

 

a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – Using network approaches, researchers from the US National Heart, Lung, and Blood Institute and their colleagues combined genome-wide association and mRNA expression data to home in on sets of co-expressed genes that appear to influence blood pressure regulation.

As they reported in Molecular Systems Biology today, the NHLBI-led team drew on data from more than 3,600 people participating in the Framingham Heart Study to identify four potentially causal gene modules and key driver genes contained within them.

“Our work was able to pinpoint several gene networks closely linked to the regulation of blood pressure,” first author Tianxiao Huan from NHLBI said in a statement.

In addition, Huan and her colleagues traced the function of one key driver gene — SH2B3 — to response to angiotensin II infusion in a mouse model, indicating that this approach may help identify new treatment targets.

For this study, Huan and her colleagues examined the gene expression profiles of 3,679 Framingham Heart Study participants of European descent who were not taking an antihypertensive drug. They correlated gene expression changes they observed in this cohort with systolic blood pressure, diastolic blood pressure, and hypertension and, after accounting for age, BMI, gender, and other factors, came up with 83 associated genes.

At the same time, the researchers constructed gene co-expression networks from that gene expression data to develop gene co-expression network modules that they then also correlated to blood pressure phenotypes. Of these 27 gene co-expression network modules, seven were significantly associated with either systolic or diastolic blood pressure, the researchers said.

While that set of 83 blood pressure-related genes wasn’t significantly enriched for any gene ontology terms, the seven gene co-expression network modules were linked to a variety of functions, including chromatin modification, immune cell-mediated cytotoxicity, inflammatory response, and more. This suggested to the researchers that genes involved in a range of biological processes are tightly co-regulated with respect to blood pressure.

Using a SNP set enrichment analysis approach, the researchers found that four of the gene co-expression network modules appeared to be potentially causal and that more than a dozen genes in those modules appeared to contribute to their association with blood pressure regulation.

For instance, one SNP, dubbed rs3184504, had been linked with blood pressure through a genome-wide association study, and it is linked with the expression of four genes in the set of genetically inferred causal blood pressure genes.

Using blood Bayesian networks and protein-protein interaction networks other groups had developed, Huan and her colleagues further zoomed in on key driver genes by testing whether the surrounding region of each gene in those four gene co-expression network modules was enriched for other potentially causal blood pressure genes.

These top key driver genes, they noted, were involved in subnetworks that appeared to regulate blood pressure-related genes.

For example, a missense SNP in an exon of SH2B3 has been associated with blood pressure and hypertension in a GWAS and is linked to expression changes in 10 other genes the researchers identified. These genes, Huan and her colleagues said, were enriched for activity in the intracellular signaling cascade, T-cell activation, and T-cell differentiation. This SH2B3-subnework was also enriched for genes known to be linked to blood pressure.

Previous work had linked SH2B3 to blood pressure regulation, Huan and her colleagues said, but how it had its effect wasn’t clear.

Mice lacking the SH2B3 gene, they noted, had normal baseline blood pressure, though it became elevated in response to a low dose of angiotensin II, an effect not seen in wild-type mice.

In addition, RNA sequencing of the whole-blood transcriptomes from wild-type and Sh2b3-/- mice indicated that more than 2,240 genes were differentially expressed between the two, especially ones involved in immune and inflammatory response. These genes significantly overlapped with the SH2B3 genetic subnetwork, and those overlapping genes were enriched for ones involved in the intracellular signaling cascade and T-cell activation, the researchers reported.

“Moving forward, it should be possible to study additional key driver genes in this way, which should help in our efforts to identify novel targets for the prevention and treatment of hypertension,” Huan added.

 

Related Articles

Mar 10, 2015

Researchers Link Innate Immune Function to PTSD Development Risk

Mar 20, 2015

Gene Expression Meta-analysis Leads to Blood Pressure Signature

Jan 23, 2015

Imperial College London-led Team Uncovers Regulator of Epilepsy Gene Network

Mar 05, 2015

Study Links Regulatory Changes during Development to Human Cerebral Cortex Evolution

May 01, 2014

Comparative Genomic Study Underscores Distinct Properties of Specialized Metabolites in Plants

Nov 06, 2014

Tools & Techniques: RNAi Delivery Tech, RNA-seq Co-expression Database

Premium

 

SOURCE

https://www.genomeweb.com/cardiovascular-disease/nhlbi-led-team-untangles-gene-networks-involved-blood-pressure-regulation

 

 

Read Full Post »

Stress and Anxiety

Writer and Curator: Larry H Bernstein, MD, FCAP

 

Introduction

This article follows immediately after two on diet and obesity and diet and exercise. The hypothalamus has been discussed in some detail, although There is more that needs to be said about glutamate receptors, which is a topic in itself. However, this material fits in place quite well.  There is a considerable amount of obesity, and exercise is limited by time and commitment.  The shrinking middle class and the working poor, and the unemployed poor as well, have a struggle to make ends meet, and with the divorce rates that we are seeing, it is stressful for a single mother to carry on a complete life as mother and caregiver, and it is not unusual to see one or both couples in a household, regardless of sex, to hold two jobs.  Students enter colleges for higher education and leave with significant debts.  Graduates with advanced degrees may have to compete with a crowd of qualified applicants for an academic position, or even for a job in technology.  In addition, there is an increase in stress related disorders in the   pre-school, elementary and middle school population.  We no longer have to read the front pages to learn that a violent act has been carried out somewhere, in some neighborhood in our great nation that has experienced a great civil war, two world wars, the Mc Carthy hearings, the Cold War, and Vietnam, and the Iraq War, all of which was accompanied by migrations, immigration, and outsourcing of jobs.  The following is another look at how we are adjusting.

 

Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder

Sang Hyuk Lee, Seung Chan Ahn, Yu Jin Lee, Tae Kyu Choi, et al.
J Psychosomatic Research 62 (2007) 189–195
http://dx.doi.org:/10.1016/j.jpsychores.2006.09.009

Objective: The objective of this study was to examine the effectiveness of a meditation-based stress management program in patients with anxiety disorder.
Methods: Patients with anxiety disorder were randomly assigned to an 8-week clinical trial of either a meditation-based stress management program or an anxiety disorder education program. The Hamilton Anxiety Rating Scale (HAM-A), the Hamilton Depression Rating Scale (HAM-D), the State–Trait Anxiety Inventory (STAI), the Beck Depression Inventory, and the Symptom Checklist- 90 — Revised (SCL-90-R) were used to measure outcome at 0, 2, 4, and 8 weeks of the program. Results: Compared to the education group, the meditation-based stress management group showed significant improvement in scores on all anxiety scales (HAM-A, P=.001; STAI state, P=.001; STAI trait, P=.001; anxiety subscale of SCL-90-R,P=.001) and in the SCL-90-R hostility subscale (P=.01). Findings on depression measures were inconsistent, with no significant improvement shown by subjects in the meditation-based stress management group compared to those in the education group. The meditation-based stress management group did not show significant improvement in somatization, obsessive–compulsive symptoms, and interpersonal sensitivity scores, or in the SCL-90-R phobic anxiety subscale compared to the education group. Conclusions: A meditation-based stress management program can be effective in relieving anxiety symptoms in patients with anxiety disorder. However, well-designed, randomized, and controlled trials are needed to scientifically prove the worth of this intervention prior to treatment.

 

Evidence and Potential Mechanisms for Mindfulness Practices and Energy Psychology for Obesity and Binge-Eating Disorder

Renee Sojcher, Susan Gould Fogerite, and Adam Perlman
Explore 2012; 8(5):271-276
http://dx.doi.org/10.1016/j.explore.2012.06.003

Obesity is a growing epidemic. Chronic stress produces endocrine and immune factors that are contributors to obesity’s etiology. These biochemical alsocan affect appetite and eating behaviors that can lead to binge-eating disorder. The inadequacies of standard care and the problem of patient noncompliance have inspired a search for alternative treatments. Proposals in the literature have called for combination therapies involving behavioral or new biological therapies. This manuscript suggests that mindbody interventions would be ideal for such combinations. Two mind body modalities, energy psychology and mindfulness meditation, are reviewed for their potential in treating weight loss, stress, and behavior modification related to binge-eating disorder.

Whereas mindfulness meditation and practices show more compelling evidence, energy psychology, in the infancy stages of elucidation, exhibits initially promising outcomes but requires further evidence-based trials. “Diets Don’t Work” has been a mantra repeated over and over in the media. In fact, in a 2006 study in which investigators compared several popular diets comprising either high carbohydrates, high protein, or high fat, they found a rapid regression of compliance after six months, to the extent that it did not matter which diet had initially been more effective. In another study, authors examined a combination of diet and exercise compared with diet alone and observed that 50% of their subjects in both groups regained the weight that they lost after one year, despite their having lost more weight with the combination therapy. Despite the failure of diet alone in most studies, strategies incorporating both diet and exercise can be effective: a Cochrane review on exercise for overweight or obesity concluded that exercise had a positive effect on body weight and cardiovascular risk factors and that this effect was enhanced by a combination of exercise with dietary interventions.

The authors of a more recent study found that the benefits of exercise in inducing weight loss may come through psychological pathways rather than through actual energy expenditure. These factors include self-regulation and self-efficacy, which may mediate the relationship between exercise and weight change. Psychological interventions, particularly behavioral therapy and CBT, have been shown to be effective, especially when combined with diet and exercise. However, these interventions are costly and require extensive clinical contact for long durations to achieve efficacy. The authors of a recent randomized controlled trial (RCT) with a three-year follow-up period looked at a new form of CBT that addresses patients’ overeating and low level of activity, as well as factors that impede weight maintenance, and found that this form of therapy did not result in improved weight maintenance. These authors concluded that CBT is not sufficiently effective in helping patients maintain their weight loss in the long term. Although 20% of people will not change their eating behaviors under stress, most do; approximately 40% will increase and 40% will decrease their eating.

The emotional eaters, who tend to increase food intake, are more likely to crave high-fat/sweet and rewarding comfort foods. The basis for this behavior is becoming understood to entail brain pathways that involve learning and memory of reward and pleasure. Habit formation and decreased cognitive control are also involved. These habits form the basis of BED. Binge eating occurs when a person eats larger amounts of food than normal in a short amount of time. It therefore involves a loss of control and is often precipitated by a range of negative emotions, such as anxiety, depression, anger, and loneliness. Overweight subjects may or may not be characterized as binge eaters.

The stress response, also known as the “fight or flight response,” involves the interaction of the autonomic nervous system, which includes the sympathetic and the parasympathetic nervous systems, the hypothalamic pituitary adrenal axis and endocrine secretion. Together, these systems comprise neuro-endocrine pathways that collaborate to maintain the body’s regulation of homeostasis. This mechanism is very effective when stress is acute, but in the case of chronic stress, the effect can be injurious to one’s physiological state. Over time, chronic exposure to stress hormones contributes to“ allostatic load.” The stress hormones released by the body, mostly cortisol, can alter the body’s fuel metabolism, especially by adipose tissue, leading to an increase in upper-body obesity. Furthermore, hormones such as leptin, ghrelin, and neuropeptide Y can affect appetite and cause changes in fat mass storage. This results in the linking of stress and obesity.

Given the limited success of conventional approaches and the new information about the psychological and physiological mechanisms underlying obesity, we propose that a specific sub-group of mind-body therapies, including energy psychology and mindfulness-based approaches, could add an important new dimension to the integrative treatment of eating disorders. Energy psychology refers to a family of therapies that are used for treating physical disorders and psychological symptoms, which includes Thought Field Therapy, Emotional Freedom Techniques (EFT), Eye Movement Desensitization and Reprocessing, and Tapas Acupressure Technique (TAT). These therapies incorporate concepts originating from non-Western healing and spiritual systems, including acupuncture, acupressure, yoga, meditation, and qigong, and they combine physical activity with mental activation on the basis of the premise that the body is composed of electrical signals or energy fields. Energy psychology has been quite controversial among psychotherapists and has been the subject of much heated debate in the literature. Nonetheless, the clinical application of these practices is growing and is beginning to be investigated for efficacy. Mindfulness-Based Eating Awareness Training (ie,MB-EAT) involves the cultivation of mindfulness, mindful eating, emotional balance, and self-acceptance.

A pilot trial of a six-week group curriculum for providing mindfulness training to obese individuals, called Mindful Eating and Living (ie,MEAL), showed significant increases in measures of mindfulness and cognitive restraint around eating and significant decreases in weight, eating disinhibition, bingeeating, depression, perceived stress, physical symptoms, negative affect ,and C-reactive protein. In a recent systematic review of eight studies, authors examined a variety of mindfulness techniques in treating eating disorders, including anorexia, bulimia, and BED. Because trial quality varied and sample sizes were small, the researchers concluded that mindfulness may be effective in treating eating disorders but that further research was needed. The authors noted, however, that all of the articles that met the study’s criterion reported positive outcomes for the mindfulness intervention. Two additional studies recently addressed the treatment of obesity with a combination of mindfulness strategies and ACT. Lillis et al. conducted a RCT on 87 subjects who had all completed at least a six-month weight loss program. Using a wait list control against treatment of the experimental group through a one-day workshop, the authors found that, compared with the control group, the experimental group showed greater improvements in obesity-related stigma, quality of life, psychological distress, and reduction of body mass in a three-month follow-up. Alberts et al. conducted an RCT on 19 participants in a 10-week dietary group treatment that examined the effect of mindfulness plus ACT on food cravings. Experimental subjects underwent an additional seven-week, manual-based mindfulness/acceptance training. The control group received information on healthy food choices. The experimental group showed significantly lower food cravings, a lower preoccupation with food in four subscales, less loss of control, and better positive outcome expectancy, as compared with the control group. There was no significant effect observed for emotional craving. The authors of both of these studies conclude that mindfulness strategies combined with acceptance are effective in reducing the behaviors that lead many obese patients to overeat. With regards to stress, mindfulness can reduce psychological factors that have been shown to contribute to obesity.

In a recent well conducted systematic review, Mars and Abbey examined 22 studies with conditions ranging from participants with Axis I disorders, various diagnosed medical disorders, and healthy subjects. Axis I disorders include a range of psychopathologies such as childhood developmental and adjustment abnormalities, adult anxiety, and mood, sleep, and sexual disorders. Subjects with BED are known to have greater comorbidity forAxis I disorders. The authors report that five studies examining Axis I disorders showed statistically significant results for an eight-week, two hours per week MBCT program in reducing psychological stress, recurring bouts of depression, and pain. They conclude that, despite some methodological difficulties in the trials, mindfulness therapy may have a positive impact on reducing stress and depression. Despite increasing public awareness of obesity’s detrimental effects on health, the conventional approaches to managing this condition have not been effective. The recommended standard care for overweight and obesity, namely diet and exercise, are for the most part ineffective in the long term. Behavioral therapy and CBT may have some effect but are costly and difficult to implement. Issues with bariatric surgery and pharmacological therapies attributable to cost and the potential for harm, as well as lack of long-term efficacy, have limited their utility.

The effectiveness of a stress coping program based on mindfulness meditation on the stress, anxiety, and depression experienced by nursing students in Korea

Yune Sik Kang, So Young Choi, Eunjung Ryu
Nurse Education Today 29 (2009) 538–543
http://dx.doi.org:/10.1016/j.nedt.2008.12.003

This study examined the effectiveness of a stress coping program based on mindfulness meditation on the stress, anxiety, and depression experienced by nursing students in Korea. A nonequivalent, control group, pre-posttest design was used. A convenience sample of 41 nursing students were randomly assigned to experimental (n=21) and control groups (n=20). Stress was measured with the PWI-SF(5-point) developed by Chang. Anxiety was measured with Spieberger’s state anxiety y inventory. Depression was measured with the Beck depression inventory. The experimental group attended 90-min sessions for eight weeks. No intervention was administered to the control group. Nine participants were excluded from the analysis because they did not complete the study due to personal circumstances, resulting in16 participants in each group for the final analysis. Results for the two groups showed

(1) a significant difference in stress scores (F=6.145,p=0.020),

(2) a significant difference in anxiety scores (F=6.985,p=0.013), and

(3) no significant difference in depression scores (t=1.986,p=0.056).

A stress coping program based on mindfulness meditation was an effective intervention for nursing students to decrease their stress and anxiety, and could be used to manage stress in student nurses. In the future, long-term studies should be pursued to standardize and detail the program, with particular emphasis on studies to confirm the effects of the program in patients with diseases, such as cancer.

 

 

Meditation and Anxiety Reduction: A Literature Review

M. M. Delmonte Clin
Psychol Rev 1985; 5: 91-102
Meditation is increasingly being practiced as a therapeutic technique. The effects of practice on psychometrically assessed anxiety levels has been extensively researched. Prospective meditators tend to report above average anxiety. In general, high anxiety levels predict a subsequent low frequency of practice. However, the evidence suggests that those who practice regularly tend to show significant decreases in anxiety. Meditation does not appear to be more effective than comparative interventions in reducing anxiety. There is evidence to suggest that hypnotizability and expectancy may both play a role in reported anxiety decrease. Certain individuals with a capacity to engage in autonomous self-absorbed relaxation, may benefit most from meditation.

 

Meta-analysis on the effectiveness of mindfulness-based stress reduction therapy on mental health of adults with a chronic disease: What should the reader not make of it?

Ernst Bohlmeijer, Rilana Prenger, ErikTaal
Letters to the Editor/J Psychosom Res 69 (2010) 613–615
http://dx.doi.org:/10.1016/j.jpsychores.2010.09.005

In a letter to the editor, Nyklíček et al. discuss the study of Bohlmeijer et al. [1]on the meta-analysis on the effectiveness of mindfulness-based stress reduction (MBSR) therapy on mental health of adults with a chronic disease. They claim that the effects of MBSR are underestimated in this meta-analysis due to the inclusion of a study using an active education support group as control group and to the omission of some subscales for which larger effect sizes have been found. We do not agree that the study using an active education support group as a control group should not have been included in the meta-analysis. It is a common procedure to include studies with various types of control groups, e.g., waiting-list, placebo, minimal interventions, or evidence-based treatment. Normally, subgroup analyses can be conducted, contrasting studies that use differen ttypes of control groups. As seven studies used a waiting-list control condition and only one study used an education support group, this subgroup comparison was not useful. However, when we conducted a meta-analysis of the seven RCTs using a waiting-list control group an overall effect size of 0.30 instead of 0.26 was found. In addition, it is often found in meta-analyses that the largest effect sizes are reported in studies that use waiting-list control groups, e.g. ,Refs.[2,3]. The fact that almost all studies included in our meta-analysis in fact used waiting-list control groups makes it unlikely that the effects of MBSR were underestimated. As to the second claim by Nyklíček e tal.that some outcomes were selectively omitted from the meta-analysis, we can state that the subscales of the POMS were included in the meta-analysis.The program that was used in our study, Comprehensive Meta-Analysis, combined the scales that measure the same outcome, e.g., anxiety in one study. So the larger effects sizes for the subscales of the POMS were included in the meta-analysis. Lastly, Nyklíčeketal. State that ‘decentering’ is not an exclusive process of MBCT but is a central feature of MBSR as well. MBCT was specifically developed for people with recurrent depression and on the basis of a thorough analysis of the role of specific cognitions in people with recurrent depression. In ouropinion, this may explain the large effect sizes that have been found in randomized controlled trials, e.g., [4]. In general, other studies have shown that integrating MBSR in behavioral therapy is a very promising strategy for enhancing the efficacy of treatments of psychological  distress[5,6]. However, more studies with different target groups are needed to answer the question as to which mindfulness-based intervention is most effective for which target group in which setting. Overall, in response to the letter to the editor by Nyklíček et al. we cannot corroborate their claim that the effects of MBSR were underestimated and have to stand with our conclusion that, on the basis of current RCTs, MBSR has small leffects on depression and anxiety in people with chronic medical diseases.

[1] BohlmeijerET, PrengerR, TaalE, CuijpersP.
The effects of mindfulness-based stress reduction therapy on the mental health of adults with a chronic medical disease: A meta-analysis.
JPsychosom Res 2010; 68:539–44.

[2]Powers MB, Zum Vörde Sive Vörding MB, Emmelkamp PMG.
Acceptance and commitment therapy: A meta-analytic review.
Psychoth Psychosom 2009; 78:73–80.

Read Full Post »

Adrenergic receptors and Beta Blockers

Reporter: Aviva Lev-Ari, PhD, RN

Watch Video

https://www.youtube.com/v/4K2QZXFMgng?fs=1&hl=fr_FR

Adrenergic Receptors: Types, Mechanism of action, location, actions, sites, agonist and antagonist drugs, Beta Blockers: Uses, Actions, Side effects, Contra …

Source: www.youtube.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Heart-Lung-Kidney: Essential Ties

Writer and Curator: Larry H. Bernstein, MD, FCAP 

 

Introduction

The basic functioning of the heart, and the kidney have been covered in depth elsewhere, and pulmonary function less, except in this series.  The relationship between them on the basis of endocrine, signaling, and metabolic balance is the focus in this piece.

Other elated articles can be found in http://pharmaceuticalintelligence.com:

The Amazing Structure and Adaptive Functioning of the Kidneys: Nitric Oxide – Part I
http://pharmaceuticalintelligence.com/2012/11/26/the-amazing-structure-and-adaptive-functioning-of-the-kidneys/

Nitric Oxide and iNOS have Key Roles in Kidney Diseases – Part II
http://pharmaceuticalintelligence.com/2012/11/26/nitric-oxide-and-inos-have-key-roles-in-kidney-diseases/

Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease
http://pharmaceuticalintelligence.com/2012/08/16/stroke-and-bleeding-in-atrial-fibrillation-with-chronic-kidney-disease/

Risks of Hypoglycemia in Diabetics with Chronic Kidney Disease (CKD)
http://pharmaceuticalintelligence.com/2012/08/01/risks-of-hypoglycemia-in-diabetics-with-ckd/

Acute Lung Injury
http://pharmaceuticalintelligence.com/2015/02/26/acute-lung-injury/

Neonatal Pathophysiology
http://pharmaceuticalintelligence.com/2015/02/22/neonatal-pathophysiology/

Altitude Adaptation
http://pharmaceuticalintelligence.com/2015/02/24/altitude-adaptation/

Action of Hormones on the Circulation
http://pharmaceuticalintelligence.com/2015/02/17/action-of-hormones-on-the-circulation/

Innervation of Heart and Heart Rate
http://pharmaceuticalintelligence.com/2015/02/15/innervation-of-heart-and-heart-rate/

Neural Activity Regulating Endocrine Response
http://pharmaceuticalintelligence.com/2015/02/13/neural-activity-regulating-endocrine-response/

Adrenal Cortex
http://pharmaceuticalintelligence.com/2015/02/07/adrenal-cortex/

Thyroid Function and Disorders
http://pharmaceuticalintelligence.com/2015/02/05/thyroid-function-and-disorders/

Highlights in the History of Physiology
http://pharmaceuticalintelligence.com/2014/12/28/highlights-in-the-history-of-physiology/

The Evolution of Clinical Chemistry in the 20th Century
http://pharmaceuticalintelligence.com/2014/12/13/the-evolution-of-clinical-chemistry-in-the-20th-century/

Complex Models of Signaling: Therapeutic Implications
http://pharmaceuticalintelligence.com/2014/10/31/complex-models-of-signaling-therapeutic-implications/

Cholesterol and Regulation of Liver Synthetic Pathways
http://pharmaceuticalintelligence.com/2014/10/25/cholesterol-and-regulation-of-liver-synthetic-pathways/

A Brief Curation of Proteomics, Metabolomics, and Metabolism
http://pharmaceuticalintelligence.com/2014/10/03/a-brief-curation-of-proteomics-metabolomics-and-metabolism/

Natriuretic Peptides in Evaluating Dyspnea and Congestive Heart Failure
http://pharmaceuticalintelligence.com/2014/09/08/natriuretic-peptides-in-evaluating-dyspnea-and-congestive-heart-failure/

Omega-3 fatty acids, depleting the source, and protein insufficiency in renal disease
http://pharmaceuticalintelligence.com/2014/07/06/omega-3-fatty-acids-depleting-the-source-and-protein-insufficiency-in-renal-disease/

Summary – Volume 4, Part 2: Translational Medicine in Cardiovascular Diseases
http://pharmaceuticalintelligence.com/2014/05/10/summary-part-2-volume-4-translational-medicine-in-cardiovascular-diseases/

More on the Performance of High Sensitivity Troponin T and with Amino Terminal Pro BNP in Diabetes
http://pharmaceuticalintelligence.com/2014/01/20/more-on-the-performance-of-high-sensitivity-troponin-t-and-with-amino-terminal-pro-bnp-in-diabetes/

Diagnostic Value of Cardiac Biomarkers
http://pharmaceuticalintelligence.com/2014/01/04/diagnostic-value-of-cardiac-biomarkers/

Erythropoietin (EPO) and Intravenous Iron (Fe) as Therapeutics for Anemia in Severe and Resistant CHF: The Elevated N-terminal proBNP Biomarker
http://pharmaceuticalintelligence.com/2013/12/10/epo-as-therapeutics-for-anemia-in-chf/

The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – Best writers Among the WRITERS
http://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

Renal Function Biomarker, β-trace protein (BTP) as a Novel Biomarker for Cardiac Risk Diagnosis in Patients with Atrial Fibrillation
http://pharmaceuticalintelligence.com/2013/11/13/renal-function-biomarker-%CE%B2-trace-protein-btp-as-a-novel-biomarker-for-cardiac-risk-diagnosis-in-patients-with-atrial-fibrilation/

Leptin signaling in mediating the cardiac hypertrophy associated with obesity
http://pharmaceuticalintelligence.com/2013/11/03/leptin-signaling-in-mediating-the-cardiac-hypertrophy-associated-with-obesity/

The Role of Tight Junction Proteins in Water and Electrolyte Transport
http://pharmaceuticalintelligence.com/2013/10/07/the-role-of-tight-junction-proteins-in-water-and-electrolyte-transport/

Selective Ion Conduction
http://pharmaceuticalintelligence.com/2013/10/07/selective-ion-conduction/

Translational Research on the Mechanism of Water and Electrolyte Movements into the Cell
http://pharmaceuticalintelligence.com/2013/10/07/translational-research-on-the-mechanism-of-water-and-electrolyte-movements-into-the-cell/

Landscape of Cardiac Biomarkers for Improved Clinical Utilization
http://pharmaceuticalintelligence.com/2013/09/22/landscape-of-cardiac-biomarkers-for-improved-clinical-utilization/

Calcium-Channel Blocker, Calcium as Neurotransmitter Sensor and Calcium Release-related Contractile Dysfunction (Ryanopathy)
http://pharmaceuticalintelligence.com/2013/09/16/calcium-channel-blocker-calcium-as-neurotransmitter-sensor-and-calcium-release-related-contractile-dysfunction-ryanopathy/

Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism
http://pharmaceuticalintelligence.com/2013/09/12/disruption-of-calcium-homeostasis-cardiomyocytes-and-vascular-smooth-muscle-cells-the-cardiac-and-cardiovascular-calcium-signaling-mechanism/

Renal Distal Tubular Ca2+ Exchange Mechanism in Health and Disease
http://pharmaceuticalintelligence.com/2013/09/02/renal-distal-tubular-ca2-exchange-mechanism-in-health-and-disease/

Cardiac Contractility & Myocardium Performance: Therapeutic Implications for Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses
http://pharmaceuticalintelligence.com/2013/08/28/cardiac-contractility-myocardium-performance-ventricular-arrhythmias-and-non-ischemic-heart-failure-therapeutic-implications-for-cardiomyocyte-ryanopathy-calcium-release-related-contractile/

Advanced Topics in Sepsis and the Cardiovascular System at its End Stage
http://pharmaceuticalintelligence.com/2013/08/18/advanced-topics-in-sepsis-and-the-cardiovascular-system-at-its-end-stage/

The Cardio-Renal Syndrome (CRS) in Heart Failure (HF)
http://pharmaceuticalintelligence.com/2013/06/30/the-cardiorenal-syndrome-in-heart-failure/

More…

Sodium homeostasis

Icariin attenuates angiotensin IIinduced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen speciesdependent JNK and p38 pathways

H Zhou, Y Yuan, Y Liu, Wei Deng, Jing Zong, Zhou‑Yan Bian, Jia Dai and Qi‑Zhu Tang
Exper and Therapeutic Med 7: 1116-1122, 2014
http://dx.doi.org:/10.3892/etm.2014.1598

Icariin, the major active component isolated from plants of the Epimedium family, has been reported to have potential protective effects on the cardiovascular system. However, it is not known whether icariin has a direct effect on angiotensin II (Ang II)‑induced cardiomyocyte enlargement and apoptosis. In the present study, embryonic rat heart‑derived H9c2 cells were stimulated by Ang II, with or without icariin administration. Icariin treatment was found to attenuate the Ang II‑induced increase in mRNA expression levels of hypertrophic markers, including atrial natriuretic peptide and B‑type natriuretic peptide, in a concentration‑dependent manner. The cell surface area of Ang II‑treated H9c2 cells also decreased with icariin administration. Furthermore, icariin repressed Ang II‑induced cell apoptosis and protein expression levels of Bax and cleaved‑caspase 3, while the expression of Bcl‑2 was increased by icariin. In addition, 2′,7’‑dichlorofluorescein diacetate incubation revealed that icariin inhibited the production of intracellular reactive oxygen species (ROS), which were stimulated by Ang II. Phosphorylation of c‑Jun N‑terminal kinase (JNK) and p38 in Ang II‑treated H9c2 cells was blocked by icariin. Therefore, the results of the present study indicated that icariin protected H9c2 cardiomyocytes from Ang II‑induced hypertrophy and apoptosis by inhibiting the ROS‑dependent JNK and p38 pathways.

Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial

Marcelo E. Ochiai, ECO Brancalhao, RSN Puig, KRN Vieira, et al.
Clinics. 2014; 69(5):308-313
http://dx.doi.org:/10.6061/clinics/2014(05)02

OBJECTIVE: We aimed to evaluate angiotensin receptor blocker add-on therapy in patients with low cardiac output during decompensated heart failure. METHODS: We selected patients with decompensated heart failure, low cardiac output, dobutamine dependence, and an ejection fraction ,0.45 who were receiving an angiotensin-converting enzyme inhibitor. The patients were randomized to losartan or placebo and underwent invasive hemodynamic and B-type natriuretic peptide measurements at baseline and on the seventh day after intervention. ClinicalTrials.gov: NCT01857999. RESULTS: We studied 10 patients in the losartan group and 11 patients in the placebo group. The patient characteristics were as follows: age 52.7 years, ejection fraction 21.3%, dobutamine infusion 8.5 mcg/kg.min, indexed systemic vascular resistance 1918.0 dynes.sec/cm5.m2, cardiac index 2.8 L/min.m2, and B-type natriuretic peptide 1,403 pg/mL. After 7 days of intervention, there was a 37.4% reduction in the B-type natriuretic peptide levels in the losartan group compared with an 11.9% increase in the placebo group (mean difference, – 49.1%; 95% confidence interval: -88.1 to -9.8%, p = 0.018). No significant difference was observed in the hemodynamic measurements. CONCLUSION: Short-term add-on therapy with losartan reduced B-type natriuretic peptide levels in patients hospitalized for decompensated severe heart failure and low cardiac output with inotrope dependence.

Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator)

Josep Lupon, Marta de Antonio, Joan Vila, Judith Penafiel, et al.
PLoS ONE 9(1): e85466. http://dx.doi.org:/10.1371/journal.pone.0085466

Background: A combination of clinical and routine laboratory data with biomarkers reflecting different pathophysiological pathways may help to refine risk stratification in heart failure (HF). A novel calculator (BCN Bio-HF calculator) incorporating N-terminal pro B-type natriuretic peptide (NT-proBNP, a marker of myocardial stretch), high-sensitivity cardiac troponin T (hs-cTnT, a marker of myocyte injury), and high-sensitivity soluble ST2 (ST2), (reflective of myocardial fibrosis and remodeling) was developed. Methods: Model performance was evaluated using discrimination, calibration, and reclassi-fication tools for 1-, 2-, and 3-year mortality. Ten-fold cross-validation with 1000 bootstrapping was used. Results: The BCN Bio-HF calculator was derived from 864 consecutive outpatients (72% men) with mean age 68.2612 years (73%/27% New York Heart Association (NYHA) class I-II/III-IV, LVEF 36%, ischemic etiology 52.2%) and followed for a median of 3.4 years (305 deaths). After an initial evaluation of 23 variables, eight independent models were developed. The variables included in these models were age, sex, NYHA functional class, left ventricular ejection fraction, serum sodium, estimated glomerular filtration rate, hemoglobin, loop diuretic dose, β-blocker, Angiotensin converting enzyme inhibitor/Angiotensin-2 receptor blocker and statin treatments, and hs-cTnT, ST2, and NT-proBNP levels. The calculator may run with the availability of none, one, two, or the three biomarkers. The calculated risk of death was significantly changed by additive biomarker data. The average C-statistic in cross-validation analysis was 0.79. Conclusions: A new HF risk-calculator that incorporates available biomarkers reflecting different pathophysiological pathways better allowed individual prediction of death at 1, 2, and 3 years.

TNF and angiotensin type 1 receptors interact in the brain control of blood pressure in heart failure

Tymoteusz Zera, Marcin Ufnal, Ewa Szczepanska-Sadowska
Cytokine 71 (2015) 272–277
http://dx.doi.org/10.1016/j.cyto.2014.10.019

Accumulating evidence suggests that the brain renin-angiotensin system and proinflammatory cytokines, such as TNF-α, play a key role in the neuro-hormonal activation in chronic heart failure (HF). In this study we tested the involvement of TNF-α and angiotensin type 1 receptors (AT1Rs) in the central control of the cardiovascular system in HF rats. Methods: we carried out the study on male Sprague–Dawley rats subjected to the left coronary artery ligation (HF rats) or to sham surgery (sham-operated rats). The rats were pretreated for four weeks with intracerebroventricular (ICV) infusion of either saline (0.25 µl/h) or TNF-α inhibitor etanercept (0.25 µg/0.25 µl/h). At the end of the pretreatment period, we measured mean arterial blood pressure (MABP) and heart rate (HR) at baseline and during 60 min of ICV administration of either saline (5 µl/h) or AT1Rs antagonist losartan (10 µg/5 µl/h). After the experiments, we measured the left ventricle end-diastolic pressure (LVEDP) and the size of myocardial scar. Results: MABP and HR of sham-operated and HF rats were not affected by pretreatments with etanercept or saline alone. In sham-operated rats the ICV infusion of losartan did not affect MABP either in saline or in etanercept pretreated rats. In contrast, in HF rats the ICV infusion of losartan significantly decreased MABP in rats pretreated with saline, but not in those pretreated with etanercept. LVEDP was significantly elevated in HF rats but not in sham-operated ones. Surface of the infarct scar exceeded 30% of the left ventricle in HF groups, whereas sham-operated rats did not manifest evidence of cardiac scarring. Conclusions: our study provides evidence that in rats with post-infarction heart failure the regulation of blood pressure by AT1Rs depends on centrally acting endogenous TNF-α.

Statins in heart failure—With preserved and reduced ejection fraction. An update

Dimitris Tousoulis , E Oikonomou, G Siasos, C Stefanadis
Pharmacology & Therapeutics 141 (2014) 79–91
http://dx.doi.org/10.1016/j.pharmthera.2013.09.001

HMG-CoA reductase inhibitors or statins beyond their lipid lowering properties and mevalonate inhibition exert also their actions through a multiplicity of mechanisms. In heart failure (HF) the inhibition of isoprenoid intermediates and small GTPases, which control cellular function such as cell shape, secretion and proliferation, is of clinical significance. Statins share also the peroxisome proliferator-activated receptor pathway and inactivate extracellular-signal-regulated kinase phosphorylation suppressing inflammatory cascade. By down-regulating Rho/Rho kinase signaling pathways, statins increase the stability of eNOS mRNA and induce activation of eNOS through phosphatidylinositol 3-kinase/Akt/eNOS pathway restoring endothelial function. Statins change also myocardial action potential plateau by modulation of Kv1.5 and Kv4.3 channel activity and inhibit sympathetic nerve activity suppressing arrhythmogenesis. Less documented evidence proposes also that statins have antihypertrophic effects – through p21ras/mitogen activated protein kinase pathway – which modulate synthesis of matrix metalloproteinases and procollagen 1 expression affecting interstitial fibrosis and diastolic dysfunction. Clinical studies have partly confirmed the experimental findings and despite current guidelines new evidence supports the notion that statins can be beneficial in some cases of HF. In subjects with diastolic HF, moderately impaired systolic function, low B-type natriuretic peptide levels, exacerbated inflammatory response and mild interstitial fibrosis evidence supports that statins can favorably affect the outcome. Under the lights of this evidence in this review article we discuss the current knowledge on the mechanisms of statins’ actions and we link current experimental and clinical data to further understand the possible impact of statins’ treatment on HF syndrome.

Since 1980 when the first 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor or statin was introduced in clinical practice, statins have been extensively used in the treatment of patients with dyslipidemia as well as of those with coronary artery disease (CAD). Importantly, large scale trials and metanalysis have documented their significant benefits in terms of primary and secondary CAD prevention which out-weigh any potential side effects. Statins’ benefits extend, according to recent studies, even in patients with normal or low cholesterol levels and beyond their lipid lowering effects, indicating their multiple protective mechanisms.

Heart failure (HF) is a complex syndrome with different definitions and its diagnosis is based on a combination of symptoms, clinical signs and imaging or laboratory data. different categorization schemes have been used dividing HF in acute or chronic, in systolic or diastolic, and in ischemic or dilated simply reflecting the complexity of the syndrome and the multiplicity of the pathophysiologic mechanisms implicated in the disease development and progression. In addition to the diverse pathophysiology of HF the syndrome is also characterized by high morbidity and mortality. Recent treatment advantages such as angiotensin converting enzyme inhibitors and beta blockers have not yet proven their clinical benefit in subjects with diastolic HF.

As the most common cause of HF is CAD and statins have proven their benefits in a wide spectrum of diseases directly or indirectly associated with atherosclerotic cardiovascular disease, HMG-CoA reductase inhibitors have been tested in subjects with HF. Interestingly, non-randomized, observational and retrospective early studies in subjects with HF of ischemic and non-ischemic etiology have suggested that statins are associated with improved outcomes. Thereafter, two large scale randomized control trials failed to demonstrate any benefits in mortality of HF patients treated with rosuvastatin and subsequently current HF guidelines do not include recommendations for statin use except from when they are indicated for comorbidities, such as established CAD.

Statins inhibit HMG-CoA reductase. This enzyme catalyzes the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to L-mevalonic acid, which is the rate-limiting step in the cholesterol synthesis pathway. Inhibition of the mevalonate pathway and of cholesterol synthesis triggers an increase in LDL receptor activity by stimulating production of mRNA for LDL receptor in liver. The induction of LDL receptors is responsible for the observed increase in plasma clearance of LDL cholesterol. CAD is the cause of approximately two-thirds of cases of systolic HF. The beneficial effects of statins-induced LDL reduction are well established in patients with atherosclerosis and CAD. Nevertheless, the results from statin treatment, even in ischemic HF cases, are not straightforward and several mechanisms have been proposed for this paradox.

multiplicity of HMG CoA reductase inhibitors mechanisms and their effects

multiplicity of HMG CoA reductase inhibitors mechanisms and their effects

The figure demonstrates the multiplicity of HMG CoA reductase inhibitors mechanisms and their effects. ↓: decrease; ↑ increase; FPP: farnesyl pyrophosphate: GGPP: geranylgeranyl pyrophosphate; Ras, Rac, Rho; small GTPases; eNOS: endothelial nitric oxide synthase; ATP: adenosine triphosphate; PI-3 kinase: phosphatidylinositol 3-kinase; AMPK: AMP activated protein kinase; GTP: Guanosine triphosphate; NADPH: Nicotinamide adenine dinucleotide phosphate; ERK: extracellular-signal-regulated kinase; Shadow box represents adverse mechanism and actions of HGM CoA reductase inhibitors.

The anti-inflammatory effects of HMG CoA reductase inhibitors in atherosclerosis have been early recognized. Statins also have a potent anti-inflammatory effect in HF models. Importantly, there is a link between inflammation and HF pathogenesis and is now widely accepted that pro-inflammatory cytokines cause systolic dysfunction, myocardial hypertrophy, activate a fetal gene program in cardiac myocytes, disturb extracellular matrix structure, cause cardiac cachexia etc. In addition, data from the Vesnarinone trial (VEST) in 384 patients with HF demonstrate a decline in survival with increasing TNFα levels confirming the notion that circulating cytokines are associated with adverse prognosis of HF patients.

The proposed, by the aforementioned mechanisms, anti-inflammatory effects of statins have been confirmed experimentally. Indeed, in a rat HF model with preserved ejection fraction (EF), treatment with rosuvastatin resulted in a significant additional improvement in HF and cardiac remodeling, partly due to decreased myocardial inflammation. In rats after acute myocardial infarction simvastatin treatment for 4 weeks beneficially modified the levels of TNFα, interleukin (IL)-1, 6 and 10 in the infarct regions. Importantly, in 446 patients with systolic HF, followed up for a period of 24 months, statins’ treatment was associated with a decrease in serum levels of C-reactive protein (CRP), IL-6 and tumor necrosis factor-alpha receptor II. Recently, in a randomized study of 22 subjects with ischemic HF short term atorvastatin treatment achieved a significant decrease in serum levels of intracellular adhesion molecule-1.

Taken together we can conclude that HMG CoA reductase inhibitors can modify inflammatory status by modulation of PRAP and ERK pathways by down regulating Toll like receptor 4 mRNA expressions and LDL oxidation and by reducing soluble lipoprotein-associated phospholipase A2 mass and activity. Importantly, the theoretical anti-inflammatory properties were confirmed in experimental and clinical HF models.

Endothelial dysfunction contributes to the pathogenesis of HF and can enhance adverse left ventricle (LV) remodeling and increase afterload in subjects with HF. Interestingly, statins have been constantly associated with improved endothelial function in subjects with a variety of cardiovascular diseases. Endothelium derived nitric oxide (NO) is an important determinant of endothelial function and HMG-CoA reductase inhibitors can up regulate endothelial NO synthase (eNOS) by different mechanisms.

Statins induce down regulation of Rho/Rho kinase signaling pathways, increasing the stability of eNOS mRNA and its expression . In addition, in human endothelial cells the Rho-kinase inhibitor, hydroxyfasudil leads to the activation of the phosphatidylinositol 3-kinase/Akt/eNOS pathway. Statins also induce activation of eNOS through the rapid activation of the serine–threonine protein kinase Akt. The beneficial effects of Akt activation are not limited to eNOS phoshorylation but extend to the promotion of new blood vessels growth. HMG CoA reductase inhibitors can further affect endothelial function through their effect on caveolin-1. Caveolin-1 binds to eNOS inhibiting NO production. Incubation of endothelial cells with atorvastatin promotes NO production by decreasing caveolin-1 expression, regardless of the level of extracellular LDL-cholesterol. These effects were reversed with mevalonate highlighting the therapeutic potential of inhibiting cholesterol synthesis in peripheral cells to correct NO-dependent endothelial dysfunction associated with hypercholesterolemia and possibly other diseases.

Although the experimentally confirmed benefits of HMG CoA reductase inhibitors in diastolic dysfunction and left ventricle stiffness, few data exist concerning the underlying mechanisms. As diastolic dysfunction precedes myocardial hypertrophy the anti-hypertrophic pathways mentioned in the previous section (inhibition of RhoA/Ras/ERK, PRAPγ pathways, inhibition of a large G(h) protein-coupled pathway etc.), may also contribute to the restoration of diastolic function. Moreover, in angiotensin II induced diastolic dysfunction in hypertensive mice, pravastatin not only improved diastolic function but also down-regulated collagen I, transforming growth factor-beta, matrix metalloproteinases (MMPs)-2 and -3, atrial natriuretic factor, IL-6 TNFα, Rho kinase 1 gene expression, and upregulated eNOS gene expression. These findings suggest the potential involvement of Rho kinase 1 in the beneficial effects of pravastatin in diastolic HF. Taken together data suggest that HMG CoA reductase inhibitors might be beneficial in patients with diastolic HF, a hypothesis that remains to be confirmed by clinical studies. Nevertheless, mechanistic studies have not fully explored the pathways affecting diastolic function and most data until now are indirect. Therefore efforts should be focus on the underline mechanisms affecting collagen synthesis, MMPs activity extracellular matrix synthesis and overall diastolic function in HF subjects under statin treatment.

Statins through inhibition of small GTPases can modulate MMPs activity in several cell types such as endothelial cells and human macrophages. In rat and human cardiac fibroblasts, stimulated with either transforming growth factor β1 or angiotensin II, atorvastatin reduced collagen synthesis and α1-procollagen mRNA as well as gene expression of the profibrotic peptide connective tissue growth factor 4. This antifibrotic action may contribute to the anti-remodelling effect of statins. In mouse cardiac fibroblasts treated with angiotensin II, the combination of pravastatin and pioglitazone blocked angiotensin II p38 MAPK and p44/42 MAPK activation and procollagen expression-1.

Several studies have documented the impact of statin treatment on arrhythmia potential. The arrhythmic protective effects of statins can be attributed not only to anti-inflammatory properties but also to changes in myocardial action potential plateau by modulation of Kv1.5 and Kv4.3 channel activity. Atorvastatin and simvastatin block Kv1.5 and Kv4.3 channels shifting the inactivation curve to more negative potentials following a complex mechanism that does not imply the binding of the drug to the channel pore. Moreover, in hypertrophied neonatal rat ventricular myocytes simvastatin alleviated the reduction of Kv4.3 expression, I(to) currents in subepicardial myocardium from the hypertrophied left ventricle. Furthermore, pravastatin in an animal model attenuated reperfusion induced lethal ventricular arrhythmias by inhibition of calcium overload.

Taking together experimental and cellular evidence supporting an effect of statin treatment in myocardial contractility is spare and for the time being we cannot definitively conclude on the clinical impact of HMG CoA reductase inhibitors in myocardial systolic performance.

Half of the cases of HF are attributed to diastolic dysfunction and the prognosis of HF with preserved EF is as ominous as the prognosis of HF with systolic dysfunction. Unfortunately, no treatment has yet been shown, convincingly, to reduce morbidity and mortality in patients with HF and preserved EF, while this group of patients is usually excluded from large prospective randomized trials and accordingly few data exist for the role of statins in this heterogeneous population.

As there is substantially lack of evidence concerning the effects of HMG CoA reductase inhibitors in subjects with HF and preserved EF the first indirect hypothesis was extrapolated from observational prospective studies in subjects with ischemic heart disease and no evidence of congestive HF. Indeed, in a cohort of 430 consecutive patients with ischemic heart disease and a mean EF of 57% Okura et al. observed that subjects under HMG CoA reductase inhibitors treatment had decreased E/E′ ratio—corresponding to a better diastolic function—and a significantly higher survival rate (Okura et al., 2007). According to the authors those beneficially effects can be attributed to improved endothelial function and vasodilatory response to reactive hyperemia, attenuation of myocardial hypertrophy, and interstitial fibrosis.

Despite the positive results from mechanistic and experimental studies clinical studies have failed to confirm a definitive role of HMG CoA reductase inhibitors in HF. Nevertheless, by extrapolating experimental and mechanistic data in clinical settings we further understand how HMG-CoA reductase inhibitors can beneficially affect subgroups of HF subjects such as those with preserved EF, low B-type natriuretic peptide levels, exacerbated inflammatory response and limited interstitial fibrosis. Nevertheless, as a definitive mechanism is lacking, there is uncertainty about the decisive mode of action and further mechanistic studies are needed to reveal how HMG-CoA reductase inhibitors act in HF substrate.

Pro- A-Type Natriuretic Peptide, Proadrenomedullin, and N-Terminal Pro-B-Type Natriuretic Peptide Used in a Multimarker Strategy in Primary Health Care in Risk Assessment of Patients with Symptoms of Heart Failure

Urban Alehagen, Ulf Dahlstr€Om,  Jens F. Rehfeld, And Jens P. Goetze
J Cardiac Fail 2013; 19(1):31-39. http://dx.doi.org/10.1016/j.cardfail.2012.11.002

Use of new biomarkers in the handling of heart failure patients has been advocated in the literature, but most often in hospital-based populations. Therefore, we wanted to evaluate whether plasma measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-A-type  atriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM), individually or combined, gives prognostic information regarding cardiovascular and all-cause mortality that could motivate use in elderly patients presenting with symptoms suggestive of heart failure in primary health care. Methods and Results: The study included 470 elderly patients (mean age 73 years) with symptoms of heart failure in primary health care. All participants underwent clinical examination, 2-dimenstional echocardiography, and plasma measurement of the 3 propeptides and were followed for 13 years. All mortality was registered during the follow-up period. The 4th quartiles of the biomarkers were applied as cutoff values. NT-proBNP exhibited the strongest prognostic information with 4-fold increased risk for cardiovascular mortality within 5 years. For all-cause mortality MR-proADM exhibited almost 2-fold and NTproBNP 3-fold increased risk within 5 years. In the 5e13-year perspective, NT-proBNP and MR-proANP showed significant and independent cardiovascular prognostic information. NT-proBNP and MR-proADM showed significant prognostic information regarding all-cause mortality during the same time. In those with ejection fraction (EF) !40%, MR-proADM exhibited almost 5-fold increased risk of cardiovascular mortality with 5 years, whereas in those with EF O50% NT-proBNP exhibited 3-fold increased risk if analyzed as the only biomarker in the model. If instead the biomarkers were all below the cutoff value, the patients had a highly reduced mortality risk, which also could influence the handling of patients. Conclusions: The 3 biomarkers could be integrated in a multimarker strategy for use in primary health care.

Novel Biomarkers in Heart Failure with Preserved Ejection Fraction

Kevin S. Shah, Alan S. Maisel
Heart Failure Clin 10 (2014) 471–479
http://dx.doi.org/10.1016/j.hfc.2014.04.005

KEY POINTS

  • Heart failure with preserved ejection fraction (HFPEF) is a common subtype of congestive heart failure for which therapies to improve morbidity and mortality have been limited thus far.
  • Numerous biomarkers have emerged over the past decade demonstrating prognostic significance in HFPEF, including natriuretic peptides, galectin-3, soluble ST2, and high-sensitivity troponins.
  • These markers reflect the multiple mechanisms implicated in the pathogenesis of HFPEF, and future research will likely use these markers to not only help determine heart failure phenotypes but also target specific therapies.

Heart failure (HF) is a global epidemic, defined as an abnormality of cardiac function leading to the inability to deliver oxygen at a rate adequate to meet the requirements of tissues. It is truly a clinical syndrome of symptoms and signs resulting from this cardiac abnormality. Over the past decade, further characterization into 2 entities has occurred: HF with preserved ejection fraction (HFPEF) and HF with reduced ejection fraction (HFREF). HFPEF, previously termed diastolic HF, encompasses the syndrome of HF with a preserved ejection fraction. Cutoffs for this ejection fraction typically are from 45% to 50%. The prevalence of HF is upward of 1% to 2% of the adult population, with an increased prevalence found in elderly and female patients. Multiple studies have shown that the prevalence of HFPEF is actually comparable with the number of patients with HFREF. As expected, most deaths from HFPEF are cardiovascular, comprising 51% to 70% of mortality.

The pathophysiology of HFPEF is controversial and remains poorly understood. Originally, HFPEF was thought to be a primary manifestation of diastolic dysfunction of the left ventricle. However, patients with HFREF are known to also commonly have impaired ventricular relaxation. The primary mechanism of left ventricular (LV) dysfunction is based on structural remodeling and endothelial dysfunction, lending itself to LV stiffness, and increased left atrial pressure. This pressure change is what drives pulmonary venous congestion and subsequent symptomatology. The ventricular stiffness commonly seen in HFPEF is attributed to multiple mechanisms, including fibrosis, excessive collagen deposition, cardiomyocyte stiffness, and slow LV relaxation.

The natriuretic peptides (NPs) are the cornerstone biomarker in congestive HF (CHF). Many of the details of the role of NPs are covered in an article – Florea VG, Anand IS. Biomarkers. Heart Fail Clin 2012;8(2):207–24. The Breathing Not Properly trial originally helped establish the role of B-type natriuretic peptide (BNP) in the diagnosis of CHF. BNP and the N-terminal prohormone BNP (NT-proBNP) have been shown in numerous trials to be an excellent tool for ruling out CHF as a cause of acute dyspnea. Aside from a strong negative predictive value, NPs correlate with HF severity, prognostication, outpatient CHF management, and screening. When attempting to use NPs specifically to distinguish between HFPEF and HFREF, results have shown that NPs do not have a particular cutoff, but are typically elevated in HFPEF in comparison with patients without HF. These levels of NPs in HFPEF are typically lower than levels in patients with HFREF.

Although the role of novel renal biomarkers has not been fully explored specifically in HFPEF, they likely have an impactful role in the assessment and management of acute kidney injury (AKI) and the cardiorenal syndrome. Two biomarkers are briefly discussed here: neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C. NGAL is a 25-kDa protein in the lipocalin family of proteins with a role in inflammation and immune modulation.

The future of biomarkers and their utility in HF is very promising, starting with the potential for using biomarkers as end points in trials. Biomarkers serve as surrogates for various pathophysiologic mechanisms, and there are potential benefits in using them as trial end points. Advantages include the ability to obtain quick and early data, as well as possibly better understand the nature of the disease. However, the counterargument against using biomarkers as trial end points includes whether treatment effects on a biomarker reliably predict effects on a clinically meaningful end point.
Reduced cGMP signaling activates NF-κB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A

Elangovan Vellaichamy, Naveen K. Sommana, Kailash N. Pandey
Biochemical and Biophysical Research Communications 327 (2005) 106–111
http://dx.doi.org:/10.1016/j.bbrc.2004.11.153

Mice lacking natriuretic peptide receptor-A (NPRA) develop progressive cardiac hypertrophy and congestive heart failure. However, the mechanisms responsible for cardiac hypertrophic growth in the absence of NPRA signaling are not yet known. We sought to determine the activation of nuclear factor-κB (NF-κB) in Npr1 (coding for NPRA) gene-knockout (Npr1-/-) mice exhibiting cardiac hypertrophy and fibrosis. NF-κB binding activity was 4-fold greater in the nuclear extract of Npr1-/-mutant mice hearts as compared with wild-type (Npr1+/+) mice hearts. In parallel, inhibitory κB kinase-b activity and IκB-α protein phosphorylation were also increased 3- and 4-fold, respectively, in hypertrophied hearts of mutant mice. cGMP levels were significantly reduced 5-fold in plasma and 10-fold in ventricular tissues of mutant mice hearts  relative to wild-type controls. The present findings provide direct evidence that ablation of NPRA/cGMP signaling activates NF-κB binding activity associated with hypertrophic growth of mutant mice hearts.

Regulation of guanylyl cyclase/natriuretic peptide receptor-A gene expression

Renu Garg, Kailash N. Pandey
Peptides 26 (2005) 1009–1023
http://dx.doi.org:/10.1016/j.peptides.2004.09.022

Natriuretic peptide receptor-A (NPRA) is the biological receptor of the peptide hormones atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). The level and activity of this receptor determines the biological effects of ANP and BNP in different tissues mainly directed towards the maintenance of salt and water homeostasis. The core transcriptional machinery of the TATA-less Npr1 gene, which encodes NPRA, consists of three SP1 binding sites and the inverted CCAAT box. This promoter region of Npr1 gene has been shown to contain several putative binding sites for the known transcription factors, but the functional significance of most of these regulatory sequences is yet to be elucidated. The present review discusses the current knowledge of the functional significance of the promoter region of Npr1 gene and its transcriptional regulation by a number of factors including different hormones, growth factors, changes in extracellular osmolarity, and certain physiological and patho-physiological conditions.

Atrial natriuretic peptide (ANP), a member of natriuretic peptide family is a polypeptide consisting of 28 amino acids and was discovered as a potent vasodilator and diuretic hormone produced in granules of the atrium. The natriuretic peptide family consists of the peptide hormones ANP, brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP), each of which is derived from a separate gene. ANP and BNP are cardiac derived peptides, which are secreted and up-regulated in myocardium in response to different patho-physiological stimuli, while CNP is an endothelium-derived mediator that plays an important paracrine role in the vasculature. All of these natriuretic peptides elicit a number of vascular, renal, and endocrine effects mainly directed towards the maintenance of blood pressure and extracellular fluid volume by binding to their specific cell surface receptors. ANP exerts its effects at a number of sites including the kidney, where it produces natriuretic and diuretic responses; the adrenal gland, where it inhibits aldosterone synthesis and secretion; vascular smooth muscle cells, where it produces vasorelaxation; the endothelial cells, where it may regulate vascular permeability; gonadal cells, where it affects synthesis of androgen and estradiol. Each of these target sites of ANP activity has been shown to possess specific high affinity receptors for ANP. To date, three different subtypes of natriuretic peptide receptors have been characterized, purified, and cloned, i.e. natriuretic peptide receptors A, B, and C also designated as NPRA, NPRB, and NPRC, respectively. ANP and BNP specifically bind to NPRA, which contains guanylyl cyclase catalytic activity and produces intracellular secondary messenger cGMP in response to hormone binding.

NPRA is considered the biological receptor of ANP and BNP because most of the physiological effects of these hormones are triggered by generation of cGMP or its cell permeable analogs. Recent studies with mice lacking the Npr1 gene, demonstrated that genetic disruption of NPRA increases the blood pressure and causes hypertension in these animals. On the other hand, the effect of ANP was found to be increased linearly in Npr1 gene-duplicated mice
in a manner consistent with gene copy number. All this clearly indicates that the level of NPRA expression determines the extent of the biological effects of ANP and BNP. But the intervention strategies aimed at controlling NPRA expression are limited by the paucity of studies in this area. The cDNA and gene encoding NPRA designated as Npr1 has been cloned and characterized in mouse, rat, bull frog, euryhaline eel, and medaka fish. The primary structure of this gene is essentially same in all the different species and contains 22 exons interrupted by 21 introns.  The Npr1 gene sequence has been found to be interspersed with a number of repetitive elements including (SINES), (MER2), and tandem repeat elements in all the different species.

Although the Npr1 gene transcriptional regulation is only poorly understood, the activity and expression of NPRA assessed primarily through ANP stimulated cGMP accumulation are found to be regulated by a number of factors including auto-regulation by natriuretic peptides themselves, other hormones such as endothelin, glucocorticoids, and angiotensin II (ANG II), growth factors, changes in extracellular ion composition, and certain physiological and patho-physiological conditions.

The core molecular machinery of the TATA-less Npr1 gene consisting of SP1 binding sites and the inverted CCAAT box has been authenticated to be indeed functional in rat promoter element. It has been shown that the molecular machinery that regulates the basal expression of Npr1 gene consists of three SP1 binding sites in conjunction with an inverted CCAAT box present in the proximal promoter region. Mutation in any of these SP1 binding sites which
are located within 350 bp upstream of transcription start site in rat Npr1 promoter inhibited SP1 and SP3 binding and decreased the promoter activity by 50–75%, while simultaneous mutation of all the three led to a >90% reduction in promoter activity. The proximal SP1 binding site was much more effective than the distal sites in inducing the expression implying that the proximity to the core transcriptional machinery contributes to the magnitude of the observed effect. The over-expression of either SP1 or SP3 resulted in the induction of the wild type Npr1 promoter, confirming that these transcription factors serve as positive regulators of the Npr1 gene expression.

A number of natriuretic peptides such as ANP, BNP, CNP, and urodilatin (i.e. ANP95–126) can down-regulate ligand dependent NPRA activity after as little as 2 h prior exposure to the ligand, which remains suppressed until 48 h of exposure in cultured cells. The early reduction of NPRA activity is independent of changes in Npr1 gene expression as the pretreatment of cultured cells with actinomycin D (an inhibitor of transcription) for 1 h failed to block the response to ANP implying that ligand acts, at least early on, through a post transcriptional mechanism in reducing NPRA activity. The sustained reduction of NPRA activity, on the other hand, has been shown in fact due to reduction in NPRA mRNA levels (∼50%) by treatment with 100nM ANP for 48 h. This reduction could also be affected by treatment of cultured cells with 8-Br-cGMP with similar kinetic response and was amplified by phosphodiesterase inhibitors, but was not shared by NPRC-selective ligand cANF, suggesting that the down regulation of Npr1 gene expression is mediated by elevations of intracellular cGMP involving either NPRA or NPRB. .. The cGMP regulatory region was pinpointed to position−1372 to−1354 bp from the transcription start site of Npr1 by gel shift assays and footprinting analysis, which indicated its interaction with transcriptional factor(s). Further cross-competition experiments with mutated oligonucleotides led to the definition of a consensus sequence (−1372 bp AaAtRKaNTTCaAcAKTY −1354 bp) for the novel cGMP-RE, which is conserved in the human (75% identity) and mouse (95% identity) Npr1 promoters. The combination of these transcriptional and post-transcriptional ligand-dependent regulatory mechanisms provides the cells with greater flexibility in both initiating and maintaining the suppression of NPRA activity.

The peptide hormone Ang II is an important component of renin-angiotensin system (RAS) and exerts its biological effects such as blood pressure regulation, vasoconstriction, and cell proliferation in many tissues including the kidney, adrenal glands, brain, and vasculature. The two vasoactive peptide hormones, Ang II (vasoconstrictive) and ANP (vasodilatory), interact and mutually antagonize the biological effects of each other at various levels. ANP has been shown to inhibit Ang II-induced contraction of isolated glomeruli and cultured mesangial cells, as well as Ang II-stimulated activation of protein kinase C and mitogen activated protein kinase in vascular smooth muscle cells in a cGMP-dependent manner. Inversely, Ang II has been shown to down-regulate guanylyl cyclase activity of the biological receptor of ANP, NPRA, by activating protein kinase C and/or by stimulating protein tyrosine phosphatase activity, thereby inhibiting the ANP stimulated cGMP accumulation. Ang II also reduces the ANP dependent cGMP levels by stimulating cGMP hydrolysis, apparently
via a calcium dependent cGMP phosphodiesterase.

Endothelin is a vasoconstrictor peptide that was originally isolated from porcine endothelial cells. It is produced as three isoforms (ET1-3) that bind to two receptor subtypes (ETA and ETB). ET is produced in the kidney and subject to regulation by a number of local and systemic factors including immune cytokines and extracellular tonicity. Since, endothelin is avidly expressed in the nephron segment, where NPRA is up-regulated by osmotic stimulus, it was investigated whether endothelin plays a role in the control of basal or osmotically regulated Npr1 gene expression in these cells. The endogenous endothelin and not the exogeneously administered endothelin inhibit the basal but not osmotically stimulated expression of Npr1. The type A (BQ610) and type B (IRL 1038) endothelin receptor antagonists increased the level of NPRA mRNA by two to three-fold, whereas co-administration of exogenous endothelin resulted in partial reversal of this stimulatory effect of receptor antagonists. The increase in extracellular tonicity reduces the endothelin mRNA accumulation (∼15% of control levels) in inner medullary collecting duct cells but this reduction is not found to be linked to the stimulation of NPRA activity/expression in response to osmotic stress.

Glucocorticoids influence the cardiovascular system and induce a rapid increase in blood pressure. Glucocorticoids are known to regulate
transcription in many systems, possibly by interacting with glucocorticoid responsive elements and associated chromatin proteins. These have been shown to affect the atrial endocrine system by regulating both the synthesis and secretion of ANP in vitro and in vivo. Thus, it seems plausible that glucocorticoid may also interact with the atrial endocrine system by modulating ANP receptor levels. The stimulation of vascular smooth muscle cells from rat mesenteric artery with dexa-methasone (a highly specific synthetic glucocorticoid agonist) caused an increase in NPRA mRNA levels in a time dependent manner which reached a plateau after 48 h of glucocorticoid administration. This mRNA increase was mimicked by cortisol and inhibited by glucocorticoid receptor antagonists RU38486. Also cGMP generated by NPRA in dexamethasone treated cells was higher than in control cells and this production was mimicked by cortisol and blocked by RU 38486. These results suggest that glucocorticoids exert a positive effect on NPRA transcription in rat mesenteric arteries.

Previous studies have shown that guanylyl cyclase activity of NPRA is either activated, or inhibited by an increase in extracellular tonicity. Though none of these studies were definitive in terms of elucidating the mechanisms involved, they suggested that the activation predominates with longer exposure (∼24 h), while the inhibition with short-term exposure (minutes) to the osmotic stimulus. More recently, the mechanism(s) underlying the activation of NPRA expression by osmotic stimulus has been investigated. The NaCl (75 mM) or sucrose (150 mM), but not osmotically inert solute, urea (150 mM) increased NPRA activity, gene expression, and promoter activity after as early as 4 h reaching a maximum at 24 h in inner medullary collecting duct cells. The osmotic stimulus also activated extracellular signal regulated kinase (ERK), c-Jun-NH2-terminal kinase (JNK), and p38 mitogen activated protein kinase- (p38 MAPK-β). The inhibition of p38 MAPK-βwith SB20580 completely  blocked the osmotic stimulation of receptor activity and expression, and caused a dose-dependent reduction in promoter activity, whereas inhibition of ERK with PD98059 had no effect.

The expression of NPRB, the biological receptor of CNP, has been shown to be regulated by a number of factors including natriuretic peptide ligands, intracellular cAMP levels, water deprivation, TGF-1, dexamethasone treatment, as well as renal sodium status, as its mRNA levels were upregulated in the renal cortex of sodium depleted animals. NPRB expression has also been found to be regulated by alternative splicing. Three isoforms of NPRB have been identified of which NPRB1 is the full length form and responds maximally to CNP, NPRB2 isoform contains a 25 amino acid deletion in protein kinase homology domain and NPRB3 contains a partial extracellular ligand binding domain and fails to bind the ligand. The relative expression levels of the three isoforms vary across different tissues. Since, the smaller splice variants of NPRB act as dominant negative isoforms by blocking formation of active NPRB1 homodimers, these isoforms might play important role in the tissue specific regulation of receptor, NPRB.

The NPRC expression has also been found to be down-regulated by its ligands and their secondary messenger, cGMP, hormones, growth factors, dietary salt supplementation, β-adrenergic blocker, and physiological as well as patho-physiological conditions. On the other hand, NPRC expression gets augmented by TGF-β1, 1,25-dihydroxy VitaminD3 and during conditions like chronic heart failure.

Hypertension is the leading cause of human deaths in today’s world. The natriuretic peptide system plays a well defined role in the regulation of blood pressure and fluid volume. The cellular and physiological effects of natriuretic peptides (ANP, BNP, and CNP) are mediated by their specific receptors NPRA, NPRB, and NPRC. The transcriptional regulation of these receptors has been studied since their identification, but still remains poorly understood. Better understanding and the elucidation of different molecular mechanisms responsible for the regulation of NPRA expression would provide us the framework to develop the therapeutic strategies to manipulate the expression levels of this receptor and to control the biological actions of ANP and BNP during different patho-physiological conditions.

Inhibition of Heat Shock Protein 90 (Hsp90) in Proliferating Endothelial Cells Uncouples Endothelial Nitric Oxide Synthase Activity

Jingsong Ou, Zhijun Ou, AW Ackerman, KT Oldham, & KA Pritchard, Jr.
Free Radical Biol Med 2003; 34(2):269–276
PII S0891-5849(02)01299-6

Dual increases in nitric oxide (•NO) and superoxide anion (O2•-) production are one of the hallmarks of endothelial cell proliferation. Increased expression of endothelial nitric oxide synthase (eNOS) has been shown to play an important role in maintaining high levels of •NO generation to offset the increase in O2•- that occurs during proliferation. Although recent reports indicate that heat shock protein 90 (hsp90) associates with eNOS to increase •NO generation, the role of hsp90 association with eNOS during endothelial cell proliferation remains unknown. In this report, we examine the effects of endothelial cell proliferation on eNOS expression, hsp90 association with eNOS, and the mechanisms governing eNOS generation of •NO and O2•-. Western analysis revealed that endothelial cells not only increased eNOS expression during proliferation but also hsp90 interactions with the enzyme. Pretreatment of cultures with radicicol (RAD, 20 µM), a specific inhibitor that does not redox cycle, decreased A23187-stimulated •NO production and increased Lω-nitroargininemethylester (L-NAME)-inhibitable O2•-generation. In contrast, A23187 stimulation of controls in the presence of L-NAME increased O2•- generation, confirming that during proliferation eNOS generates •NO. Our findings demonstrate that hsp90 plays an important role in maintaining •NO generation during proliferation. Inhibition of hsp90 in vascular endothelium provides a convenient mechanism for uncoupling eNOS activity to inhibit •NO production. This study provides new understanding of the mechanisms by which ansamycin antibiotics inhibit endothelial cell proliferation. Such information may be useful in the development and design of new antineoplastic agents in the future.

Natriuretic Peptides, Ejection Fraction, and Prognosis – Parsing the Phenotypes of Heart Failure

James L. Januzzi, JR
J Amer Coll Cardiol 2013; 61(14): 1507-9
http://dx.doi.org/10.1016/j.jacc.2013.01.039

Since the first pivotal studies introduced the natriuretic peptides as biomarkers for the diagnosis of heart failure (HF), use of both B-type natriuretic peptide (BNP) and its N-terminal equivalent (NT-proBNP) has grown not only for this indication, but also for establishing HF prognosis as well. Indeed, a vast array of studies has established the natriuretic peptides as the biomarker gold standard to prognosticate risk for a wide array of relevant complications in HF (ranging from ventricular arrhythmias to pump failure). In these studies, the prognostic information provided by BNP and NT-proBNP in HF was independent of a number of relevant covariates, including left ventricular ejection fraction (LVEF).

It has been known for quite a while that patients with heart failure and preserved ejection fraction (HFpEF) typically have lower natriuretic peptide values than do those with heart failure and reduced ejection fraction (HFrEF). A conundrum is thus present: whereas both BNP and NTproBNP tend to be lower in HFpEF, when these peptides are elevated in this setting, they remain prognostic; this intriguing circumstance has been relatively poorly studied. It is in this setting that van Veldhuisen et al. examined the impact of LVEF on the prognostic merits of BNP in the COACH (Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) study in the present issue of the Journal. The investigators found—as expected—that BNP levels were lower in HFpEF, but for a given BNP concentration, prognosis of those with HFpEF in COACH was just as poor as those with HFrEF at matched BNP values. Stated differently, a high BNP in a patient with HFpEF imparted similar prognostic information as it would in someone with HFrEF. Actually, whereas LVEF was not obviously prognostically impactful, when considered across the range of ventricular function, an elevated BNP concentration in the most normal range of LVEF seemed to be associated with a higher risk than at the lower ranges of pump function. Although it is previously established that BNP or NT-proBNP are prognostic independently of LVEF, the well-executed analysis by van Veldhuisen et al. (van Veldhuisen DJ, Linssen GCM, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61:1498–506.) allows for a more in-depth examination of this phenomenon and raises some important questions.

Phenotypic Definition of the Patient With Heart Failure

Phenotypic Definition of the Patient With Heart Failure

Phenotypic Definition of the Patient With Heart Failure

Natriuretic Peptides in Heart Failure with Preserved Ejection Fraction

Mark Richards, James L. Januzzi Jr, Richard W. Troughton
Heart Failure Clin 10 (2014) 453–470
http://dx.doi.org/10.1016/j.hfc.2014.04.006

KEY POINTS

  • Threshold values of B-type natriuretic peptide (BNP) and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) validated for diagnosis of undifferentiated acutely decompensated heart failure (ADHF) remain useful in patients with heart failure with preserved ejection fraction (HFPEF), with minor loss of diagnostic performance.
  • BNP and NT-proBNP measured on admission with ADHF are powerfully predictive of in-hospital mortality in both HFPEF and heart failure with reduced EF (HFREF), with similar or greater risk in HFPEF as in HFREF associated with any given level of either peptide.
  • In stable treated heart failure, plasma natriuretic peptide concentrations often fall below cut-point values used for the diagnosis of ADHF in the emergency department; in HFPEF, levels average approximately half those in HFREF.
  • BNP and NT-proBNP are powerful independent prognostic markers in both chronic HFREF and chronic HFPEF, and the risk of important clinical adverse outcomes for a given peptide level is similar regardless of left ventricular ejection fraction.
  • Serial measurement of BNP or NT-proBNP to monitor status and guide treatment in chronic heart failure may be more applicable in HFREF than in HFPEF.

 

The bioactivity of atrial NP (ANP) and B-type NP (BNP) encompasses short-term and longterm hemodynamic, renal, neurohormonal, and trophic effects. The relationship between cardiac hemodynamic load, plasma concentrations of ANP and BNP, and the cardioprotective profile of NP bioactivity have led to investigation of both biomarker and therapeutic potential of

NPs in HF.

PlasmaBNPandNT-proBNP thresholds (100pg/mL and 300 pg/mL, respectively) used in the diagnosis of undifferentiated ADHF retain good diagnosticperformance for acute HFPEF

 

Plasma NPs are related to multiple echo indicators of cardiac structure and function in both HFREF and HFPEF.
Box 1Causes of increased plasma cardiac natriuretic peptides

Cardiac

Heart failure, acute and chronic

Acute coronary syndromes

Atrial fibrillation

Valvular heart disease

Cardiomyopathies

Myocarditis

Cardioversion

Left ventricular hypertrophy

Noncardiac

Age

Female sex

Renal impairment

Pulmonary embolism

Pneumonia (severe)

Obstructive sleep apnea

Critical illness

Bacterial sepsis

Severe burns

Cancer chemotherapy

Toxic and metabolic insults

 

BNP and NT-proBNP fall below ADHF thresholds in stable HFREF in approximately 50% and 20% of cases, respectively. Levels in stable HFPEF are even lower, approximately half those in HFREF.
Whereas BNPs have 90% sensitivity for asymptomatic LVEF of less than 40% in the community (a precursor state for HFREF), they offer no clear guide to the presence of early community based HFPEF.
Guidelines recommend BNP and NT-proBNP as adjuncts to the diagnosis of acute and chronic HF and for risk stratification. Refinements for application to HFPEF are needed.
The prognostic power of NPs is similar in HFREF and HFPEF. Defined levels of BNP and NT-proBNP correlate with similar short-term and long-term risks of important clinical adverse outcomes in both HFREF and HFPEF.
Diagnostic algorithm for suspected heart failure presenting either acutely or nonacutely

Diagnostic algorithm for suspected heart failure presenting either acutely or nonacutely

Diagnostic algorithm for suspected heart failure presenting either acutely or nonacutely. a In the acute setting, mid-regional pro–atrial natriuretic peptide may also be used (cutoff point 120 pmol/L; ie, <120 pmol/L 5 heart failure unlikely). b Other causes of elevated natriuretic peptide levels in the acute setting are an acute coronary syndrome, atrial or ventricular arrhythmias, pulmonary embolism, and severe chronic obstructive pulmonary disease with elevated right heart pressures, renal failure, and sepsis. Other causes of an elevated natriuretic level in the nonacute setting are old age (>75 years), atrial arrhythmias, left ventricular hypertrophy, chronic obstructive pulmonary disease, and chronic kidney disease. c Exclusion cutoff points for natriuretic peptides are chosen to minimize the false-negative rate while reducing unnecessary referrals for echocardiography. d Treatment may reduce natriuretic peptide concentration, and natriuretic peptide concentrations may not be markedly elevated in patients with heart failure with preserved ejection fraction. BNP, B-type natriuretic peptide; ECG, electrocardiogram; NT-proBNP, N-terminal prohormone of B-type natriuretic peptide. (From McMurray JJ, Adamopoulos S, Anker SD, et al. The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787–847; with permission.)

Natriuretic Peptide Receptor-A Negatively Regulates Mitogen-Activated Protein Kinase and Proliferation of Mesangial Cells: Role of cGMP-Dependent Protein Kinase

Kailash N. Pandey, Houng T. Nguyen, Ming Li, and John W. Boyle
Biochem Biophys Res Commun 271, 374–379 (2000)
http://dx.doi.org:/10.1006/bbrc.2000.2627

peptide (ANP) and its guanylyl cyclase/natriuretic peptide receptor-A (NPRA) on mitogen-activated protein kinase/extracellular signal-regulated kinase 2 (MAPK/ERK2) activity in rat mesangial cells overexpressing NPRA. Agonist hormones such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), angiotensin II (ANG II), and endothelin-1 (ET-1) stimulated 2.5- to 3.5-fold immunoreactive MAPK/ERK2 activity in these cells. ANP inhibited agonist-stimulated activity of MAPK/ERK2 by 65–75% in cells overexpressing NPRA, whereas in vector transfected cells, its inhibitory effect was only 18–20%. NPRA antagonist A71915 and KT5823, a specific inhibitor of cGMP-dependent protein kinase (PKG) completely reversed the inhibitory effect of ANP on MAPK/ERK2 activity. ANP also inhibited the PDGF stimulated [3H]thymidine uptake by almost 70% in cells overexpressing NPRA, as compared with only 20–25% inhibition in vector-transfected cells. These
results demonstrate that ANP/NPRA system negatively regulates MAPK/ERK2 activity and proliferation of mesangial cells in a PKG-dependent manner.

 

Regulation of lipoprotein lipase by Angptl4

Wieneke Dijk and Sander Kersten
Trends in Endocrin and Metab, Mar2014; 25(3):146-155
http://dx.doi.org/10.1016/j.tem.2013.12.005

Triglyceride (TG)-rich chylomicrons and very low density lipoproteins (VLDL) distribute fatty acids (FA) to various tissues by interacting with the enzyme lipoprotein lipase (LPL). The protein angiopoietin-like 4 (Angptl4) is under sensitive transcriptional control by FA and the FA-activated peroxisome proliferator activated receptors (PPARs), and its tissue expression largely overlaps with that of LPL. Growing evidence indicates that Angptl4 mediates the physiological fluctuations in LPL activity, including the decrease in
adipose tissue LPL activity during fasting. This review focuses on the major ambiguities concerning the mechanism of LPL inhibition by Angptl4, as well as on the physiological role of Angptl4 in lipid metabolism, highlighting its function in a variety of tissues, and uses this information to make suggestions for further research.

Box 1. LPL and TG metabolism

LPL belongs to a family of lipases that also includes hepatic lipase, pancreatic lipase, and endothelial lipase. Because LPL is essential in the lipolytic processing of chylomicrons and VLDL, LPL is primarily expressed in tissues that either require large amounts of FA as fuel or are responsible for TG storage, which include heart, skeletal muscle, and adipose tissue. Upon production by the underlying parenchymal cells, LPL is released into the subendothelial space and is transported to the luminal side of the capillary endothelium by the GPI-anchored protein GPIHBP1, which after transport continues to anchor LPL to the capillary endothelium. The essential role for LPL in the clearance of plasma TG is well-demonstrated by the severe hypertriglyceridemia of patients carrying homozygous mutations in the LPL gene. Generalized deletion of LPL in mice results in severe hypertriglycer-idemia, resulting in the premature death of pups within 24 h after birth. Analogous to the deletion of LPL, the mislocalization of LPL to the subendothelial spaces due the absence or misfolding of GPIHBP1 also results in severe chylomicronemia and hypertriglyceridemia. The LPL enzyme is catalytically active as a non-covalent head-to-tail dimer with a catalytic N-terminal domain and a non-catalytic C terminal domain. Folding of LPL into its dimer conformation occurs in the endoplasmic reticulum, chaperoned by lipase maturation factor 1, calreticulin, and calnexin. In its active 3D conformation, the catalytic site of LPL is postulated to be covered by a lid, which can be opened by the binding of chylomicrons and VLDL to the C terminus. The active LPL dimers rapidly exchange subunits, indicating that a dynamic equilibrium exists between LPL dimers and dimerization-competent monomers. Dimerization-competent monomers have, however, not yet been isolated, and it is unclear whether this monomer is catalytically active. The enzymatic activity of LPL is lost when the LPL dimer is converted into inactive, folded monomers. This conversion to inactive monomers is mainly regulated via post-translational mechanisms and is dependent on nutritional state. Enzymatic activity of inactive monomers can be regained in vitro by the addition of calcium, indicating that inactivation of LPL is a reversible process.

One of the key questions is whether (patho)physiological variations in LPL activity are mediated via regulation of Angptl4 cleavage and/or oligomerization, and which factors are involved in modulating Angptl4 in vivo. Recent biochemical evidence suggests that FA may be able to promote dissociation of oligomers, which, by destabilizing the protein, would impair its ability to inhibit LPL. Destabilization of Angptl4 by FA is, however, seemingly at odds with the marked stimulatory effect of FA on Angptl4 production observed in vitro and in vivo.

The currently accepted molecular model for the inhibition of LPL by Angptl4 is that Angptl4 stimulates the conversion of catalytically active LPL dimers into inactive monomers – following in vitro studies showing that coincubation of LPL and Angptl4 increases the abundance of LPL monomers. Subsequent studies revealed that the proportion of LPL dimers is reduced in post-heparin plasma of mice that overexpress Angptl4 in favor of LPL monomers, providing in vivo support for the dimer-to monomer conversion. The elucidation of the purported biochemical mechanism has strengthened the status of Angptl4 as a LPL inhibitor, but several questions related to the in vivo mechanism remain unanswered. Whereas the original in vitro experiments favored the hypothesis that Angptl4 enzymatically and irreversibly catalyzes the LPL dimer-to-monomer conversion, an in vivo study of Angptl4 transgenic mice suggested that Angptl4 is physically bound to LPL monomers, thereby driving the LPL dimer–monomer equilibrium towards inactive monomers. The latter study also revealed that the relative decrease in post-heparin plasma LPL activity upon Angptl4 overexpression is much more pronounced than the relative decrease in heparin-releasable LPL dimers, pointing to an additional or alternative mechanism. In support, a recently published study suggests that Angptl4, instead of acting as a catalyst, functions as a conventional, non-competitive inhibitor that binds to LPL to prevent the hydrolysis of substrate LPL and Angptl4 are regulated by changes in nutritional state in a tissue-specific manner, reflecting the different functions of these tissues and the corresponding variations in physiological requirements for lipids. Below, we discuss current knowledge on the regulation of Angptl4 and LPL in response to various physiological stimuli and address the importance of Angptl4 in lipid uptake. An overview of the role of Angptl4 in physiological regulation of lipid metabolism is presented in Figure 2.

model for mechanisms of lipoprotein lipase (LPL) inhibition by Angptl4.

model for mechanisms of lipoprotein lipase (LPL) inhibition by Angptl4.

Figure 1. Hypothetical model for mechanisms of lipoprotein lipase (LPL) inhibition by Angptl4. Angiopoietin-like 4 (Angptl4) and LPL are expressed in the parenchymal cells of muscle, heart, and adipose tissue. Following secretion of LPL and Angptl4 into the subendothelial space, transport of LPL to the capillary lumen is mediated by two mechanisms. The principal transport mechanism (1) relies on GPIHBP1 [glycosylphosphatidylinositol (GPI)-anchored high density lipoprotein-binding protein] picking up LPL from the subendothelial space and transporting it to the capillary lumen. This action by GPIHBP1 is opposed by Angptl4, which is bound to extracellular matrix (ECM) proteins and which retains and inhibits LPL. In the presence of GPIHBP1, high expression levels of Angptl4 are needed to overcome the competition with GPIHBP1. Angptl4 secreted into the capillary lumen, primarily as N-terminal truncation fragment generated by cleavage by proprotein convertases (PCs), inhibits LPL activity on the endothelium by promoting the irreversible conversion of LPL dimers into inactive monomers and/or via a reversible mechanism that requires binding of Angptl4 to LPL. The second transport mechanism involves a so far unidentified carrier and can be disrupted by Angptl4. In the absence of GPIHBP1, Angptl4 fully retains LPL in the subendothelial space (a). The additional loss of Angptl4 liberates LPL and allows it to be transported to the endothelial surface via the unidentified carrier (b). This model suggests that Angptl4 and LPL start interacting before arrival in the capillary lumen, either in the parenchymal cells or in the subendothelial space. Abbreviation: HSPG, heparan sulfate proteoglycan.

Regulation and role of angiopoietin-like 4 (Angptl4)

Regulation and role of angiopoietin-like 4 (Angptl4)

Figure 2. Regulation and role of angiopoietin-like 4 (Angptl4) in lipid metabolism. Angptl4 is expressed in parenchymal cells of white adipose tissue (WAT), liver, intestine, heart and muscle, as well as in macrophages, where it is subject to cell- and tissue-specific regulation. Angptl4 is a sensitive target of peroxisome proliferator-activated receptor (PPAR) transcription factors in several tissues. In WAT the expression of Angptl4 is induced during fasting and by the transcription factors PPARg, glucocorticoid receptor (GR), and hypoxia inducible factor 1a (HIF1a). In WAT Angptl4 stimulates lipolysis of stored triglycerides (TG) and inhibits lipoprotein lipase (LPL) activity. Expression of Angptl4 in liver is stimulated by PPARa, PPARd, and GR. Because the liver does not express LPL, Angptl4 is mainly released into the blood, affecting LPL activity in peripheral tissues. Angptl4 may also impact upon hepatic lipase activity in liver. Expression of Angptl4 in heart and skeletal muscle is potently induced by fatty acids (FA) via PPARd activation. Angptl4 inhibits LPL activities in cardiac and likely skeletal muscle. FA also stimulate Angptl4 expression in macrophages via PPARd, leading to local inhibition of LPL activity. We hypothesize that macrophage LPL enables uptake of remnant particles containing lipid antigens, which are subsequently presented to natural killer T cells. In the intestine, FA stimulate Angptl4 expression via one of the PPARs. Angptl4 produced by enterocytes may be released towards the lumen and inhibit pancreatic lipase activity. Angptl4 produced by enteroendocrine cells is released towards the blood and may inhibit LPL in distant tissues.

Box 2. Outstanding questions

  1. What is the importance of Angptl4 cleavage and oligomerization to Angptl4 function in vivo?
  2. What is the precise biochemical mechanism behind the inhibition of LPL activity by Angptl4?
  3. At which cellular location(s) does the inhibition of LPL by Angptl4 occur and, if at multiple locations, what is the relative contribution of both tissue-produced Angptl4 compared to circulating Angptl4 with respect to inhibition of tissue LPL activity.
  4. What is the interplay between GPIHBP1 and Angptl4 in the regulation of LPL activity?
  5. What is the protein structure of Angptl4 and LPL?
  6. Does Angptl4 also regulate LPL activity in brown adipose tissue and skeletal muscle and, if so, how is the expression of Angptl4 regulated in these tissues?
  7. What is the potential of Angptl4 as a biomarker in the context of disorders of lipid metabolism?

In the past decade, angiopoietin-like proteins have been demonstrated to regulate plasma TG levels powerfully in mice and humans. The elucidation of these proteins as inhibitors of LPL activity has led to a paradigm shift in how clearance of circulating TG and thereby tissue uptake of FA are regulated. Most of our understanding of angiopoietin-like proteins has resulted from detailed study of Angptl4.

A major portion of the physiological variation in LPL activity in various tissues can be attributed to regulation of Angptl4 production. We predict that Angptl4 will turn out to be equally important for governing LPL activity in muscle during exercise, in brown adipose tissue during cold, and in several tissues during fasting.

Besides the increasing recognition of the pivotal role of Angptl4 in lipid metabolism as an inhibitor of LPL, major insight has been gained into the molecular mechanism of action of Angptl4. Key questions remain, however, especially related to the interaction between LPL, GPIHBP1, and Angptl4 on the endothelium and in the subendothelial space. Several points of interest have been highlighted throughout the text; these include the elucidation of the molecular structure for LPL and Angptl4 by X-ray crystallography and the clarification of in vivo Angptl4 cleavage and oligomerization.

Native Low-Density Lipoprotein Induces Endothelial Nitric Oxide Synthase Dysfunction: Role of Heat Shock Protein 90 And Caveolin-1

Kirkwood A. Pritchard, Jr., Allan W. Ackerman, Jingsong Ou, et al.
Free Radical Biol & Med 2002; 33(1):52–62 PII S0891-5849(02)00851-1

Although native LDL (n-LDL) is well recognized for inducing endothelial cell (EC) dysfunction, the mechanisms remain unclear. One hypothesis is n-LDL increases caveolin-1 (Cav-1), which decreases nitric oxide (•NO) production by binding endothelial nitric oxide synthase (eNOS) in an inactive state. Another is n-LDL increases superoxide anion (O2•-), which inactivates •NO. To test these hypotheses, EC were incubated with n-LDL and then analyzed for •NO, O2•-, phospho-eNOS (S1179), eNOS, Cav-1, calmodulin (CaM), and heat shock protein 90 (hsp90). n-LDL increased NOx by more than 4-fold while having little effect on A23187-stimulated nitrite production. In contrast, n-LDL decreased cGMP under basal and A23187-stimulated conditions and increased O2•-by a mechanism that could be inhibited by L-nitroargininemethylester (L-NAME) and BAPTA/AM. n-LDL increased phospho-eNOS by 149%, eNOS by [1]34%, and Cav-1 by 28%, and decreased the association of hsp90 with eNOS by 49%. n-LDL did not appear to alter eNOS distribution between membrane fractions (-85%) and cytosol (-15%). Only 3–6% of eNOS in membrane fractions was associated with Cav-1. These data support the hypothesis that n-LDL increases O2•-, which scavenges •NO, and suggest that n-LDL uncouples eNOS activity by decreasing the association of hsp90 as an initial step in signaling eNOS to generate O2•-.

In conclusion, n-LDL decreases the association of hsp90 with eNOS, increases phospho-eNOS levels, and increases eNOS-dependent O2•-generation. These findings suggest that activation of eNOS without adequate levels of hsp90 may signal eNOS to switch from •NO to O2•-generation. Such changes in eNOS radical product generation may play an important role in impairing endothelial and vascular function.

New insights into IGF-1 signaling in the heart

Rodrigo Troncoso, C Ibarra, JM Vicencio, E Jaimovich, and S Lavandero
Trends in Endocrin and Metab, Mar 2014; 25(3):128-131
http://dx.doi.org/10.1016/j.tem.2013.12.002

Insulin-like growth factor 1 (IGF-1) signaling regulates contractility, metabolism, hypertrophy, autophagy, senescence, and apoptosis in the heart. IGF-1 deficiency is associated with an increased risk of cardiovascular disease, whereas cardiac activation of IGF-1 receptor (IGF-1R) protects from the detrimental effects of a high-fat diet and myocardial infarction. IGF-1R activates multiple pathways through its intrinsic tyrosine kinase activity and through coupling to heterotrimeric G protein. These pathways involve classic second messengers, phosphorylation cascades, lipid signaling, Ca2+ transients, and gene expression. In addition, IGF-1R triggers signaling in different subcellular locations including the plasma membrane, perinuclear T tubules, and also in internalized vesicles. In this review, we provide a fresh and updated view of the complex IGF-1 scenario in the heart, including a critical focus on therapeutic strategies.

The hormone insulin-like growth factor 1 (IGF-1) is a small peptide of 7.6 kDa, which is composed of 70 amino acids and shares 50% homology with insulin. IGF-1 plays key roles in regulating proliferation, differentiation, metabolism, and cell survival. It is mainly synthesized and secreted by the liver in response to hypothalamic growth hormone (GH); its plasma concentration is finely regulated (Box 1). However, other tissues also produce IGF-1, which acts locally as an autocrine and paracrine hormone. IGF-1 exhibits pleiotropic effects in many organs and is also involved in the development of several pathologies.

Box 1. IGF-1 synthesis and biodisponibilityInsulin-like growth factor 1 (IGF-1) is a 70 amino acid peptide

hormone with endocrine, paracrine, and autocrine effects. It shares

>60% structure homology with IGF-2 and 50% with pro-insulin. IGF-

1 is mainly synthesized in the liver in response to hypothalamic

growth hormone (GH). In the peripheral circulation it exerts negative

feedback on the somatotrophic axis suppressing pituitary GH

release. IGF-1 can also be generated in almost all tissues, but liver

synthesis accounts for nearly 75% of circulating IGF-1 levels. As a

hormone with a wide range of physiological roles, IGF-1 circulating

levels must be strictly controlled. Around 98% of circulating IGF-1 is

bound to insulin-like growth factor binding protein (IGFBP). Six

forms of high affinity IGFBP have been described, with IGFBP3

binding approximately 90% of circulating IGF-1. Also, IGFBP1–6 and

their fragments have significant intrinsic biological activity independent

of IGF-1 interaction.

Canonical and noncanonical IGF-1 signaling pathways Activation of IGF-1R requires the sequential phosphorylation of three conserved tyrosine residues within the activation loop of the catalytic domain. From these phosphorylated motifs, tyrosine 950 contained in an NPXY motif provides a docking site for the recruitment of adaptor proteins, such as insulin receptor substrate-1 (IRS-1) and Shc, as an obligatory step to initiate signaling cascades. Two canonical pathways are activated by IGF-1R in cardiomyocytes – the phosphatidylinositol-3 kinase (PI3K)/Akt pathway and the extracellular signal-regulated kinase (ERK) pathway. Both pathways have been extensively studied, and their involvement in the pro-hypertrophic and pro-survival actions in cardiomyocytes is well established. Interestingly, a noncanonical signaling mechanism for IGF-1R in cardiomyocytes has been described in several recent studies. These studies show that some of the effects of IGF-1 are inhibited by the heterotrimeric Gi protein blocker Pertussis toxin (PTX) in several cell lines, suggesting that IGF-1R is a dual-activity receptor that triggers tyrosine-kinase-dependent responses as well as Gi-protein-dependent pathways. This duality has been reported in cultured neonatal cardiomyocytes; IGF-1R can activate ERK and Akt but also phospholipase C (PLC), which increases inositol 1,4,5 triphosphate (InsP3; IP3) leading to nuclear Ca2+ signals.

The cardiac effects of IGF-1 are mediated by activation of the plasma membrane IGF-1R, which belongs to the receptor tyrosine kinase (RTK) family. IGF-1R comprises a α2β2 heterotetrameric complex of approximately 400 kDa. Structurally, IGF-1R has two extracellular a-subunits that contain the ligand-binding sites. Each α-subunit couples to one of two membrane-spanning β-subunits, which contain an intracellular domain with intrinsic tyrosine kinase activity. Both subunits of IGF-1R are the product of one single gene, which is synthesized as a 180 kDa precursor. The immature IGF-1R full peptide is further glycosylated, dimerized, and proteolytically processed for assembly of the mature receptor isoforms a and b. In neonatal and adult rat cardiomyocytes, the IGF-1R precursor peptide and the processed α and β receptor subunits have been detected. Binding of IGF-1 to its receptor initiates a complex signaling cascade in cardiomyocytes.

Figure 1. not shown. Canonical and noncanonical signaling pathways activated by insulin-like growth factor 1 (IGF-1) in cardiomyocytes. Binding of IGF-1 to plasma membrane IGF-1 receptor (IGF-1R) leads to receptor autophosphorylation in the intracellular β-subunits. Docking of Grβ2 to the phosphorylated IGF-1Rβ subunits leads to extracellular signal-regulated kinase (ERK) phosphorylation through the Ras/Raf/Mitogen-activated protein kinase (MEK) axis. Phosphorylated ERK can translocate to the nucleus to control gene expression. Phosphorylated β-subunits also provide docking sites for insulin receptor substrate-1 (IRS-1), which mediates phosphatidylinositol-3 kinase (PI3K) activation and Akt phosphorylation. Downstream targets of activated Akt are mechanistic target of rapamycin (mTOR), which suppresses autophagy and promotes protein synthesis by activating S6K and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1). Akt also phosphorylates and inactivates Bad, thus inhibiting apoptosis. IGF-1R activation also promotes its interaction with a Pertussis-toxin-sensitive heterotrimeric Gi protein, which mediates the activation of phospholipase C (PLC) and hydrolysis of plasma membrane phosphatidylinositol 4,5 biphosphate (PIP2) to form inositol 1,4,5 triphosphate (InsP3; IP3) which activates InsP3 receptors located at the endoplasmin reticulum (ER)/nuclear envelope Ca2+ store, producing nucleoplasmic and cytoplasmic Ca2+ increases. The former is involved in the regulation of specific target genes and the latter promotes mitochondrial Ca2+ uptake, which increases mitochondrial respiration and metabolism, further preventing apoptosis and regulating autophagy. Canonical signaling pathways include the ERK and Akt axes, and are shown in red, whereas the noncanonical G protein pathway is shown in blue. Both pathways interact as Ca2+ contributes to ERK activation and additionally both Akt and ERK can compensate each other’s activation. Abbreviations: MEK, Mitogen-activated protein kinase; mTOR, mechanistic target of rapamycin; 4EBP1, eukaryotic translation initiation factor 4E binding protein 1; PIP2, phosphatidylinositol 4,5 biphosphate.

Figure 2. not shown. Classical versus proposed models of nuclear Ca2+ signaling in cardiomyocytes. The insulin-like growth factor 1 receptor (IGF-1R) can specifically regulate nuclear Ca2+ signaling independently of the role of Ca2+ on excitation–contraction coupling. On the classic model, inositol 1,4,5 triphosphate (InsP3; IP3) produced after IGF-1R activation travels from the peripheral plasma membrane to the nucleus, where it activates InsP3 receptors. In this model InsP3 bypasses its receptors present on the sarcoplasmic reticulum, which would lead to cytosolic Ca2+ signals. The novel model that we propose is based on recent findings, where the IGF-1R signaling complex is present in T-tubule invaginations toward the nucleus. In these compartments, IGF-1R activation leads to locally restricted InsP3 production that allows nuclear Ca2+ signals to regulate gene expression of genes associated with the development of cardiomyocyte hypertrophy. Abbreviations: RyR, ryanodine receptor; ECC, excitation–contraction coupling; PLC, phospholipase C; DHPR, dihydropyridine receptor.

The beneficial roles of IGF-1 in the cardiovascular system largely explain the interest in the development of new IGF-1-based treatments for cardiovascular disease. So far the FDA has approved two drugs for the treatment of IGF-1 deficiency: mecasermin (Increlex1), a human recombinant IGF-1 analog; and mecasermin rinfabate (IPLEX1), a binary protein complex of human recombinant IGF-1 and human recombinant IGBP-3. The safety of a chronic systemic IGF-1 therapy is open to question because it could promote severe adverse effects, such as an increased risk of cancer. To avoid these problems, several researchers have selectively overexpressed IGF-1 and IGF-1R in the heart.

Box 2. Outstanding questionsInsulin-like growth factor 1 (IGF-1) is an old friend of the heart. Despite the well-known protective effects of IGF-1 on cardiac function and the antiapoptotic effects of this peptide, novel evidence opens new questions to this longstanding relationship.

·       How do the multiple signaling pathways triggered by IGF-1 receptor (IGF-1R) interact with each other?

·       What lies further than extracellular signal-regulated kinase (ERK)/Akt/Ca2+ activation toward heart function?

·       Do these signaling pathways regulate cardiac fibroblast or endothelial cell function?

·       Which are the specific downstream signaling pathways of the different pools of IGF-1R and their role in regulating cardiomyocyte survival, hypertrophy, metabolism, proliferation?

·       What drives IGF-1R to such specific subcellular compartments?

·       What is the relevance of the hybrid IGF-1R/insulin receptors on cardiovascular disease?

·       Does a crosstalk exist between insulin receptor and IGF-1R in the heart under physiological and pathological conditions?

·       Is one pathway more beneficial than the other?

·       Will stem cell therapy of cardiac progenitors be able to provide concrete treatment opportunities?

·       Is IGF-1 a key regulator of this outcome?

Abundant evidence supports the key physiological roles of IGF-1 in the heart. In cardiomyocytes, IGF-1 activates multiple downstream signaling pathways for controlling cell death, metabolism, autophagy, differentiation, transcription, and protein synthesis (Figure 1). Of great interest are the findings that the entire IGF-1R complex is strategically located in perinuclear sarcolemmal invaginations that locally control nuclear Ca2+ signaling and transcriptional upregulation (Figure 2). This novel evidence changesmthe classical paradigm of IGF-1 signaling and adds a new level of complexity that may be relevant for other signaling receptors in the heart: interorganelle communication between plasma membrane invaginations and the nucleus.
The strategic localization of IGF-1R in these structures and the association with heterotrimeric G proteins may explain the differences in the phenotypic response induced by IGF-1 and others agonists, like endothelin-1 and angiotensin II, that also signal through intracellular Ca2+. By activating a noncanonical, selective mechanism of nuclear Ca2+ release, IGF-1 can regulate the expression of a specific set of cardiac genes via the generation of a particular signal-encoding pattern, leading to adaptive cardiac hypertrophy, antiapoptotic effects, and metabolic adaptation.

Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction – any Pathophysiological Role of Mitral Regurgitation

Marco Guazzi
http://dx.doi.org:/10.1016/j.jacc.2009.04.088

read with interest the study by Lam et al. (1) as an important contribution to the pathophysiological and clinical impact of pulmonary hypertension (PH) in hypertensive patients with heart failure and preserved left ventricular ejection fraction (HFpEF). Recent guidelines on arterial PH recognize HFpEF as a growing cause of left-sided PH, but a definitive appreciation of its true prevalence and prognostic relevance is lacking. The present study provides some new important information on this subject.

It is noteworthy that HFpEF was associated, in a high rate of cases (83%), with a typical hemodynamic pattern of precapillary PH, and a strong correlation was found between pulmonary artery systolic pressure and pulmonary capillary wedge pressure. Most important, pulmonary artery systolic pressure, rather than other echocardiography-derived measures of diastolic dysfunction, was the only significant multivariate predictor of mortality, a finding that was confirmed even when combined comorbid diseases potentially contributing to PH development, such as chronic obstructive pulmonary disease, were taken into account.

In patients with systolic heart failure, a major determinant of PH development is mitral regurgitation. Whether mitral regurgitation could be a putative factor in the pathogenesis of PH in HFpEF patients remains an open and intriguing question.

Accordingly, it would be of interest if the authors could provide some details on how many HFpEF patients exhibited mitral regurgitation, especially in comparison with control hypertensive patients without HFpEF.

Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53:1119–23.

Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting with Acute Dyspnea Results from the BACH (Biomarkers in Acute Heart Failure) Trial

Alan Maisel, MD, Christian Mueller, Richard M. Nowak,W. Frank Peacock, et al.
J Am Coll Cardiol 2011; 58(10):1057–67
http://dx.doi.org:/10.1016/j.jacc.2011.06.006

Objectives The aim of this study was to determine the prognostic utility of midregion proadrenomedullin (MR-proADM) in all patients, cardiac and noncardiac, presenting with acute shortness of breath.
Background
The recently published BACH (Biomarkers in Acute Heart Failure) study demonstrated that MR-proADM had superior accuracy for predicting 90-day mortality compared with B-type natriuretic peptide (area under the curve: 0.674 vs. 0.606, respectively, p < 0.001) in acute heart failure.
Methods The BACH trial was a prospective, 15-center, international study of 1,641 patients presenting to the emergency department with dyspnea. Using this dataset, the prognostic accuracy of MR-proADM was evaluated in all patients enrolled for predicting 90-day mortality with respect to other biomarkers, the added value in addition to clinical variables, as well as the added value of additional measurements during hospital admission.
Results Compared with B-type natriuretic peptide or troponin, MR-proADM was superior for predicting 90-day all-cause mortality in patients presenting with acute dyspnea (c index = 0.755, p < 0.0001). Furthermore, MR-proADM added significantly to all clinical variables (all adjusted hazard ratios: HR=3.28), and it was also superior to all other biomarkers. MRproADM added significantly to the best clinical model (bootstrap-corrected c index increase: 0.775 to 0.807; adjusted standardized hazard ratio: 2.59; 95% confidence interval: 1.91 to 3.50; p < 0.0001). Within the model, MR-proADM was the biggest contributor to the predictive performance, with a net reclassification improvement of 8.9%. Serial evaluation of MR-proADM performed in patients admitted provided a significant added value compared with a model with admission values only (p< 0.0005). More than one-third of patients originally at high risk could be identified by the biomarker evaluation at discharge as low-risk patients. Conclusions MR-proADM identifies patients with high 90-day mortality and adds prognostic value to natriuretic peptides in patients presenting with acute shortness of breath. Serial measurement of this biomarker may also prove useful for monitoring, although further studies will be required. (Biomarkers in Acute Heart Failure [BACH]; NCT00537628)

Invasive Hemodynamic Characterization of Heart Failure with Preserved Ejection Fraction

Mads J. Andersen, Barry A. Borlaug
Heart Failure Clin 10 (2014) 435–444
http://dx.doi.org/10.1016/j.hfc.2014.03.001

KEY POINTS

  • Invasive hemodynamic assessment in heart failure with preserved ejection fraction (HFpEF) was originally a primary research tool to advance the understanding of the pathophysiology of HFpEF.
  • The role of invasive hemodynamic assessment in HFpEF is expanding to the diagnostic arena where invasive assessment offers a robust, sensitive, and specific way to diagnose or exclude HFpEF in patients with unexplained dyspnea and normal ejection fraction.
  • In future years, invasive hemodynamic profiling may more rigorously phenotype patients to individualized therapy and, potentially, deliver novel device-based structural interventions.

The circulatory system serves to deliver substrates to the body via the bloodstream while removing the byproducts of cellular metabolism. Hemodynamics broadly refers to the study of the forces involved in the circulation of blood, which are governed by to the physical properties of the heart and vasculature and their dynamic regulation by the autonomic nervous system.

Afterload represents the forces opposing ventricular ejection and can be quantified by systolic left ventricular (LV) wall stress and aortic input impedance or its individual components (resistance, compliance, characteristic impedance). Wall stress is inconvenient because it depends on heart size and geometry, whereas impedance is cumbersome because it is a frequency-domain parameter that cannot be easily coupled with time-domain measures of ventricular function. Effective arterial elastance (Ea), defined by the ratio of LV end-systolic pressure (ESP) to stroke volume, provides a robust measure of total arterial load. Ea is not a directly measured parameter but, instead, a net or lumped stiffness of the vasculature that incorporates both mean and oscillatory components of afterload (Fig. 1). Preload reflects the degree of myofiber stretch before the onset of contraction, which, in turn, dictates the force and velocity of contraction according to the Frank-Starling principle. In everyday practice, preload is often conceptualized as equivalent to LV filling pressures. However, in fact, preload is most accurately reflected by the LV volume at end-diastole volume (EDV). Filling pressures are related to EDV by the LV diastolic chamber stiffness, which differs in healthy volunteers and subjects with HFpEF.

Fig. 1. Not shown. Ventricular-arterial coupling in the pressure-volume plane. Pressure volume loop at steady state is shown in dark black. The area subtended by the loop (shaded) represents the stroke work. Stroke volume is the difference between end-diastolic volume (EDV) and end-systolic volume (ESV). Ea is defined by the negative slope connecting the ESP and ESV coordinates with EDV and pressure = 0. With acute preload reduction (dotted line loops) there is progressive reduction in EDV, ESV, and ESP. The linear slope of the endsystolic pressure volume relationship (ESPVR) is LV end-systolic elastance (Ees). The curvilinear slope of the end diastolic pressure–volume relationship (EDVPR) is derived by fitting pressure volume coordinates measured during diastasis to the equation shown. The exponential power or stiffness constant (b) obtained is a measure of LV diastolic stiffness. (Adapted from Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Heart Fail Clin 2009;5(2):217–28; with permission.)

Fig. 3. Not shown. Left ventricular diastolic reserve in HFpEF. In the normal healthy adult, the rate of LV pressure decay during isovolumic contraction (t) is rapid and increases markedly during exercise in association with a reduction in LVmin, allowing for suction of blood into the LV, with no increase in left atrial pressure or LV end-diastolic pressure (LVEDP) despite an increase in LV end-diastolic volume and marked shortening of the cycle length. In HFpEF, relaxation is prolonged at baseline (increased t) with inadequate hastening (shortening of t) during exercise, contributing to an inability to reduce LVmin and, consequently, a complete lack of suction effects. LV filling then completely depends on left atrial hypertension, which develops in tandem with marked elevation in LVEDP. (Data from Borlaug BA, Jaber WA, Ommen SR, et al. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 2011;97(12):964–9.)

Fig. 4. Preload and filling pressures in HFpEF. (A) Cumulative distribution plot shows that acute changes in stroke volume with nitroprusside infusion are lower in HFpEF (black) compared with HFrEF (red). Because afterload (Ea) is lowered, any acute reduction in SV must be related to reduction in preload volume (EDV) and nearly 40% of HFpEF patients experienced stroke volume reduction with nitroprusside, despite high filling pressures (PCWP 20–25 mm Hg), indicating increased reliance on high pressures to achieve adequate EDV. *p<0.0001 compared with HFrEF. (B) LVEDP in a healthy adult (blue) and in a HFpEF patient with increased LV diastolic stiffness (green). At the same preload (EDV), pressure is more than twofold higher in HFpEF. In contrast, at the same LV diastolic pressure (15 mm Hg), LV volume is much lower in HFpEF, indicating decreased LV diastolic capacitance. V15, volume at end-diastolic pressure = 15 mm Hg; LVEDP. (Adapted from Schwartzenberg S, Redfield MM, From AM, et al. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012;59(5):442–51; with permission.)

Updated Clinical Classification of Pulmonary Hypertension

Gérald Simonneau, Ivan M. Robbins, Maurice Beghetti, et al.
J Am Coll of Cardiol   2009; 54(1), Suppl S
http://dx.doi.org:/10.1016/j.jacc.2009.04.012

The aim of a clinical classification of pulmonary hypertension (PH) is to group together different manifestations of disease sharing similarities in pathophysiologic mechanisms, clinical presentation, and therapeutic approaches. In 2003, during the 3rd World Symposium on Pulmonary Hypertension, the clinical classification of PH initially adopted in 1998 during the 2nd World Symposium was slightly modified. During the 4th World Symposium held in 2008, it was decided to maintain the general architecture and philosophy of the previous clinical classifications. The modifications adopted during this meeting principally concern Group 1, pulmonary arterial hypertension (PAH). This subgroup includes patients with PAH with a family history or patients with idiopathic PAH with germline mutations (e.g., bone morphogenetic protein receptor-2, activin receptor-like kinase type 1, and endoglin). In the new classification, schistosomiasis and chronic hemolytic anemia appear as separate entities in the subgroup of PAH associated with identified diseases. Finally, it was decided to place pulmonary venoocclusive disease and pulmonary capillary hemangiomatosis in a separate group, distinct from but very close to Group 1 (now called Group 1=). Thus, Group 1 of PAH is now more homogeneous. (J Am Coll Cardiol 2009; 54: S43–54)
Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension

Robyn J. Barst,  J. Simon R. Gibbs, Hossein A. Ghofrani, et al.
J Am Coll Cardiol 2009; 54(1), Suppl S,

Uncontrolled and controlled clinical trials with different compounds and procedures are reviewed to define the risk benefit profiles for therapeutic options in pulmonary arterial hypertension (PAH). A grading system for the level of evidence of treatments based on the controlled clinical trials performed with each compound is used to propose an evidence-based treatment algorithm. The algorithm includes drugs approved by regulatory agencies for the treatment of PAH and/or drugs available for other indications. The different treatments have been evaluated mainly in idiopathic PAH, heritable PAH, and in PAH associated with the scleroderma spectrum of diseases or with anorexigen use. Extrapolation of these recommendations to other PAH subgroups should be done with caution. Oral anticoagulation is proposed for most patients; diuretic treatment and supplemental oxygen are indicated in cases of fluid retention and hypoxemia, respectively. High doses of calcium-channel blockers are indicated only in the minority of patients who respond to acute vasoreactivity testing. Nonresponders to acute vasoreactivity testing or responders who remain in World Health Organization (WHO) functional class III, should be considered candidates for treatment with either an oral phosphodiesterase-5 inhibitor or an oral endothelin-receptor antagonist. Continuous intravenous administration of epoprostenol remains the treatment of choice in WHO functional class IV patients. Combination therapy is recommended for patients treated with PAH monotherapy who remain in WHO functional class III. Atrial septostomy and lung transplantation are indicated for refractory patients or where medical treatment is unavailable. (J Am Coll Cardiol 2009;54:S78–84)

Inhibition and down-regulation of gene transcription and guanylyl cyclase activity of NPRA by angiotensin II involving protein kinase C

Kiran K. Arise, Kailash N. Pandey
Biochem and Biophys Res Commun 349 (2006) 131–135
http://dx.doi.org:/10.1016/j.bbrc.2006.08.003

The objective of this study was to investigate the role of protein kinase C (PKC) in the angiotensin II (Ang II)-dependent repression of Npr1 (coding for natriuretic peptide receptor-A, NPRA) gene transcription. Mouse mesangial cells (MMCs) were transfected with Npr1 gene promoter-luciferase construct and treated with Ang II and PKC agonist or antagonist. The results showed that the treatment of MMCs with 10 nM Ang II produced a 60% reduction in the promoter activity of Npr1 gene. MMCs treated with 10 nM Ang II exhibited 55% reduction in NPRA mRNA levels, and subsequent stimulation with 100 nM ANP resulted in 50% reduction in guanylyl cyclase (GC) activity. Furthermore, the treatment of MMCs with Ang II in the presence of PKC agonist phorbol ester (100 nM) produced an almost 75% reduction in NPRA mRNA and 70% reduction in the intracellular accumulation of cGMP levels. PKC antagonist staurosporine completely reversed the effect of Ang II and phorbol ester. This is the first report to demonstrate that ANG II-dependent transcriptional repression of Npr1 gene promoter activity and down-regulation of GC activity of translated protein, NPRA is regulated by PKC pathways.

Transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-A gene

Prerna Kumar, Kiran K. Arise, Kailash N. Pandey
peptides 27 (2006) 1762–1769
http://dx.doi.org:/10.1016/j.peptides.2006.01.004

Activation of natriuretic peptide receptor-A (NPRA) produces the second messenger cGMP, which plays a pivotal role in maintaining blood pressure and cardiovascular homeostasis. In the present study, we have examined the role of trans-acting factor Ets-1 in transcriptional regulation of Npr1 gene (coding for NPRA).Using deletional analysis of the Npr1 promoter, we have defined a 400 base pair (bp) region as the core promoter, which contains consensus binding sites for transcription factors including: Ets-1, Lyf-1, and GATA-1/2. Over-expression of Ets-1 in mouse mesangial cells (MMCs) enhanced Npr1 gene transcription by 12-fold. However, overexpression of GATA-1 or Lyf-1 repressed Npr1 basal promoter activity by 50% and 80%, respectively. The constructs having a mutant Ets-1 binding site or lacking this site failed to respond to Ets-1 activation of Npr1 gene transcription. Collectively, the present results demonstrate that Ets-1 greatly stimulates Npr1 gene promoter activity, implicating its critical role in the regulation and function of NPRA at the molecular level.

Several agents that are known to upregulate Ets-1 transcription, include RA, TNF-alpha, VEGF, and TPA. Ets-1 is upregulated at exposure to agonists such as serum in vitro and is expressed in injured vasculature. MAPK-mediated phosphorylation positively regulates the transcriptional activation functions of Ets-1 by recruiting CBP/p300. Not much is known about Ets-1 expression or regulation in mesangial cells. A temporal increase of mesangial cell Ets-1 expression has been reported which correlates with mesangial cell activation
in mesangioproliferative glomerulonephritis suggesting involvement of PDGF-B. There might be a possibility that during glomerulonephritis increased Ets-1 expression upregulates Npr1 gene as a protective mechanism. Npr1 gene has been shown to negatively regulate mitogen-activated protein kinase and proliferation of mesangial cells.

In conclusion, our results demonstrate that the precise control of Npr1 gene transcriptional activity is achieved through a synergy of activators and repressors in which Ets-1 plays an integral role as a transcriptional activator. Comparatively, Lyf-1 and GATA-1 act as repressors, inhibiting and regulating the transcriptional activity of Npr1 gene promoter. The present findings suggest that Ets-1 plays a critical role in enhancing Npr1 gene transcription and may have an important influence in hypertension and cardiovascular homeostasis at the molecular level.

Krüppel-like transcription factor 11 (KLF11) overexpression inhibits cardiac hypertrophy and fibrosis in mice

Yue Zheng, Ye Kong, Feng Li
Biochem and Biophys Res Commun 443 (2014) 683–688
http://dx.doi.org/10.1016/j.bbrc.2013.12.024

The Krüppel-like factors (KLFs) belong to a subclass of Cys2/His2 zinc-finger DNA-binding proteins. The KLF family member KLF11 is originally identified as a transforming growth factor b (TGF-b)-inducible gene and is one of the most studied in this family. KLF11 is expressed ubiquitously and participates  in diabetes and regulates hepatic lipid metabolism. However, the role of KLF11 in cardiovascular system is largely unknown. Here in this study, we reported that KLF11 expression is down-regulated in failing human hearts and hypertrophic murine hearts. To evaluate the roles of KLF11 in cardiac hypertrophy, we generated cardiac-specific KLF11 transgenic mice. KLF11 transgenic mice do not show any difference from their littermates at baseline. However, cardiac-specific KLF11 overexpression protects mice from TAC-induced cardiac hypertrophy, with reduced radios of heart weight (HW)/body weight (BW), lung weight/BW and HW/tibia length, decreased left ventricular wall thickness and increased fractional shortening. We also observe lower expression of hypertrophic fetal genes in TAC-challenged KLF11 transgenic mice compared with WT mice. In addition, KLF11 reduces cardiac fibrosis in mice underwent hypertrophy. The expression of fibrosis markers are also down-regulated when KLF11 is overexpressed in TAC-challenged mice. Taken together, our findings identify a novel anti-hypertrophic and anti-fibrotic role of KLF11, and KLF11 activator may serve as candidate drug for heart failure patients.

Read Full Post »

Protein Clue to Sudden Cardiac Death: Research @Oxford University

Reporter: Aviva Lev-Ari, PhD, RN

Protein Clue to Sudden Cardiac Death

 

iASPP, a previously unidentified regulator of desmosomes, prevents arrhythmogenic right ventricular cardiomyopathy (ARVC)-induced sudden death

Mario NotariYing HuGopinath SutendraZinaida DedeićMin LuLaurent DupaysArash YavariCarolyn A. CarrShan ZhongAaisha OpelAndrew TinkerKieran ClarkeHugh WatkinsDavid J. P. FergusonDavid P. KelsellSofia de NoronhaMary N. SheppardMike HollinsheadTimothy J. Mohun, and Xin Lu

Significance

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease that is selective to the right side of the heart and results in heart failure and sudden death. Genetic defects in desmosome components account for approximately 50% of human ARVC cases; in the other 50% of patients, however, the causes remain unknown. We show that inhibitor of apoptosis-stimulating protein of p53 (iASPP) is an important regulator of desmosomes. It interacts with desmoplakin and desmin in cardiomyocytes and regulates desmosome integrity and intermediate filaments. iASPP-deficient mice display pathological features of ARVC and die of sudden death. In human ARVC patients, cardiomyocytes exhibit reduced levels of iASPP at the cell junctions, suggesting that iASPP may be critical in ARVC pathogenesis.

Abstract

Desmosomes are anchoring junctions that exist in cells that endure physical stress such as cardiac myocytes. The importance of desmosomes in maintaining the homeostasis of the myocardium is underscored by frequent mutations of desmosome components found in human patients and animal models. Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a phenotype caused by mutations in desmosomal components in ∼50% of patients, however, the causes in the remaining 50% of patients still remain unknown. A deficiency of inhibitor of apoptosis-stimulating protein of p53 (iASPP), an evolutionarily conserved inhibitor of p53, caused by spontaneous mutation recently has been associated with a lethal autosomal recessive cardiomyopathy in Poll Hereford calves and Wa3 mice. However, the molecular mechanisms that mediate this putative function of iASPP are completely unknown. Here, we show that iASPP is expressed at intercalated discs in human and mouse postmitotic cardiomyocytes. iASPP interacts with desmoplakin and desmin in cardiomyocytes to maintain the integrity of desmosomes and intermediate filament networks in vitro and in vivo. iASPP deficiency specifically induces right ventricular dilatation in mouse embryos at embryonic day 16.5. iASPP-deficient mice with exon 8 deletion (Ppp1r13lΔ8/Δ8) die of sudden cardiac death, displaying features of ARVC. Intercalated discs in cardiomyocytes from four of six human ARVC cases show reduced or loss of iASPP. ARVC-derived desmoplakin mutants DSP-1-V30M and DSP-1-S299R exhibit weaker binding to iASPP. These data demonstrate that by interacting with desmoplakin and desmin, iASPP is an important regulator of desmosomal function both in vitro and in vivo. This newly identified property of iASPP may provide new molecular insight into the pathogenesis of ARVC.

Tue, 02/17/2015 – 3:56pm
Oxford University

A team led by Oxford University researchers was looking at how a protein, iASPP, might be involved in the growth of tumours. However, serendipitously they found that mice lacking this gene died prematurely of sudden cardiac death. More detailed investigations showed that these mice had an irregular conductance in the right side of the heart, a condition known as arrhythmogenic right ventricular cardiomyopathy (ARVC).

The researchers discovered that iASPP had a previously unknown role in controlling desmosomes – one of the main structures that ‘glue’ individual heart muscle cells (cardiomyocytes) together. The genetic defect was shown to weaken desmosome function at the junctions of heart muscle cells: this affected the structural integrity of the heart, making mice lacking iASPP prone to ARVC.

Further studies of heart tissue from human patients who had died from ARVC showed that some of them have similar defects in desmosomes as in the mice suggesting that the faulty iASPP gene could also be responsible for ARVC deaths in humans. This finding also explains why a previously reported cattle herd with spontaneous iASPP gene deletion died of sudden cardiac death.

 

 

A team led by Oxford University researchers was looking at how a protein, iASPP, might be involved in the growth of tumours. However, serendipitously they found that mice lacking this gene died prematurely of sudden cardiac death. More detailed investigations showed that these mice had an irregular conductance in the right side of the heart, a condition known as arrhythmogenic right ventricular cardiomyopathy (ARVC).

 

 

Read Full Post »

Innervation of Heart and Heart Rate

Writer and Curator: Larry H Bernstein, MD, FCAP

 

 

The heart is a four-chambered 350 gm semi-oval muscular organ composed of syncytial myocardium, innervated by the vagus nerve with a sino-atrial (SA) and a atrial ventricular (AV) node.  The blood circulates through it by way of the pulmonary artery and aorta, carrying blood away from the ventricles, to the lungs and the systemic circulation, respectively, and two veins, the vena cava and pulmonary, carrying blood to the atria from the systemic circulation and lungs, respectively.  The coronary arterial supply is the left anterior and left circumflex artery, and posteriorly, the right coronary artery, supplied by the aorta.  Much of the pathology has been referred to in the introduction, except for the molecular pathology of atherosclerosis, which has been well covered in this journal. The chambers are divided centrally by the interventricular septum, which is not completely closed in the blue-baby syndrome, which was repaired surgically by Helen Taussig and Richard Bing.  The piece that follows is primarily directed to the sympathetic innervation of the heart, variation in heart rate, and exercise or reaction to external threats.

What are the common observable events that stimulate or relax the heart:

  1. Running or a treadmill test
  2. Rowing or arm movement exercise
  3. A whole body workout
  4. Yoga or Ayurveda
  5. Sleep – normal or disruptive

Some things that can cause a disruption of balance in integrated circulation, neural innervation, innate immune and hormonal response are:

  1. Traumatic experience and/or Injuries
  2. Climate and seasonal changes
  3. Age
  4. Emotions

The basis for the physiological distress has long been the primary basis for acupuncture, holistic and transcendental medicine, and stress management.

I shall here examine the experimental work that supports such an approach – in principle.

Seattle Heart Watch: Initial Clinical, Circulatory and Electrocardiographic Responses to Maximal Exercise

Robert A Bruce, G0 Gey, Jr., Mn Cooper, Ld Fisher, Dr Peterson
Amer J Cardiol 1974; 33(4): 459-469.

A network of 15 maximal exercise testing facilities in four teaching hospitals, 10 private offices and clinics and an industrial medical department was organized in July 1971 to study prospectively the antecedents of myocardial infarction and sudden cardiac death. Within 18 months 2,332 men were tested: 1,275 healthy “normal” subjects, 97 with prior myocardial infarction, 306 with angina pectoris, 193 with hypertension and 461 with various mutually exclusive combinations of these diagnoses; among these clinical groups were five patients who had had a prior episode of ventricular fibrillation.
Historical, physical and laboratory data were recorded on self-teaching printed forms, with normal, borderline and abnormal responses arranged in three columns. Classification with respect to “unlikely,” “questionable” or “likely” risk of future cardiac events was assessed from the highest tally of items in these columns.
Analysis showed computer-averaged S-T segment responses were more consistent and reliable predictors than visual interpretations. Cardiac manifestations in healthy men varled with age and risk assessment, and in patients with cardiovascular disease varied with diagnosis and natural history of disease. Many significant differences provided insights into mechanisms of impaired cardiac function in relation to type of clinical disease. Testing was responsible for one post-exertional cardiac arrest. Recovery was effected promptly by defibrillation; there was no mortality.

Normal and Abnormal Heart Rate Responses to Exercise

  1. Kirk Hammond and Victor F. Froelicher
    Prog Cardiovasc Dis 1985; XXVII(4) (January/February), pp 27l-296

Of the many factors ultimately important in determining the cardiac output, the heart rate is certainly the easiest to measure. By analysis of the heart rate response to exercise in a variety of disease states we felt that the interrelationships of inotropic state, stroke volume, autonomic dysfunction, and myocardial disease could be clarified. This paper reviews the normal and abnormal heart rate responses to exercise.

The normal heart rate is determined by the frequency of depolarization of specialized cells within the sino-atrial node (S-A node). The S-A node, the vestigal sinus venosus, lies in the posterior portion of the heart near the demarcation between the right atrium and the superior vena cava. In about 80% of humans it receives its primary source of blood from a branch of the right coronary artery. Unlike other myocardial cells, the specialized cells of the S-A node have a slow sodium channel and a low resting potential which give these cells their special property. The slowly rising diastolic depolarization (stage four) leads to a rhythmic slow rising action potential.

The autonomic nervous system plays a key role in the regulation of heart rate (Fig 1). The sympathetic nervous system input to the heart originates in a nucleus in the medulla oblongata. Stimulation of this area with implanted electrodes results in increased heart rate and systemic vascular resistance due to increased sympathetic output. Axons from these nuclei descend to the sympathetic trunk via the intermediolateral columns of the spinal cord. From their synapses in cervical ganglia, postganglionic fibers directly innervate the atrial and ventricular musculature, the S-A node, and the A-V node. The effector neurotransmitter is norepinephrine and the receptors are of the beta adrenergic type. There is evidence from competitive binding studies that the postganglionic fibers are predominantly associated with type I beta receptors. The parasympathetic influence to the S-A node and the myocardium originates from nuclei very near the origin of the sympathetic nerves. From the motor nuclei of the vagus and the nucleus solitarius come fibers that form part of the vagus nerve. These fibers terminate at ganglia in the wall of the heart. The postganglionic cholinergic fibers end mostly near the S-A node and the A-V node; there is little evidence for the distribution of parasympathetic nerves to the ventricular myocardium although cholinergic muscarinic receptors have been characterized. In normal conditions there exists a well balanced autonomic tone influencing the S-A node.

There is a complex interrelation among many systems to determine the autonomic tone at the S-A node (Fig 2). [Arterial mechanoreceptors of the carotid sinus and aortic arch respond to changes in arterial pressure and result in appropriate adjustment in the sympathetic and vagal outflow to the heart and resistance and capacitance vessels. (Reprinted with permission from Shepherd JT, Van Houlte PM: The Human Cardiovascular System, Facts and Concepts. New York, Raven Press, 1979).]

There are cortical inputs to the medullary centers; for example, fear results in tachycardia by this pathway. Visceral afferent inputs increase parasympathetic tone resulting in bradycardia. Several reflexes are present for homeostasis. For example, the baroreflex is important in sensing changes in blood pressure and increasing or decreasing the heart rate via autonomic influences at the S-A node to maintain appropriate cardiac output.

Arterial mechanoreceptors of the carotid sinus and aortic arch respond to changes in arterial pressure and result in appropriate adjustment in the sympathetic and vagal outflow to the heart and resistance and capacitance vessels. (Reprinted with permission from Shepherd JT, Van Houlte PM: The Human Cardiovascular System, Facts and Concepts. New York, Raven Press, 1979).

Although the importance of autonomic influence is well accepted in the usual cardioacceleration to exercise, the role of the recovery or deceleration of heart rate following exercise may not be influenced by autonomic input. Six men were studied after peak treadmill exercise. To assess the contribution of autonomic factors in heart rate recovery, the men were given atropine, propranolol, or both agents. It was found that exponential cardio-deceleration occurred under each experimental condition. They concluded that heart rate recovery after exercise is regulated by changes in venous return mediated through atrial stretch receptors of pacemaker tissue. This study implies that deceleration depends primarily on factors intrinsic to the intact circulation that are independent of autonomic control.

The control of heart rate is complex; autonomic tone, central and peripheral reflexes, hormonal influences, and factors intrinsic to the heart are all important. Although easily measured, the heart rate reflects an integrated physiologic response.

The physiologic response to exercise depends on the type of exercise performed; the two major types are isometric and isotonic. Creating muscle tension with no movement against resistance is a pure form of isometric exercise; this results in increased muscle mass and strength. Isotonic exercise is the repetitive, rhythmic movement of large muscle masses against little resistance, known also as dynamic or aerobic exercise. Although most activities involve degrees of both, running is predominantly dynamic, and weight lifting is predominantly isometric.

Bezucha and colleagues investigated the cardiovascular responses to isometric (static) exercise (leg extension) and compared these to those observed during static-dynamic exercise (one arm cranking) and dynamic exercise (leg cycling) in normal men. Heart rate responses to these three tasks were markedly different with static exercise (holding a 30% of maximum voluntary contraction for 3 minutes) resulting in a mean heart rate of 110 + 6 compared with 164 + 4 beats/min in bicycle exercise at 80% of Vo max. Cardiac outputs were raised in all three activities in a proportional manner: 6.8 + 0.7 for static, 10.8 f 0.7 for arm cranking, and 31.9 + 1.0 L/min for bicycling. Stroke volume did not significantly change in the static or combined static-dynamic exercises. The increases in cardiac output were primarily the result of increases in heart rate. This study demonstrates the predominant pressor response and modest cardio-acceleration of isometric exercise.

Longhurst and coworkers, examined the response to acute and chronic exercise in two groups of athletes who typify the two major types of exercise: long distance runners (dynamic) and weight lifters (isometric). The runners responded to isometric exercise with lower double products than the weight lifters. The end-diastolic volume index (evaluated by echocardiography) in the runners was greater than control subjects both at rest and with exercise. In contrast, the weight lifters’ responses were similar to weight matched controls. Not only is the type of exercise an important determinant of acute physiologic response, but chronic static exercise results in physiologic responses that are no different from the responses of sedentary men.

Dynamic exercise, also called isotonic or aerobic, involves the rapid movement of large muscle masses that results in the need for the body to respond with increased ventilation to increase oxygen consumption. Such exercise is called aerobic since it must be performed by using oxygen. The heart must increase its output and performs flow work rather than pressure work. The response to dynamic muscular exercise consists of a complex series of cardiovascular adjustments designed to:

(1) see that active muscles receive a blood supply appropriate to their metabolic needs;

(2) dissipate the heat generated by active muscles; and,

(3) maintain the blood supply to the brain and the heart.

The regulation of the circulation during exercise involves the four following adaptations?

  • Local
  • Nervous adaptations
  • Humoral adaptations
  • Mechanical adaptations

The relationship of pressure, flow, and resistance in rigid tubes is defined by Poiseuille’s law. This law states that resistance is proportional to pressure divided by flow. Peripheral resistance increases in the tissues that do not function in the performance of the ongoing exercise and decreases in active muscle. The result is a decrease in systemic vascular resistance. While pressure only increases mildly, flow can increase by as much as five times during dynamic exercise. Since flow increases much more than pressure, the result is a decrease in systemic resistance. Another mechanical adaptation occurs when the increasing venous return dilates the left ventricle and cardiac function is enhanced via the Frank-Starling mechanism.

There is a highly predictable relationship between total body oxygen consumption and both the cardiovascular and respiratory responses to exercise (Fig 4). [ (A) The linear relationship between heart rate and oxygen uptake. The data was collected from 86 adult male and female subjects. (B) The linear relationship between cardiac output and oxygen uptake. C The data was collected from 23 adult male and female subjects. (C) The linear relationship between minute ventilation and oxygen uptake. ] The data was collected from 225 subjects.  (Reprinted with permission.) Both parameters increase linearly with increasing oxygen consumption until maximal oxygen consumption is approached.

In summary, the type of exercise is an important determinant of both acute and chronic cardiovascular responses. Isometric exercise can be viewed as a pressure load and dynamic exercise as a volume load to the left ventricle. The acute physiological adjustments to dynamic exercise include peripheral vasodilation in exercising muscle, neural mediated increases in sympathetic tone to the heart and the periphery, the release of catecholamines from the adrenal medulla, and changes in venous return due to mechanical and humoral factors. A linear relationship exists between the consumption of oxygen and cardiac output and minute ventilation such that the work performed is highly correlated with the amount of blood pumped and the oxygen consumed.

An increase in heart rate is a major factor contributing to the exercise-induced increased cardiac output. Bowditch demonstrated that the time interval between beats is a determinant of the force of myocardial contraction. This has been called the frequency-force relationship (Fig 5). [The frequency force relationship is demonstrated by a sudden increase in beat frequency in papillary muscle fixed for isometric contraction. A slow increase in isometric tension results from the change in rate implying in increased contractile state. Each vertical line represents an isometric contraction. (Reprinted with permission of W.B. Saunders.)] The increased tension that accompanies an increased heart rate is the result of increased contractility. Although the mechanism of this phenomenon is not known, it may have to do with calcium availability to contractile elements. Thus an increase in heart rate results in an increase in the force of contraction.

Variations in and Significance of Systolic Pressure During Maximal Exercise (Treadmill) Testing: Relation to Severity of Coronary Artery Disease and Cardiac Mortality

John B. Irving, Robert A. Bruce,, Timothy A. Derouen
Amer J Cardiol 1977; 39: 841-848.

Variations in clinical noninvasive systolic pressure at the point of symptom-limited exercise on a treadmill were examined in six groups of subjects: 5,459 men and 749 women classified into three categories each. Among the men, 2,532 were asymptomatic healthy, 592 were hypertensive and 1,586 had clinical manifestations of coronary heart disease (that is, typical angina pectoris, prior myocardial Infarction or sudden cardiac arrest with resuscitation). Among the women, 244, 158 and 347 were in the corresponding clinical categories. None had had cardiac surgery; all had follow-up status ascertained by periodic mail questionnaires.
Reported deaths were reviewed and classified by three cardiologists; 140 deaths were attributed to coronary heart disease, 118 of them in the men classified as having coronary heart disease. The majority of maximal systolic blood pressure readings were reported to the nearest centimeter rather than millimeter of pressure. Retesting of 156 persons from 1 to 32 months later showed that pressure values agreed within 10 percent in two thirds, the overall mean difference was only 8.6 mm Hg and the correlation at maximal exercise was superior to that of the resting observations just before exercise. Hypertensive patients had a significantly greater body weight than normotensive persons. Among men, the lowest maximal systolic pressure was observed in the group with coronary heart disease; among women, the lowest mean pressure was found in the healthy group. Patients with coronary heart disease were slightly older, and only the women showed a significant correlation in maximal pressure with age. Only 5 percent of the variation in maximal systolic pressure in the patients with coronary heart disease was due to a shortened duration of exercise. Maximal systolic pressures correlated fairly well (r = 0.46 to 0.68 for the various groups) with resting systolic pressure, and this relation was independent of the diagnosis of cardiovascular disease in both men and women. Relations between pressure and the number of stenotic coronary arteries and Impaired ejection fraction at rest were examined in 22 men without and 162 men with coronary artery disease. Lower maximal systolic pressures were often associated with two or three vessel disease or reduced ejection fraction, or both.

The prognostic value of maximal systolic pressure for subsequent death due to coronary heart disease was examined in the men with coronary heart disease. The annual rate of sudden cardiac death decreased from 97.9 per 1,000 men to 25.3 and 6.6 per 1,000 men as the range of maximal systolic pressure increased from less than 140 to 140 to 199 and to 200 mm Hg or more, respectively. Cardiomegaly, Q waves in the resting electrocardiogram and persistent postexertional S-T depression were more common in men with the lowest systolic pressure at maximal exercise.

Circulatory Adjustments to Dynamic Exercise and Effect of Physical Training in Normal Subjects and in Patients With Coronary Artery Disease

Jan Praetorius Clausen
Prog Cardiov Dis 1976; XVIII(6): 459-496

The present paper focuses upon the importance of peripheral circulatory alterations during adjustments to exercise and training. Although training results in central circulatory adaptations and may also improve left ventricular function, the prime importance of such adaptations as regards the circulatory and metabolic response to training will be questioned. The thesis that increased maximal exercise capacity can at least in part be attributed to local alterations in the trained muscles will be presented and analyzed. While it is accepted that maximal oxygen uptake is limited by the blood oxygen transport capacity, it will be postulated that the primary event normally responsible for an enhanced oxygen supply after training is an increased ability to reduce resistance to blood flow in exercising muscles rather than improved performance of the central pump.

adjustment to exercise is limited to factors pertinent to physical training of patients with CAD. More detailed accounts of the normal response to exercise can be found in recent books or reviews.

  1. Astrand, P-O, Rodahl K: Textbook of Work Physiology. New York, McGraw-Hill, 1970
  2. Ekblom B, Hermansen L: Cardiac outputs in athletes. J Appl Physiol 25:619, 1968
  3. Christensen EH: Beitrlge zur Physiologie schwerer kijrperlicher Arbeit. Arbeits physiol 4:470, 1931
  4. Saltin B, Blomqvist G, Mitchell JH, et al: Response to exercise after bed rest and after training. Circulation 38 (Suppl 7): 1, 1968
  5. Clausen JP, Klausen K, Blomqvist G, et al. Central and peripheral circulatory changes after training of the arms or legs. Am J Physiol 225:675, 1973

In connection with patients with CAD, only one type of muscular work is of interest; namely, rhythmic or dynamic exercise, in which a considerable part of the skeletal muscle mass is active. This applies to naturally occurring physical activity. Only these types of activity will be referred to and only at work intensities that can be continued for 3-5 min or more.

Dynamic muscular exercise is characterized by a high metabolic rate in the muscle cells with the skeletal muscle functioning in a manner similar to the myocardium, with regularly alternating contraction and relaxation phases. The mechanical energy expended is grossly proportional to the force and the frequency of contraction, and it is derived from the breakdown of adenosine triphosphate (ATP) and creatine phosphate (CP). Only a limited number of a muscle’s fibers, and thus, of its maximal contractile power, can be used in dynamic work continuing for several minutes. During maximal exercise on a bicycle ergometer with a pedaling frequency of 60 rpm, about 15%-2% of the maximal isometric strength of the quadriceps muscle is mobilized. This is thought related to the fact that skeletal muscle, in contrast to myocardium, is composed of several types of fibers with different enzymatic characteristics.29 Some fibers are similar to cardiac muscle being rich in oxidative intramitochondrial enzymes connected to the citric acid cycle, the fatty acid cycle, and the respiratory chain. These are the classical “red” muscle fibers. At the other end of a continuous spectrum is the typical “white” muscle fiber, with a high content of enzymes necessary for anaerobic glycolysis, but containing few mitochondria. Due to their great capability for aerobic metabolism, red fibers sustain rhythmic contractions for long periods of time, whereas the anaerobic white fibers require longer restitution phases even after short periods of activity.

Oxygen extraction per milliliter of blood perfusing the muscle may increase three- to fourfold, and the enhanced muscle blood flow (MBF) is responsible for the remainder of the augmented oxygen uptake. In human muscle, maximal MBF is in the order of 70-100 ml X 100 g-r X min--1 against a resting value of 2-5 ml X 100 g-r X min--1. The increase in MBF is locally controlled by release of vasodilator metabolites and thereby closely geared to the metabolic demands. Muscle blood flow per unit weight of muscle is closely related to the relative work load; i.e., percentage of maximal work load. The metabolites responsible for the exercise-induced vasodilation and hyperemia in muscle are not yet conclusively identified. The finding that both MBF and ATP-CP depletion are related to the relative work load supports the speculation that split products from high energy phosphates may be involved.

During strenuous exercise, VO2  can attain individually varying maximal values, typically ranging from 2.0 to 6.0 1 02/min. The maximal oxygen consumption (VO2 max) is a highly reproducible measure of a given subject’s capability to perform this type of exercise, and it constitutes a useful physiologic reference standard. The conditions required to obtain VO2 max, and its physiologic implications have recently been reviewed in detail by Rowe and by Hermansen. The VO2 max  for a given type of work is normally achieved at a work intensity that can be sustained for at least 3 min, but will cause complete exhaustion within 5-10 min.  At this intensity of exercise, the cardiovascular functional capacity with respect to increase in cardiac output (Q), widening of systemic arteriovenous oxygen difference (AVDO2), and elevation of heart rate (HR) will be challenged maximally for the given type of exercise. However, the relative contribution of Q and AVDO2.

The above description of the normal central and peripheral circulatory adjustment to exercise can be recapitulated as follows:

During dynamic exercise, Q increases in direct proportion to the augmentation of 30,. The increase in Q is directed to exercising skeletal muscles, to the myocardium and-if exercise is continued for more than approximately 5 min-also to the skin. Blood flow to most “nonexercising” tissues (SBF, RBF,
and noncontracting muscles) is reduced due to a general sympathetic vasoconstriction. At submaximal levels, muscle blood flow per unit tissue,
the degree of peripheral vasoconstriction, the acceleration of HR, and in consequence, the increase in myocardial blood flow and oxygen consumption are all functions of the relative V02 ; i.e., the actual VO2 expressed as a percentage of the highest achievable V02 for the given type of exercise.

Most patients with CAD who have been included in exercise and training studies have had healed myocardial infarction and/or stable angina pectoris and have been between 35 and 65 years of age. Both the aging process and myocardial lesions contribute to the modification of the circulatory response to exercise in this group, as compared to healthy young people. In advanced age-especially after 60 years-the circulation tends to become hypokinetic; i.e., Q/VO2 is reduced.  The decline of Q in l/min is almost the same during submaximal exercise as at rest, and thus the increase in Q with VO2 is essentially the same in older as in younger subjects. Stroke volume is lower at a given VO2 , while arterial blood pressures are higher; Q, HR, and VO2 max decline with aging.

Although patients with angina pectoris often exhibit a more profound impairment of left ventricular function and of working capacity than patients with CAD without angina, there seems not to be any specific differences in their central or peripheral circulatory response to exercise. Accordingly, the abnormalities in hemodynamic adaptations in a patient with angina pectoris are present also at workloads that do not provoke angina pectoris.

From the point of view of an exercise physiologist, the patient with angina pectoris is peculiar in that his capacity for dynamic work is not limited by his total body VO2 max, but by VO2 max in myocardial regions supplied by narrowed coronary arteries. If pain is prevented by prophylactic administration of nitroglycerin, a patient with angina pectoris can exercise longer at a given work load or achieve higher workloads and thus obtain a higher VO2 max.

The circulatory adjustment to exercise in patients with CAD typically differs from that of normal subjects in that the maximal values for Q (and thus for VO2), for HR, and for blood pressures are lower. During submaximal exercise, the relation between Q and VO2 tends to be reduced. Moreover, most of the patients with CAD exhibit signs of left ventricular failure during exercise, including a decrease in SV at higher workloads, reduced myocardial contractility, and increased LVEDp. Nonetheless, the peripheral circulatory regulation in patients with CAD corresponds in principle to that seen in healthy subjects of the same age.

Training changes the different local flows during exercise in such a way that, within the framework of an unchanged or reduced Q, its regional distribution at a given submaximal work load deviates less from that seen at rest: the perfusion of nonworking tissues is relatively greater and the flow to active muscles less elevated. However, this is only valid for exercise performed with trained muscles.

Although the precise mechanism mediating exercise hyperemia is unknown, it seems acceptable that enhanced content of oxidative enzymes enables a reduction in MBF at a given submaximal VO2 . After training, due to the increased capacity for oxidative phosphorylation, ATP and CP in active muscles stabilize at a higher steady state level. At the same time glycolysis occurs at a slower rate, pH is relatively increased, and the concentration of multiple intermediate metabolic products may be lower. In consequence, the intra- and intercellular biochemical milieu-concentrations of electrolytes and osmolality included-is less disturbed as compared to the conditions at rest. Whatever substance or combinations of chemical alterations cause the vasodilation, their extent of change is probably reduced at a given respiratory rate in trained muscle tissue, and the vasodilation is thus diminished.

Training improves exercise tolerance in most patients with angina pectoris. The main part of this effect can be related to the training-induced reduction in HR and SBP that decreases myocardial O2 requirements at a given total body O2 uptake. However, at the same time, higher values for the product of HR and SBP are tolerated before pain is provoked after training, suggesting that training has additional economizing effects on myocardial function or directly improves myocardial O2 supply. As judged from the results obtained in exercise tests, training and nitroglycerin seem almost equally potent in alleviating or preventing angina pectoris on exertion. Beta receptor blockade may be somewhat less efficient, whereas aorto-coronary bypass surgery, when practicable, may be the most efficient treatment of exertional angina available today.

Physical training is efficient in improving exercise capacity in about two thirds of all patients with angina pectoris. Patients with angina pectoris provoked only by exercise will often respond favorably to training, even if their exercise capacity is low.  In contrast, patients who suffer from angina at rest, especially nocturnal attacks, may be less likely to increase their exercise tolerance by training. Accordingly, Hellerstein reports that in patients with more severe coronary arteriosclerosis as assessed from coronary arteriograms and left ventricular function, physical fitness fails to improve from training.

Unfortunately, it appears that the patients who cannot be expected to respond favorably to training are also less likely to improve from other modes of treatment. According to Balcon, only younger patients with normal left ventricular function are prone to achieve substantial improvement in physical working capacity by vein graft surgery. Furthermore, the mortality from the operation is higher in patients with abnormal ventricular function. Thus, the appearance of an apparently efficient surgical intervention has not simplified the selection of treatment.

Characteristics of the Ventilatory Exercise Stimulus

F.M. Bennett and W.E. Fordyce
Respiration Physiology 1985; 59, 55-63

Simple mathematical models were used to quantitatively examine a number of hypotheses concerning the nature of the exercise stimulus. The modelling demonstrated the following for an exercise intensity of 5 times the resting metabolic rate.

(1) During the steady state, a deviation in the coupling between VE and metabolic rate by + 25 % of the value necessary for isocapnia, results in a deviation of Paco2 of + 2 torr from isocapnia.

(2) In the transient phase, a mismatch between VE and Q (and thus CO2 flow) of 50% results in a change of Paco2 of only 1 torr.

(3)When resting Paco2 is changed by 10 torr and it is assumed that the coupling between VE and Paco2 does not change, Paco2 deviates from isocapnia by less than 2 torr.

It is concluded that –

(1) to experimentally test hypotheses of the exercise stimulus requires resolution of small changes in Paco2;

(2)  good regulation of Paco2 does not necessarily imply precise coupling between VE and Vco2;

(3) the ventilatory exercise stimulus need not be a precise function of metabolic rate;

(4) in the steady state, the normal CO2 controller will be very effective in minimizing changes in Paco2 due to a mismatch between ventilation and metabolic rate.

Cardiorespiratory and Metabolic Responses to Positive, Negative and
Minimum-Load Dynamic Leg Exercise

Carl Magnus Hesser, Dag Linnarsson And Hilding Bjurstedt
Respiration Physiology 1977; 30, 5 I-67

Cardiorespiratory and metabolic responses to steady-state dynamic leg exercise were studied in seven male subjects who performed positive and negative work on a modified Krogh cycle ergometer at loads of 0. 16,33,49.98, and 147 W with a pedaling rate of60 rpm.
In positive work, O2 uptake increased with the ergometric load in a parabolic fashion. Net O2 uptake averaged 220 ml*min– 1 at 0 W (loadless pedaling), and was 75 ml* min– 1 lower at the point of physiological minimum load which occurred in negative work at approximately 9 W. The O2 cost of loadless pedaling is for one-third attributed to the work of overcoming elastic and viscous resistance, the remaining part being due mainly to the work of antagonistic muscle contraction in the moving legs. Although at a given Vo2 work rate was much higher in negative than in positive work, corresponding values for VE were similar, suggesting that the mechanical tension in working muscles is of little or no importance in the control of ventilation in steady-state exercise.
Heart rate increased linearly with Vo2 in both positive and negative work, with a steeper slope in negative work. Evidence is presented that none of the current definitions of muscular efficiency yields the true efficiency of muscular contraction in cycle ergometry, net efficiency calculation resulting in too low estimates, and work and delta efficiency calculations in overestimated values in the low-intensity work range, and in underestimated values in the high-intensity range.

The effect of exercise on left ventricular ejection time in patients with hypertension or angina pectoris

James R. Bowlby
Amer Heart J 1979; 97(3): 348-350

Using the method and regression equation of Lewis and associates, the present study confirms their findings in normal men up to the age of 65 years. Despite the significantly higher myocardial oxygen consumption, as measured by the double product, the hypertensive patients responded in a similar fashion. The patients with angina pectoris, however, showed a significantly prolonged post-exercise ejection time.

Cardiac Effects of Prolonged and Intense Exercise Training in Patients With Coronary Artery Disease

Ali A. Ehsani, Wade H. Martin Iii, Gregory W. Heath, Edward F. Coyle
Amer J Cardiol 1982; 50: 246-254

The effects of intense and prolonged exercise training on the heart were studied with echocardiography in eight men with coronary artery disease with a mean age (standard error of the mean) of 52 + 3 years. Training consisted of endurance exercise 3 times/week at 50 to 60 percent of the measured maximal oxygen uptake for 3 months followed by exercise 4 to 5 days/week at 70 to 60 percent of maximal oxygen uptake for 9 months. Maximal oxygen uptake capacity increased by 42 percent (26 + 1 versus 37 + 2 ml/kg per min; p <0.001). Heart rate at rest and submaximal heart rate and systolic blood pressure at a given work rate were significantly lower after training. Systolic blood pressure at the time of maximal exercise increased (145 + 9 before versus 166 + 6 mm Hg after training; probability [p] <0.01). Left ventricular end-diastolic diameter was increased after 12 months of training (from 47 + 1 to 51 + 1 mm; p <0.01. Left ventricular fractional shortening and mean velocity of circumferential shortening decreased progressively in response to graded iisometric handgrip exercise before training but not after training. At comparable levels of blood pressure during static exercise, mean velocity of circumferential shortening was significantly higher after training (0.76 + 0.04 versus 0.96 + 0.07 diameter/set, p <0.01). No improvement in echocardio-graphic or exercise variables was observed over a 12 month period in another group of five patients who did not exercise. Thus the data suggest that prolonged and vigorous exercise training in selected patients with coronary artery disease can elicit cardiac adaptations.

Physical activity and resting pulse rate in older adults: Findings from a randomized controlled trial

Bríain O’Hartaigh, Marco Pahor, Thomas W. Buford, John A. Dodson, et al.
Am Heart J 2014;168:597-604

Background Elevated resting pulse rate (RPR) is a well-recognized risk factor for adverse outcomes. Epidemiological evidence supports the beneficial effects of regular exercise for lowering RPR, but studies are mainly confined to persons younger than 65 years. We set out to evaluate the utility of a physical activity (PA) intervention for slowing RPR among older adults.
Methods A total of 424 seniors (ages 70-89 years) were randomized to a moderate intensity PA intervention or an education-based “successful aging” health program. Resting pulse rate was assessed at baseline, 6 months, and 12 months. Longitudinal differences in RPR were evaluated between treatment groups using generalized estimating equation models, reporting unstandardized β coefficients with robust SEs.
Results Increased frequency and duration of aerobic training were observed for the PA group at 6 and 12 months as compared with the successful aging group (P = 0.001). In both groups, RPR remained unchanged over the course of the 12-month study period (P = .67). No significant improvement was observed (β [SE] = 0.58 [0.88]; P = .51) for RPR when treatment groups were compared using the generalized estimating equation method. Comparable results were found after omitting participants with a pacemaker, cardiac arrhythmia, or who were receiving β-blockers.
Conclusions Twelve months of moderate intensity aerobic training did not improve RPR among older adults. Additional studies are needed to determine whether PA of longer duration and/or greater intensity can slow RPR in older persons.

Autonomic regulation and maze-learning performance in older and younger dults

Karen J. Mathewson, J Dywan, PJ Snyder, WJ Tays, SJ Segalowitz
Biological Psychology 88 (2011) 20– 27
http://dx.doi.org:/10.1016/j.biopsycho.2011.06.003

There is growing evidence that centrally modulated autonomic regulation can influence performance on complex cognitive tasks but the specificity of these influences and the effects of age-related decline in these systems have not been determined. We recorded pre-task levels of respiratory sinus arrhythmia (RSA; an index of phasic vagal cardiac control) and rate pressure produce (RPP; an index of cardiac workload) to determine their relationship to performance on a cumulative maze learning task. Maze performance has been shown to reflect executive error monitoring capacity and non-executive visuomotor processing speed. Error monitoring was predicted by RSA in both older and younger adults but by RPP only in the older group. Non-executive processes were unrelated to either measure. These data suggest that vagal regulation is more closely associated with executive than nonexecutive aspects of maze performance and that, in later life, pre-task levels of cardiac workload also influence executive control.

Sympathovagal Imbalance Contributes to Prehypertension Status and Cardiovascular Risks Attributed by Insulin Resistance, Inflammation, Dyslipidemia and Oxidative Stress in First Degree Relatives of Type 2 Diabetics

Gopal Krushna Pal, C Adithan, P Hariharan Ananthanarayanan, Pravati Pal, et al.
PLoS OME 2013; 8(11), e78072 http://dx.doi.org:/10.1371/journal.pone.0078072

Background: Though cardiovascular (CV) risks are reported in first-degree relatives (FDR) of type 2 diabetics, the pathophysiological mechanisms contributing to these risks are not known. We investigated the association of sympathovagal imbalance (SVI) with CV risks in these subjects.
Subjects and Methods: Body mass index (BMI), basal heart rate (BHR), blood pressure (BP), rate-pressure product (RPP), spectral indices of heart rate variability (HRV), autonomic function tests, insulin resistance (HOMA-IR), lipid profile, inflammatory markers, oxidative stress (OS) marker, rennin, thyroid profile and serum electrolytes were measured and analyzed in subjects of study group (FDR of type 2 diabetics, n = 72) and control group (subjects with no family history of diabetes, n = 104).
Results: BMI, BP, BHR, HOMA-IR, lipid profile, inflammatory and OS markers, renin, LF-HF (ratio of low-frequency to high frequency power of HRV, a sensitive marker of SVI) were significantly increased (p,0.0001) in study group compared to the control group. SVI in study group was due to concomitant sympathetic activation and vagal inhibition. There was significant correlation and independent contribution of markers of insulin resistance, dyslipidemia, inflammation and OS to LF-HF ratio. Multiple-regression analysis demonstrated an independent contribution of LF-HF ratio to prehypertension status (standardized beta 0.415, p,0.001) and bivariate logistic-regression showed significant prediction (OR 2.40, CI 1.128–5.326, p = 0.002) of LF-HF ratio of HRV to increased RPP, the marker of CV risk, in study group.
Conclusion: SVI in FDR of type 2 diabetics occurs due to sympathetic activation and vagal withdrawal. The SVI contributes to prehypertension status and CV risks caused by insulin resistance, dyslipidemia, inflammation and oxidative stress in FDR of type 2 diabetics.

Exercise prescription for patients with type 2 diabetes and pre-diabetes: A position statement from Exercise and Sport Science Australia

Matthew D. Hordern, DW Dunstan, JB Prins, MK Baker, et al.
Journal of Science and Medicine in Sport 15 (2012) 25–31
http://dx.doi.org:/10.1016/j.jsams.2011.04.005

Type 2 diabetes mellitus (T2DM) and pre-diabetic conditions such as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) are rapidly increasing in prevalence. There is compelling evidence that T2DM is more likely to develop in individuals who are insufficiently active. Exercise training, often in combination with other lifestyle strategies, has beneficial effects on preventing the onset of T2DM and improving glycaemic control in those with pre-diabetes. In addition, exercise training improves cardiovascular risk profile, body composition and cardiorespiratory fitness, all strongly related to better health outcomes. Based on the evidence, it is recommended that patients with T2DM or pre-diabetes accumulate a minimum of 210 min per week of moderate-intensity exercise or 125 min per week of vigorous intensity exercise with no more than two consecutive days without training. Vigorous intensity exercise is more time efficient and may also result in greater benefits in appropriate individuals with consideration of complications and contraindications. It is further recommended that two or more resistance training sessions per week (2–4 sets of 8–10 repetitions) should be included in the total 210 or 125 min of moderate or vigorous exercise, respectively. It is also recommended that, due to the high prevalence and incidence of comorbid conditions in patients with T2DM, exercise training programs should be written and delivered by individuals with appropriate qualifications and experience to recognise and accommodate comorbidities and complications.

Estimation of the Ejection Fraction in Patients with Myocardial Infarction Obtained from the Combined Index of Systolic and Diastolic Left Ventricular Function: A New Method

Jorge A. Lax, Alejandra M. Bermann, Tomás F. Cianciulli, Luis A. Morita, et al.
J Am Soc Echocardiogr 2000;13:116-23.

The index of myocardial performance combining systolic and diastolic time intervals (Index) is a useful method, already explained in past studies, that offers new values that have not been widely known among clinical cardiologists. The aim of this study is to obtain from this Index a measurement of the ejection fraction (EF), which is a very well-known value.
The study involved 97 patients with myocardial infarction, 55 of whom were studied retrospectively (group A, aged 46-62 years, 50 men) to obtain and test the formula EF = 60 – (34 × Index). The second group (group B, aged 47-63 years, 40 men) included 42 patients who were evaluated prospectively. The EF obtained was compared with that reached through the use of radionuclide angiography (EF-RNA).
The Index was obtained through the use of the formula (a – b)/b, where a is the interval between cessation and onset of the mitral inflow, and b is the ejection time. In group A the EF obtained by the Index (EF-Index) was 37.5% ± .8%, and the EF-RNA was 37.7% ± 11% (r = 0.76). In group B the EF-Index was 41.6% ± 7%, and the EF-RNA was 41.2% ± 10% (r = 0.75).
Conclusion: Through the new formula described here it is possible to obtain a reliable measurement of the EF in patients with myocardial infarction, a well known and extremely useful value, especially for those patients with poor acoustic windows.

HCN channels: new roles in sinoatrial node function

Christian Wahl-Schott, Stefanie Fenske and Martin Biel
Current Opinion in Pharmacology 2014, 15:83–90
http://dx.doi.org/10.1016/j.coph.2013.12.005

Hyperpolarization-activated cyclic nucleotide gated (HCN) channels pass a cationic current (Ih/If) that crucially contributes to the slow diastolic depolarization (SDD) of sinoatrial pacemaker cells and, hence, is a key determinant of cardiac automaticity and the generation of the heart beat. There is growing evidence, that HCN channel functions in the sinoatrial node (SAN) are not restricted to impulse formation but are also required for impulse propagation. In addition, HCN channels are involved in coordination and maintenance of sinoatrial network activity and, hence, are crucial for stabilizing cardiac rhythmicity. In the present review we will outline these new concepts.

In this review we will focus on HCN channel functions in the sinoatrial node beyond the established concepts described above. We will outline recent advances involving the characterization of the HCN1-deficient mouse line (HCN1-/- mouse) which have provided evidence that HCN channels are required for impulse propagation and the precision of the heart beat [19**]. Furthermore, we show how these properties can be generalized across the other HCN channel subtypes in the sinoatrial node.

19** Fenske S, Krause SC, Hassan SI, Becirovic E, Auer F, Bernard R, Kupatt C, Lange P, Ziegler T, Wotjak CT et al.: Sick sinus syndrome in HCN1-deficient Mice. Circulation 2013. Epub 2013 Nov 11.
First demonstration of a functional relevance of HCN1 channels in the murine sinoatrial node. The authors demonstrate that mice lacking the pacemaker channel HCN1 display congenital sinoatrial node dysfunction characterized by bradycardia, sinus dysrhythmia, prolonged sinoatrial node recovery time, increased sinoatrial conduction time and recurrent sinus pauses. As a consequence of sinoatrial node dysfunction HCN1-deficient mice display a severely reduced cardiac output.

Recent studies indicate that the role of cardiac HCN channels extends well beyond generation of pacemaker potentials. In addition to being merely ‘pacemaker channels’, HCN channels are important for sinoatrial impulse propagation, cardiac excitability and for the precision of the heartbeat. Furthermore, cardiac HCN channels are involved in the repolarization process of heart ventricles [56**,57]. It will be important to consider the full spectrum of these diverse cardiac functions when exploring agents acting on HCN channels for a specific clinical purpose such as reduction of heart rate.

56.** Fenske S, Mader R, Scharr A, Paparizos C, Cao-Ehlker X, et al.: HCN3 contributes to the ventricular action potential waveform in the murine heart. Circ Res 2011, 109:1015-1023.
First study demonstrating a functional role of HCN3 channels in the heart. Using HCN3-deficient mouse line the authors show that HCN3 together with other members of the HCN channel family confers a depolarizing background current that regulates ventricular resting potential and counteracts the action of hyperpolarizing potassium currents in late repolarization.
57. Fenske S, Krause S, Biel M, Wahl-Schott C: The role of HCN channels in ventricular repolarization. Trends Cardiovasc Med 2011, 21:216-220.

Roles of HCN1 channels for sinoatrial impulse conduction (source-sink relation) The primary impulse initiating the heart beat is generated in the leading pacemaker cell(s) of the sinoatrial node. Once the leading pacemaker cell(s) reaches the threshold for L-type Ca2+ channels an action potential is generated. Since pacemaker cells are interconnected via gap junctions, the impulse is conducted through the sinoatrial network and to the atrium. During impulse propagation the source cell (the cell which first reached AP threshold and is firing the action potential) charges the neighboring cell (sink), in which the membrane potential is below threshold (Figure 1) [24*]. Impulse propagation depends on the source-sink relation [24*, 25–29]. HCN1 deletion increases the sinoatrial conduction time suggesting the existence of a source sink mismatch in the HCN1-deficient mouse [19**].

Role of HCN1 channels for impulse formation and impulse conduction in the sinoatrial node. Schematic pacemaker potential in sinoatrial node cells of wild type (a) and HCN1-/- mice.
(b) HCN channels contribute to the slow diastolic depolarization. In the absence of HCN1 the slope of SDD isdecreased and the time to threshold for an action potential increased. HCN channels decrease the maximal diastolic potential (MDP). In the absence of HCN1 the MDP is increased. This results in an increased distance and time to threshold for an action potential and a decrease in impulse propagation.  [SDD: slow diastolic depolarization; MDD: maximal diastolic depolarization; Vthr: threshold potential for the generation of an action potential.]
(c) Direction of intracellular and extracellular current flow during propagation of an action potential from depolarized (source) to resting cells (sink).
(d)Source sink relationship in propagation. Charge from excited cells (source) flows into unexcited cell (sink) and provides the charge to depolarize them to activation threshold. Arrows and dotted lines indicate changes observed in HCN1-/- mice of parameter indicated leading to source sink mismatch and prolonged sinoatrial conduction. Modified from [24*].

24.* Spector P: Principles of cardiac electric propagation and their implications for re-entrant arrhythmias. Circ Arrhythm Electrophysiol 2013, 6:655-661.
The authors provide an excellent review of the principles of impulse propagation in relation to arrhythmia.

HCN1 channels increase the temporal and spatial precision of impulse formation in sinoatrial node

HCN1 channels increase the temporal and spatial precision of impulse formation in sinoatrial node

HCN1 channels increase the temporal and spatial precision of impulse formation in sinoatrial node.
(a) Schematic of the sinoatrial node. Atrial cells invaginate into the central sinoatrial node. Putative localization of HCN1 channels at contact interface between strands of atrial myocytes which extend into the central SAN and sinoatrial node pacemaker cells. Green: autonomous innervation. HCN1 channels dampen network noise generated by neighboring pacemaker cells in the sinoatrial network, by invading hyperpolarization of atrial cells and by autonomous regulation. SAN: sinoatrial node, RA: right atrium, CT: crista terminalis.
(b) Model of sinoatrial node function (for detail see text). Note that individual cells display different phases and slightly different periods.

Pharmacological inhibition of cardiac HCN channels

HCN channels have emerged as interesting targets for the development of drugs that lower the heart rate. Ivabradine is the first and currently the only clinically approved compound that specifically targets HCN channels. The therapeutic indication of ivabradine is the symptomatic treatment of chronic stable angina pectoris in patients with coronary artery disease with a normal sinus rhythm (for details see [48], the international trial on the treatment of angina with ivabradine vs. atenolol (INITIATIVE) trial (n = 939) [49] and the antianginal efficacy and safety of the association of the Ih/If current inhibitor ivabradine with a beta-blocker (ASSOCIATE) study (n = 889) [50]).

The Role of HCN Channels in Ventricular Repolarization

Stefanie Fenske, Stefanie Krause, Martin Biel, and Christian Wahl-Schott
Trends Cardiovasc Med 2011; 21:216-220
PII S1050-1738(12)00143-0

Hyperpolarization-activated cyclic nucleotide gated (HCN) channels pass a cationic current (Ih/If) that crucially contributes to the slow diastolic depolarization (SDD) of sinoatrial pacemaker cells and, hence, is a key determinant of cardiac automaticity and the generation of the heartbeat. However, there is growing evidence that HCN channels are not restricted to the spontaneously active cells of the sinoatrial node and the conduction system but are also present in ventricular cardiomyocytes that produce an action potential lacking SDD. This observation raises the question of the principal function(s) of HCN channels in working myocardium. Our recent analysis of an HCN3-deficient (HCN3–/–) mouse line has shed new light on this central question.

We propose that HCN channels contribute to the ventricular action potential waveform, specifically during late repolarization. In this review, we outline this new concept.

In the late 1970s, the hyperpolarization activated current (Ih/If) was discovered and characterized in sinoatrial node cells (Brown and Difrancesco 1980). This current displays several unique biophysical properties: activation upon hyperpolarization and deactivation by depolarization, with a small but substantial degree of activation at resting potentials typically observed in sinoatrial node pacemaker cells (–60 to –50 mV) and ventricular cells (–85 to –75 mV); shift of the activation curve to more positive potentials by cAMP;  block by millimolar concentrations of external Cs+; and permeability for Na+ and K+ions with a reversal potential near –35 mV.

  • HCN3 Is a Component of Ventricular Ih
  • HCN Channels Prolong Action Potentials During Late Repolarization
  • HCN3 Forms Background Channels That Do Not Deactivate During the Action Potential
  • HCN channels need to be open at the resting membrane potential;
    (2) HCN channels remain open during the entire time course of the action potential—de novo opening of HCN channels during the AP does not occur because these channels are activated by hyperpolarization and depolarization decreases open probability; and
    (3) a driving force is needed to sustain an HCN-mediated current during the AP. A detailed analysis of the functional properties of heterologously expressed HCN3 channels revealed that these three prerequisites are met.

Neurophysiology of HCN channels: From cellular functions to multiple regulations

Chao He, Fang Chen, Bo Li, Zhian Hu
Progress in Neurobiology 112 (2014) 1–23
http://dx.doi.org/10.1016/j.pneurobio.2013.10.001

Hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels are encoded by HCN1-4 gene family and have four subtypes. These channels are activated upon hyperpolarization of membrane potential and conduct an inward, excitatory current Ih in the nervous system. Ih acts as pacemaker current to initiate rhythmic firing, dampen dendritic excitability and regulate presynaptic neurotransmitter release. This review summarizes recent insights into the cellular functions of Ih and associated behavior such as learning and memory, sleep and arousal. HCN channels are excellent targets of various cellular signals to finely regulate neuronal responses to external stimuli. Numerous mechanisms, including transcriptional control, trafficking, as well as channel assembly and modification, underlie HCN channel regulation. In the next section, we discuss how the intracellular signals, especially recent findings concerning protein kinases and interacting proteins such as cGKII, Ca2+/CaMKII and TRIP8b, regulate function and expression of HCN channels, and subsequently provide an overview of the effects of neurotransmitters on HCN channels and their corresponding intracellular mechanisms. We also discuss the dysregulation of HCN channels in pathological conditions. Finally, insight into future directions in this exciting area of ion channel research is provided.

The hyperpolarization-activated current, Ih, was first observed in sino-atrial node tissue in 1976 and later was identified in rod photoreceptors and hippocampal pyramidal neurons (Noma and Irisawa, 1976). Due to its unique properties, particularly the activation upon hyperpolarization of the membrane potential, Ih has been also termed If (f for funny) or Iq (q for queer). The hyperpolarization-activated cyclic nucleotide-gated (HCN) cation ion channels underlying Ih were discovered in the late 1990s and subsequently, the genes encoding these channels were identified, which enable the expression of HCN channels in heterologous systems.

HCN channels belong to the superfamily of voltage-gated pore loop channels with four pore-forming subunits (HCN1-4) encoded by the HCN1-4 gene family in mammals (Robinson and Siegelbaum, 2003). Each subunit has six transmembrane helices (S1–S6), with the positively charged voltage sensor (S4) and the pore region carrying the GYG motif between S5 and S6, which forms the ion selectivity filter (Macri et al., 2012). Following S6 is the 80-residue C-linker comprising six a-helices (A0–F0) and the cyclic nucleotide binding domain (CNBD). The CNBD consists of three a-helices (A–C) and a b-roll between the A- and B-helices (Fig. 1) (Biel et al., 2009; Wahl-Schott and Biel, 2009; Wicks et al., 2011). Together, the C-linker and CBND can be referred to as the ‘‘cAMP-sensing domain’’ (CSD) because they are of functional importance for the cAMP-induced positive shift of the voltage-dependent activation of HCN channels. The crystal structure of CSD has been elucidated at an atomic resolution, but a high-resolution structure of the transmembrane core remains unsolved.

Structure of HCN channels

Structure of HCN channels

Structure of HCN channels. Left: one subunit is composed of six transmembrane segments (S1–S6), with the positive charged voltage sensor (S4) and the pore region carrying the GYG motif between S5 and S6. The C-terminal of HCN channels is composed of the C-linker and the cyclic nucleotide-binding domain (CNBD) which mediates their responses to cAMP. The C-linker consists of six a-helices: A0 to F0 . The CNBD follows the C-linker domain and consists of a-helices A–C with a b-roll between the A- and B-helices. Right: the four subunits assemble in homomeric or heteromeric tetramer configurations in vivo.

Regulatory mechanisms of Ih function by the small molecules, protein kinases and interacting proteins.

Regulatory mechanisms of Ih function by the small molecules, protein kinases and interacting proteins.

Regulatory mechanisms of Ih function by the small molecules, protein kinases and interacting proteins. Black arrows indicate known sites of HCN channels interaction with small molecules, protein kinases and interacting proteins. Broken lines indicate the speculated interaction sites. Filamin A interacts with HCN1 via a region of 22 amino acids located downstream from the CNBD. Tamalin and Mint2 bind to the CNBD-downstream sequence of HCN2. The binding of the PDZ domain of S-SCAM occurs at the cyclic nucleotide-binding domain (CNBD) and the CNBD downstream sequence of the carboxy-terminal tail. CNBD, cyclic nucleotide binding domain; SNL, C-terminal tripeptide of HCN1, HCN2 and HCN4.

modulation of HCN channels by neurotransmitters and associated intracellular signal pathways

modulation of HCN channels by neurotransmitters and associated intracellular signal pathways

The modulation of HCN channels by neurotransmitters and associated intracellular signal pathways. Glutamate (Glu) activates N-methyl-D-aspartate receptors (NMDARs) and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) which results in the Ca2+ influx and subsequently activates calcium calmodulin kinase (CaMKII). CaMKII increases channels surface expression through the interacting protein TRIP8b (1a-4) or reduces the HCN1 gene transcription via Neuronal Restrictive Silencing Factor (NRSF) in pathological conditions. Glu, norepinephrine (NE, in rats), 5-hydroxytryptamine (5-HT) and triphosphate (ATP) bind to specific G-coupled receptors and modulate the activity of HCN channels via the PLC-PKC or p38-MAPK signaling pathways. Activation of PKC suppresses the activation of HCN channels, whereas p38-MAPK causes a positive shift of HCN channels voltage-dependent activation. Adenosine, NE (in monkey), 5-HT, dopamine (DA) and Ach (acetylcholine) bind to Gs- or Gi coupled receptors. Gs or Gi oppositely control the activity of adenylate cyclase (AC), which catalyzes the ATP to cAMP. cAMP could shift the HCN channels voltage-dependent activation to positive direction and accelerate the kinetics of channels activation. Nitric oxide (NO) interacts with soluble guanylyl cyclase (GC) and thus increases the intracellular concentration of cGMP, which induces a positive shift of HCN channels voltage-dependent activation. Sharp and blunted arrows represent the positive and negative regulation, respectively. Broken lines indicate the speculated signal pathway.

Ultimately, the study of the HCN channels will provide an overall picture underlying the real-time in vivo regulation of the function and expression of HCN channels to fulfill complex functions in different contexts.

Oxygen uptake kinetics during high-intensity arm and leg exercise

Katrien Koppo, Jacques Bouckaert, Andrew M. Jones
Respiratory Physiology & Neurobiology 133 (2002) 241-250
PII: S1569 – 9048 ( 02 ) 00184 – 2

The purpose of the present study was to examine the oxygen uptake kinetics during heavy arm exercise using appropriate modelling techniques, and to compare the responses to those observed during heavy leg exercise at the same relative intensity. We hypothesized that any differences in the response might be related to differences in muscle fiber composition that are known to exist between the upper and lower body musculature. To test this, ten subjects completed several bouts of constant-load cycling and arm cranking exercise at 90% of the mode specific ˙VO2 peak. There was no difference in plasma [lactate] at the end of arm and leg exercise. The time constant of the fast component response was significantly longer in arm exercise compared to leg exercise (mean ­+ S.D., 489 +12 vs. 219 + 5 sec; P < 0.01), while the fast component gain was significantly greater in arm exercise (12.19 + 1.0 vs. 9.29 + 0.5 ml min-1 W-1; P < 0.01). The ˙VO2 slow component emerged later in arm exercise (1269 + 27 vs. 959 + 20 sec; P < 0.01) and, in relative terms, increased more per unit time (5.5 vs. 4.4% min-1; P < 0.01). These differences between arm crank and leg cycle exercise are consistent with a greater and/or earlier recruitment of type II muscle fibers during arm crank exercise.

Probability and magnitude of response to cardiac resynchronization therapy according to QRS duration and gender in nonischemic cardiomyopathy and LBBB

Niraj Varma, Mahesh Manne, Dat Nguyen, …, Patrick Tchou
Heart Rhythm 2014; 11: 1139–1147
http://dx.doi.org/10.1016/j.hrthm.2014.04.001

BACKGROUND QRS morphology and QRS duration (QRSd) determine cardiac resynchronization therapy (CRT) candidate selection but criteria require refinement.
OBJECTIVE To assess CRT effect according to QRSd, treated by dichotomization vs a continuous function, and modulation by gender.
METHODS Patients selected were those with New York Heart Association classIII/IV heart failure and with left bundle branch block and nonischemic cardiomyopathy (totest “pure” CRT effect) with pre-and post- implant echocardiographic evaluations. Positive response was defined as increased left ventricular ejection fraction (LVEF) post-CRT.
RESULTS In 212 patients (LVEF 19% +  7.1%; QRSd 160 + 23 ms; 105 (49.5%) women), CRT increased LVEF to 30% + 15% (P < .001) during a median follow-up of 2 years. Positive response occurred in 150 of 212 (71%) patients. Genders did not differ for QRSd, pharmacotherapy, and comorbidities, but response to CRT among women was greater: incidence 84% (88of105) in women vs 58% (62of107) in men (P < .001); increase in LVEF 15%+ 14% vs 7.2% + 13%, respectively (P < .001). Overall, the response rate was 58% when QRSd <150 ms and 76% when QRSd > 150 ms (P <.009). This probability differed between genders: 86% in women vs 36% in men (P < .001) when QRSd <150 ms and 83% vs 69%, respectively, when QRSd >150 ms (P < .05). Thus, female response rates remained high whether QRSd was < 150 ms >150 ms (86% vs 83%; P = .77) but differed in men (36% vs 69%; P < .001). With QRSd as a continuum, the CRT-response relationship was nonlinear and significantly different between genders. Female superiority at shorter QRSd inverted with prolongation > 180 ms.
CONCLUSION The QRSd-CRT response relationship in patients with heart failure and with left bundle branch block and non-ischemic cardiomyopathy is better  described by a sex-specific continuous function and not by dichotomization by 150ms, which excludes a large proportion of women with potentially favorable outcome.

Comparison of eterminants Myocardial Oxygen Consumption During Arm and Leg Exercise in Normal Persons

Gary J. Balady, et al.  Am J Cardiol 1985; 57: 1385-87.

The effects of arm exercise on myocardiai oxygen consumption are not well understood; they may differ from the effects of leg exercise. Previous studies have shown that the ischemic threshold is higher in patients performing arm exercise and leg exercise at the same heart rate-blood pressure product. The contribution of other determinants of myocardiai oxygen consumption-left ventricular (LV) peak meridional systolic wail stress and contractility-to these observed differences were studied.
Thirty healthy subjects exercised to the same peak rate-pressure product during dynamic upper- and lower-extremity exercise. Peak workload was lower
during arm exercise (100 + 16 W) leg exercise (170 + 21 W, p < 0.001). LV wail stress did not differ during either form of exercise (197 + 44 vs 204 + 33 dynes/cm2 X 103, arm vs leg, respectively). This was also true of contractility as assessed by the velocity of circumferential fiber shortening (2.6 + 0.6 vs 2.5 + 0.4 circ/s, arm vs leg, respectively) and the preejection period/LV ejection time ratio (0.33 + 0.11 vs 0.31 + 0.07, arm vs leg, respectively). Normal subjects exercising to a similar rate-pressure product showed the same levels at LV wail stress and contractility for arm and leg exercise despite the lower rkioad performed with arm exercise.

Anti-hypertensive effect of radiofrequency renal denervation in spontaneously hypertensive rats

Takeshi Machino, N Murakoshi, A Sato, …, T Hoshi, T Kimura, K Aonuma
Life Sciences 110 (2014) 86–92 http://dx.doi.org/10.1016/j.lfs.2014.06.015

Aims: We aimed to investigate the anti-hypertensive effect of radiofrequency (RF) renal denervation (RDN) in an animal model of hypertension.           Materials and methods: RF energy was delivered to bilateral renal arteries through a 2 Fr catheter with opening abdomen in 8 spontaneously hypertensive rats (SHRs) and 8 Wistar–Kyoto rats (WKYs). Sham operation was performed in other 8 SHRs and 8 WKYs. Blood pressure (BP), heart rate (HR), and urinary norepinephrine excretion were followed up for 3 months. Plasma and renal tissue concentrations of norepinephrine and plasma renin activity were measured 3 months after the procedure. The RDN was confirmed by a decrease in renal tissue norepinephrine.
Key findings: RF-RDN restrained a spontaneous rise in systolic BP (46 ± 12% increase from 158 ± 8 to 230 ± 14 mmHg vs. 21 ± 18% increase from 165 ± 9 to 197 ± 20 mmHg, p= 0.01) and diastolic BP (55 ± 27% increase from 117 ± 9 to 179 ± 23 mmHg vs. 28 ± 13% increase from 120 ± 7 to 154 ± 13 mm Hg, p= 0.04) in SHRs; however, WKYs were not affected. Although there were no changes in HR and systemic norepinephrine, the renal tissue norepinephrine was decreased by RF-RDN in both SHR (302±41 vs. 159±44 ng/g kidney, p b 0.01) and WKY (203 ± 33 vs. 145 ± 26 ng/g kidney, p= 0.01). Plasma renin activity was reduced by the RF-RDN only in SHR (35.3 ± 9.5 vs. 21.4 ±  8.6 ng/mL/h, p < 0.01).
Significance: RF-RDN demonstrated an anti-hypertensive effect with a reduction of renal tissue norepinephrine and plasma renin activity in SHR.

Effectiveness of Renal Denervation Therapy for Resistant Hypertension: A Systematic Review and Meta-Analysis

Mark I. Davis, KB Filion, D Zhang, MJ Eisenberg, …, EL Schiffrin, D Joyal
J Am Coll  Cardiol 2013; 62(3): 231-241.
http://dx.doi.org/10.1016/j.jacc.2013.04.010

Objectives This study sought to determine the current effectiveness and safety of sympathetic renal denervation (RDN) for resistant hypertension.               Background RDN is a novel approach that has been evaluated in multiple small studies.
Methods We performed a systematic review and meta-analysis of published studies evaluating the effect of RDN in patients with resistant hypertension. Studies were stratified according to controlled versus uncontrolled design and analyzed using random-effects meta-analysis models.                                    Results We identified 2 randomized controlled trials, 1 observational study with a control group, and 9 observational studies without a control group. In controlled studies, there was a reduction in mean systolic and diastolic blood pressure (BP) at 6 months of –28.9 mm Hg (95% confidence interval [CI]: –37.2 to –20.6 mm Hg) and –11.0 mm Hg (95% CI: –16.4 to –5.7 mm Hg), respectively, compared with medically treated patients (for both, p < 0.0001). In uncontrolled studies, there was a reduction in mean systolic and diastolic BP at 6 months of –25.0 mm Hg (95% CI: –29.9 to –20.1 mm Hg) and –10.0 mm Hg (95% CI: –12.5 to –7.5 mm Hg), respectively, compared with pre-RDN values (for both, p < 0.00001). There was no difference in the effect of RDN according to the 5 catheters employed. Reported procedural complications included 1 renal artery dissection and 4 femoral pseudoaneurysms.
Conclusions RDN resulted in a substantial reduction in mean BP at 6 months in patients with resistant hypertension. The decrease in BP was similar irrespective of study design and type of catheter employed. Large randomized controlled trials with long-term follow-up are needed to confirm the sustained efficacy and safety of RDN.

Effects of renal denervation on the development of post-myocardial infarction heart failure and cardiac autonomic nervous system in rats

Jialu Hu, Yan Yan, Qina Zhou, Meng Ji, Conway Niu, Yuemei Hou, Junbo Ge
Intl J Cardiol 172 (2014) e414–e416 http://dx.doi.org/10.1016/j.ijcard.2013.12.254

Prior studies indicated that radiofrequency renal denervation (RD) had beneficial effects on post-myocardial infarction (MI) heart failure (HF) in rats. In this study we aimed to assess its effects on cardiac autonomic nervous system (CANS) which might be one of the most important mechanisms of RD’s therapeutic effect on post-MI HF and determine the best timing for RD.

One hundred Wistar rats were randomly assigned into five experimental groups: MI group (n = 20), RD group (n = 20), MI-1d + RD group (RD performed one day post-MI, n = 20), MI-4w + RD group (RD performed four weeks post-MI, n = 20), and N group (control group, n = 20).MI was produced through ligation of the anterior descending artery. RD was performed through stripping of the renal nerves. The experimental design and implementation were conducted in accordance with animal welfare guidelines.

Eight weeks post-MI, significant improvements were observed in both MI-1d + RD and MI-4w + RD groups compared to the MI group, that include

(1) improved left ventricular (LV) function and hemodynamics with increased water and sodium excretion;
(2) decreased plasma and renal tissue norepinephrine levels while tissue norepinephrine content increased in myocardium;
(3) increased β1-receptor in myocardium and improved heart rate variability;  (4) decreased plasma renin, angiotensin II, aldosterone, BNP and endothelin levels.

More therapeutic effects were found in the MI-1d + RD group than the MI-4w + RD group.

Firstly, our study showed that RD attenuated the remodeling of CANS and modulated its activities. RD leads to preservation of β1 receptors content along with the β1 mRNA expression in noninfarcted cardiac tissue in this HF model (Fig. 1). This correlated with an improvement in heart function and cardiac remodeling. HRV is a sensitive marker for the CANS. RD led to a slower HR and higher SDNN in both intervention groups.

Secondly, we found that RD blocked both peripheral and central RAAS and sympathetic nervous system (SNS) at the same time. And this may answer the question how RD exerted effect on CANS. In our study RD restores renin, angiotensin II, and aldosterone to near normal levels. This not only explains the increase in sodium and water excretion, but also confirms that RD blocks renal RAAS via blockage of the efferent renal sympathetic nerves which is consistent with our previous study.

Thirdly, early RD, performed one day post-MI, resulted in greater excretion of urinary sodium, lower circulating BNP and ET-1 levels compared to late interventions (four weeks post-MI). This suggests that RD performed in the acute phase of MI may not only reverse cardiac remodeling but also has a preventive effect against the development of HF, as what was observed with β-blockers. RD alleviated cardiac preload and afterload by increasing water and sodium retention, blocking cardiac sympathetic activation and decreasing a variety of vasomotor factors which may lead to alleviated acute and chronic ischemia of the heart.

RD improves hemodynamics, decreases neuro-hormonal activations, modulates cardiac autonomic activities, and attenuates LV remodeling in HF. Early intervention appears to have greater beneficial effects on cardiac functional recovery and reverse remodeling after myocardial injury. Circulating neuro-hormones may be effective indicators to evaluate the therapeutic effect of RD on HF. Our data suggested that RD is a safe, non-pharmaceutical treatment of HF after cardiac injury, with unique benefits in stabilizing cardiac autonomic activity and remodeling post-MI.

The cardiac pacemaker current

Mirko Baruscotti, Andrea Barbuti, Annalisa Bucchi
Journal of Molecular and Cellular Cardiology 48 (2010) 55–64
http://dx.doi.org:/10.1016/j.yjmcc.2009.06.019

In mammals cardiac rate is determined by the duration of the diastolic depolarization of sinoatrial node (SAN) cells which is mainly determined by the pacemaker If current. f-channels are encoded by four members of the hyperpolarization-activated cyclic nucleotide-gated gene (HCN1–4) family. HCN4 is the most abundant isoform in the SAN, and its relevance to pacemaking has been further supported by the discovery of four loss-of-function mutations in patients with mild or severe forms of cardiac rate disturbances. Due to its selective contribution to pacemaking, the If current is also the pharmacological target of a selective heart rate-reducing agent (ivabradine) currently used in the clinical practice. Albeit to a minor extent, the If current is also present in other spontaneously active myocytes of the cardiac conduction system (atrioventricular node and Purkinje fibres). In working atrial and ventricular myocytes f-channels are expressed at a very low level and do not play any physiological role; however in certain pathological conditions over-expression of HCN proteins may represent an arrhythmogenic mechanism. In this review some of the most recent findings on f/HCN channels contribution to pacemaking are described.

Cardiac pacemaking originates in the sinoatrial node (SAN) as a consequence of spontaneous firing of rhythmic action potentials generated by specialized myocytes. Although the electrical behavior of a typical SAN cell differs in several aspects from that of a working myocyte, the functional hallmark can be precisely identified in the events that take place during the diastolic interval. During this phase atrial and ventricular myocytes rest in a standby-like condition at a stable voltage (∼−80 mV); a quite different situation characterizes SAN cells, where the cell potential slowly creeps up from the
maximum diastolic potential of about −60 mV to the threshold for the ignition of a new action potential. Since this time interval sets the pace of the heart, this phase is named “pacemaker depolarization”. Given the large spectrum of heart rates observed in mammals the duration of this phase can vary substantially, however the voltage range encompassed is extremely constant and roughly extends from −60 to−40 mV . To sustain this phase several ionic currents and pumps enter in action at variable times and voltages, and this complexity allows for a highly flexible system since the chronotropic fine tuning operated by neuro-hormonal regulators can target different effectors.

In this review we will focus on the If current which is responsiblefor initiating the diastolic depolarization of SAN cells. Due to its fundamental role and its unusual characteristics of being activated in hyperpolarization, this current was named “pacemaker current” or “funny” (If) current. The unique property of a reverse voltage dependence, together with the inward nature of the current at diastolic potentials, makes this current apt to initiate and support the diastolic depolarization. In addition, the direct modulation of the current operated by the second messenger cAMP, represents one of the main pathways by which the autonomic nervous system controls cardiac chronotropism. Two recent clinical findings further confirm the role of f-channels in setting the cardiac rate: one is the evidence of a causative link between the presence of loss-of-function mutations found in these channels and the arrhythmic state of individuals carrying the mutations, and the other is the specific heart rate reduction observed in patients treated with ivabradine, a drug that at therapeutic doses selectively reduces the If current (see specific sections in this review).

Although originally discovered in the heart, the If current is also abundantly present in a large fraction of neuronal elements, where it contributes to rhythmic firing, synaptic integration, and dendritic integration.

Molecular and functional properties of SAN myocytes

Molecular and functional properties of SAN myocytes

Molecular and functional properties of SAN myocytes. (A) Spontaneous action potentials (left) and If current traces (right) recorded from typical rabbit SANmyocytes; currents were elicited by hyperpolarizing voltage steps in the range−45 to −75 mV. (B) Immunofluorescence analysis of rabbit SAN tissue slice labelled with anti-connexin 43 (Cx43, red) and anti-HCN4 (green) antibodies. HCN4 is strongly expressed in the central region of the SAN, while the opposite staining is observed for Cx43; crista terminalis (CT), interatrial septum (IS). (C) HCN4 labelling of single myocytes isolated from CT, SAN and IS (top), and  representative current traces recorded at−125mV frommyocytes isolated from the same regions (bottom). Both If current density and HCN4 labelling are more abundant in the central nodal area. (Panels B and C from [61] with permission).

[61] Brioschi C, Micheloni S, Tellez JO, Pisoni G, Longhi R, Moroni P, et al. Distribution of the pacemaker HCN4 channel mRNA and protein in the rabbit sinoatrial node. J Mol Cell Cardiol 2009;47:221–7.

The search of new therapeutic tools consisting of gene- and/or cell-based intervention aimed to restore compromised cardiac functions has prompted researchers to exploit the use of HCN channels to alter cellular electrical activity in order to generate, in normally quiescent substrates, stable rhythmic activity similar to that of native pacemaker myocytes. The specific features of pacemaker channels and in particular the fact that they are activated only at diastolic potentials and do not contribute to other phases of the action potentials, make them particularly suitable for such purpose. Early in vitro studies demonstrated that virus-mediated over-expression of HCN2 channels induced a significant increase in the rate of spontaneously beating neonatal ventricular myocytes by causing an If-mediated increase of the diastolic depolarization slope. This approach was later confirmed in vivo by showing that direct injection of the HCN2-adenovirus in the left atrium or into the ventricular conduction system of dogs, was able to induce ectopic regular spontaneous activity after AV block. Similarly, adenovirus-mediated over-expression of HCN1 or HCN4 was sufficient to induce a regular rhythm in quiescent cardiomyocyte. Alternative cell-based strategies, aimed to avoid the use of viruses, have been developed by engineering cells in order to express high levels of HCN channels. Engineered human mesenchymal stem cells (hMSCs) expressing either HCN2 or HCN4 have been shown in vitro to properly connect to neonatal cardiomyocytes and to increase their intrinsic spontaneous rhythm. HCN2-expressing hMSCs have also been successfully transplanted in canine left ventricular wall where they were able to induce stable ectopic beats.

Currently, ivabradine is marketed for treatment of chronic stable angina in patients with normal sinus rhythm who have a contraindication or intolerance to β-blockers; clinical studies of patients with chronic stable angina have shown that ivabradine acts as a pure heart rate-reducing agent and has anti-ischemic and anti-anginal properties equivalent to β-blockers and Ca2+ channel blockers and presents a good safety and tolerability profile even during long-term treatment. Mild visual symptoms (phosphenes) were occasionally reported, but were generally well tolerated. Additional information comes from results from a recent large clinical trial (BEAUTIFUL) which indicate that ivabradine treatment of patients with stable coronary artery disease (CAD) and heart rate ≥70 bpm can reduce the incidence of some CAD outcomes such as hospitalization for myocardial infarction and coronary revascularization.

The beat goes on: Cardiac pacemaking in extreme conditions

Christopher M.Wilson, Georgina K. Cox, Anthony P. Farrell
Comparative Biochemistry and Physiology, Part A xxx (2014) xxx–xxx
http://dx.doi.org/10.1016/j.cbpa.2014.08.014

In order for an animal to survive, the heart beat must go on in all environmental conditions, or at least restart its beat. This review is about maintaining a rhythmic heartbeat under the extreme conditions of anoxia (or very severe hypoxia) and high temperatures. It starts by considering the primitive versions of the protein channels that are responsible for initiating the heartbeat, HCN channels, divulging recent findings from the ancestral craniate, the Pacific hagfish (Eptatretus stoutii). It then explores how a heartbeat can maintain a rhythm, albeit slower, for hours without any oxygen, and sometimes without autonomic innervation. It closes with a discussion of recent work on fishes, where the cardiac rhythm can become arrhythmic when a fish experiences extreme heat.

Sympathetic renal denervation: Hypertension beyond SYMPLICITY

Israel M. Barbash, Ron Waksman
Cardiovascular Revascularization Medicine 14 (2013) 229–235
http://dx.doi.org/10.1016/j.carrev.2013.02.004

Despite a wide range of drug treatment for hypertension, resistant hypertension rates remain high. The Symplicity™ Renal Denervation System (Medtronic, Santa Rosa, CA), which creates renal nerve denervation, has shown initial success in lowering blood pressure among patients with resistant  hypertension. Given the enormous market for this treatment approach, an estimated two dozen other companies are pursuing technologies with alternative approaches. Despite this fact, very little has been published on preclinical and clinical experience with these new devices. The current review summarizes the most prominent technologies in the pipeline and provides insight into the mechanism of action, preclinical, and clinical experience with these new devices

A large body of evidence has established the central role of the kidneys in hypertension, both as an affector and effector of the central sympathetic system [9]. Renal efferent sympathetic activity initiates processes towards fluid retention, such as the release of renin and increased tubular sodium reabsorption. Moreover, afferent sympathetic activity increases central sympathetic drive, which plays a major role in sustaining hypertension. In fact, historic studies of surgical sympathectomy in patients with resistant hypertension or malignant hypertension uncontrolled by pharmacotherapy were shown to be effective in reducing blood pressure, albeit with severe side effects. Thus, with the introduction of more effective medications, this procedure was abandoned. Renal sympathetic nerves run alongside the renal artery adventitia to enter the hilus of the kidney. Thereafter, they divide into smaller nerve bundles following the anatomic course of the renal blood vessels, penetrating the cortical and juxtamedullary areas inside the kidneys. Based on these anatomic features, it was postulated that creating local nerve injury along the renal arteries may achieve effective denervation.

A key issue in accomplishing effective RDN is to target the sympathetic nerve bundles lying in the adventitia of the renal arteries. Because the vast majority of devices currently under development are percutaneous, RDN is performed from within the vessel lumen. Thus, one of the most important features of such a device is the ability to minimize the damage to the renal artery wall.

Ultrasound energy consists of high-frequency sound waves emitted by a transducer within the catheter. This high energy can pass through surrounding fluids and can generate frictional heating in tissues resulting in a temperature increase that is sufficient to cause injury to the surrounding tissue, specifically the renal nerves. Based on these principles, several systems were developed and are currently being evaluated. ReCor Medical’s (Ronkonkoma, NY) PARADISE™ Percutaneous Renal Denervation System is based on delivery of high ultrasonic energy to induce nerve tissue injury. The PARADISE system is composed of two components: a 6 F-compatible balloon catheter with a cylindrical ultrasound transducer that emits ultrasound energy circumferentially (Fig. 2A)[ Ultrasound based renal denervation systems: (A) Percutaneous Renal Denervation System (PARADISE™); (B) TIVUS system]  and a portable generator which controls automated balloon inflation and deflation, and energy delivery. Energy is delivered in 3 different locations along the artery with 50 s inflation and delivery of ultrasound energy at each site. This device received CE mark in February 2012. For RDN, the PARADISE balloon catheter is positioned inside the renal artery and the generator automatically inflates the balloon, delivers the ultrasonic energy, and deflates the balloon. Endothelial thermal damage is prevented by cooled fluid in the balloon.

Radiofrequency based renal denervation systems

Radiofrequency based renal denervation systems: (A) Symplicity Renal Denervation System; (B) EnligHTN Renal Denervation System; (C) V2 bipolar balloon catheter; (D) OneShot Balloon catheter

Sample Entropy and Traditional Measures of Heart Rate Dynamics Reveal Different Modes of Cardiovascular Control During Low Intensity Exercise

Matthias Weippert, Martin Behrens, Annika Rieger and Kristin Behrens
Entropy 2014, 16, 5698-5711; http://dx.doi.org:/10.3390/e16115698

Biological time series like the normal heartbeat-to-heartbeat fluctuation demonstrate complex dynamics. Based on their potential to give additional information beyond traditional heart rate variability (HRV) indices, nonlinear parameters have been applied for investigating short and long term effects of exercise on heart rate (HR) control. However, despite their diagnosticity and their clinical significance, the physiological background of their behavior is not very well established. It is assumed that complexity and regularity measures are fundamentally different from traditional HRV indices and show no correlation to these measures. However, many researchers found at least modest correlations for some nonlinear measures and traditional HRV indices under different conditions. It has also been shown that complexity of short-term HRV is under control of the autonomic nervous system. Currently, there are only few studies available that compared the cardiovascular response pattern to different exercise modes at similar HR. Lindquist et al. found a stronger increase of systolic (SBP) and diastolic arterial blood pressure (DBP) during isometric handgrip compared to cycling at comparable HR of 90 bpm.

Nonlinear parameters of heart rate variability (HRV) have proven their prognostic value in clinical settings, but their physiological background is not very well established. We assessed the effects of low intensity isometric (ISO) and dynamic (DYN) exercise of the lower limbs on heart rate matched intensity on traditional and entropy measures of HRV. Due to changes of afferent feedback under DYN and ISO a distinct autonomic response, mirrored by HRV measures, was hypothesized. Five-minute inter-beat interval measurements of 43 healthy males (26.0 ± 3.1 years) were performed during rest, DYN and ISO in a randomized order. Blood pressures and rate pressure product were higher during ISO vs. DYN (p < 0.001). HRV indicators SDNN as well as low and high frequency power were significantly higher during ISO (p < 0.001 for all measures). Compared to DYN, sample entropy (SampEn) was lower during ISO (p < 0.001). Concluding, contraction mode itself is a significant modulator of the autonomic cardiovascular response to exercise. Compared to DYN, ISO evokes a stronger blood pressure response and an enhanced interplay between both autonomic branches. Non-linear HRV measures indicate a more regular behavior under ISO. Results support the view of the reciprocal antagonism being only one of many modes of autonomic heart rate control. Under different conditions; the identical “end product” heart rate might be achieved by other modes such as sympathovagal co-activation as well.

ANOVA revealed a significant effect of experimental condition on all cardiovascular measures and autonomic indices. Average HR raised moderately from 65 ± 9 bpm at baseline to 85 ± 9 bpm during both types of exercise. HR during the first exercise perfectly matched HR of the subsequent exercise; average difference was only 0.3 ± 1.5 bpm (range: −2.6 to 4.3 bpm). Accordingly, HR and average R-R interval did not differ between DYN and ISO. The traditional vagal modulation HRV measure RMSSD was also not affected by the exercise mode, whereas SDNN was. Natural log-transformed HRV spectral indices HFP and LFP, the normalized powers LF n. u. and HF n. u. as well SampEn (Figure 1) were significantly different between DYN and ISO. Interestingly, SampEn did not differ between REST and DYN. There was no difference of the LF/HF ratio between REST and ISO, whereas comparison of REST vs. DYN showed a statistical trend (p = 0.077). Further, there was a small effect of condition on the HF peak frequency (F(2; 84) = 4.959, p < 0.01, η² = 0.106). While HF peak significantly shifted from 0.22 ± 0.07 Hz during REST to 0.26 ± 0.09 Hz during DYN (p < 0.05), no difference was found between REST and ISO (0.23 ± 0. 07 Hz). Post-hoc pair wise comparison between DYN and ISO showed a statistical trend for the HF peak shift (p = 0.063). SBP and RPP were moderately, DBP and MAP largely affected by the type of exercise. In comparison to DYN, myocardial oxygen consumption, reflected by RPP, was about 5% higher under ISO. Correlation analysis revealed only modest associations between traditional HRV indices and entropy measures during the different experimental conditions. Consistent correlation coefficients across all conditions were found for SampEn and R-R length only.

Mean ± SD of sample entropy during REST, ISO, and DYN; N = 43.

Mean ± SD of sample entropy during REST, ISO, and DYN; N = 43.
*** = significantly different from rest on a p-level < 0.001;
§§§ = significantly different from the respective exercise condition on a p-level < 0.001.

Role of neurotensin and opioid receptors in the cardiorespiratory effects of [Ile9]PK20, a novel antinociceptive chimeric peptide

Katarzyna Kaczynska, M Szereda-Przestaszewska, P Kleczkowska, AW Lipkowski European Journal of Pharmaceutical Sciences 63 (2014) 8–13 http://dx.doi.org/10.1016/j.ejps.2014.06.018

Ile9PK20 is a novel hybrid of opioid–neurotensin peptides synthesized from the C-terminal hexapeptide of neurotensin and endomorphin-2 pharmacophore. This chimeric compound shows potent central and peripheral antinociceptive activity in experimental animals, however nothing is known about its influence on the respiratory and cardiovascular parameters.

The present study was designed to determine the cardiorespiratory effects exerted by an intravenous injection (i.v.) of [Ile9]PK20. Share of the vagal afferentation and the contribution of NTS1 neurotensin and opioid receptors were tested.

Intravenous injection of the hybrid at a dose of 100 lg/kg in the intact, anaesthetized rats provoked an increase in tidal volume preceded by a prompt short-lived decrease. Immediately after the end of injection brief acceleration of the respiratory rhythm appeared, and was ensued by the slowing down of breathing. Changes in respiration were concomitant with a bi-phasic response of the blood pressure: an immediate increase was followed by a sustained hypotension. Midcervical vagotomy eliminated the increase in tidal volume and respiratory rate responses. Antagonist of opioid receptors – naloxone hydrochloride eliminated only [Ile9]PK20-evoked decline in tidal volume response. Blockade of NTS1 receptors with an intravenous dose of SR 142,948, lessened the remaining cardiorespiratory effects. This study depicts that [Ile9]PK20 acting through neurotensin NTS1 receptors augments the tidal component of the breathing pattern and activates respiratory timing response through the vagal pathway. Blood pressure effects occur outside vagal afferentation and might result from activation of the central and peripheral vascular NTS1 receptors. In summary the respiratory effects of the hybrid appeared not to be profound, but they were accompanied with unfavorable prolonged hypotension.

Integrative regulation of human brain blood flow

Christopher K.Willie, Yu-Chieh Tzeng, Joseph A. Fisher and Philip N. Ainslie
J Physiol 2014; 592(5): pp 841–859
http://dx.doi.org:/10.1113/jphysiol.2013.268953

Herein, we review mechanisms regulating cerebral blood flow (CBF), with specific focus on humans. We revisit important concepts from the older literature and describe the interaction of various mechanisms of cerebrovascular control. We amalgamate this broad scope of information into a brief review, rather than detailing any one mechanism or area of research. The relationship between regulatory mechanisms is emphasized, but the following three broad categories of control are explicated:

  • the effect of blood gases and neuronal metabolism on CBF;
  • buffering of CBF with changes in blood pressure, termed cerebral autoregulation; and
  • the role of the autonomic nervous system in CBF regulation.

With respect to these control mechanisms, we provide evidence against several canonized paradigms of CBF control. Specifically, we corroborate the following four key theses:

(1) that cerebral autoregulation does not maintain constant perfusion through a mean arterial pressure range of 60–150 mmHg;
(2) that there is important stimulatory synergism and regulatory interdependence of arterial blood gases and blood pressure on CBF regulation;

(3) that cerebral autoregulation and cerebrovascular sensitivity to changes in arterial blood gases are not modulated solely at the pial arterioles; and
(4) that neurogenic control of the cerebral vasculature is an important player in autoregulatory function and, crucially, acts to buffer surges in perfusion pressure.
Finally, we summarize the state of our knowledge with respect to these areas, outline important gaps in the literature and suggest avenues for future research.

Integrative physiological and computational approaches to understand autonomic control of cerebral autoregulation

Can Ozan Tan and J. Andrew Taylor
Exp Physiol 99.1 (2014) pp 3–15 http://dx.doi.org:/10.1113/expphysiol.2013.072355

New Findings

  1. What is the topic of this review?

This review focuses on the autonomic control of the cerebral vasculature in health and disease from an integrative physiological and computational perspective.

  1. What advances does it highlight?

This review highlights recent studies exploring autonomic effectors of cerebral autoregulation as well as recent advances in experimental and analytical approaches to understand cerebral autoregulation.

The brain requires steady delivery of oxygen and glucose, without which neurodegeneration occurs within minutes. Thus, the ability of the cerebral vasculature to maintain relatively steady blood flow in the face of changing systemic pressure, i.e. cerebral autoregulation, is critical to neurophysiological health. Although the study of autoregulation dates to the early 20th century, only the recent availability of cerebral blood flow measures with high temporal resolution has allowed rapid, beat-by-beat measurements to explore the characteristics and mechanisms of autoregulation. These explorations have been further enhanced by the ability to apply sophisticated computational approaches that exploit the large amounts of data that can be acquired. These advances have led to unique insights. For example, recent studies have revealed characteristic time scales wherein cerebral autoregulation is most active, as well as specific regions wherein autonomic mechanisms are prepotent. However, given that effective cerebral autoregulation against pressure fluctuations results in relatively unchanging flow despite changing pressure, estimating the pressure–flow relationship can be limited by the error inherent in computational models of autoregulatory function. This review focuses on the autonomic neural control of the cerebral vasculature in health and disease from an integrative physiological perspective. It also provides a critical overview of the current analytical approaches to understand cerebral autoregulation.

Read Full Post »

« Newer Posts - Older Posts »